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ABSTRACT 
Robert J. Garmise 
Novel Dry Powder Preparations of Whole Inactivated Influenza Virus for Nasal Vaccination 
(Under the direction of Dr. Anthony J. Hickey, Ph.D., D.Sc.) 
 
Nasal dry powder vaccines may provide safe, effective, stable, and affordable 
alternatives to currently available influenza vaccines. It was proposed that maximal mucosal 
and systemic antibody production would be elicited by a whole inactivated influenza virus 
dry powder nasal vaccine formulation in response to increased local residence time. Full 
factorial designed experiments examining freezing rate, solute concentration, and annealing 
(freeze-drying) and solution feed rate, atomization airflow rate, and solute concentration 
(spray-freeze-drying (SFD)) were used to produce particles suitable for nasal delivery. 
Freeze-drying followed by milling and sieving produced heterogeneous-shaped particles 
below the targeted particle size, which weren’t ideal for blending with mucoadhesive 
compounds (MA). Optimized SFD runs produced particles for human (D50=38.5µm) and rat 
(D50=26.9µm) delivery which were characterized for flow and thermal properties, surface 
area, true density, moisture content, and impact energy separation and demonstrated 
improved storage stability than liquid formulations. A modified cascade impactor was 
calibrated to characterize particles in the 10-20µm size range.  
 iii
Wettability, dissolution rate, and swelling indices were obtained as potential 
predictors of the effects MA may have on the residence time. Gamma scintigraphy allowed 
for visual imaging of nasal clearance, while residence time studies quantified mucociliary 
clearance rates. In vitro and in vivo experiments indicated that sodium alginate (SA) and 
carboxymethylcellulose (CMC-HMW) powder formulations had the greatest effect on 
increasing residence time in Brown Norway rats.  
A dose-response curve determined that a 2μg dose was appropriate to quantify 
potential differences in antibody responses of formulations. IM delivery provided equivalent 
serum antibody titers to IN powder without MA, CMC-HMW, SA, and hydroxypropyl 
methylcellulose (HPMC-HMW) after initial dosing and IN liquid and IN powder without-
MA, CMC-HMW, SA, and HPMC-HMW after boosting. IN liquid vaccine provided 
equivalent serum antibody titers to IN powder without-MA, CMC-HMW, SA, chitosan, and 
HPMC-HMW after the initial vaccination. IN liquid provided significantly greater serum 
antibody titers than IN powder with chitosan after boosting. While no significant differences 
between powder and liquid formulations were observed, trends are consistent with residence 
time studies with respect to eliciting an immune response. Maximal serum and mucosal 
antibodies were elicited following administration of IN powder with SA. 
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1 INTRODUCTION 
1.1 General Introduction 
The nasal route of administration is becoming more widely used for the delivery of 
pharmaceutical and biological compounds (Ikechukwu Ugwoke, Sam et al. 1999; Kendall 
and Latter 2003). All currently approved nasal preparations are liquid formulations which 
could be improved, specifically pertaining to the fraction of the dose reaching its intended 
site of action and residence time in the nasal cavity. Optimized dry powder formulations may 
overcome these shortcomings. Several factors, including the anatomical and physical 
characteristics of the nasal cavity, the nature of the dry powder formulation, and the use of 
mucoadhesive compounds, play a role in effective nasal drug delivery.  
1.1.1 Physiology of the Nasal Cavity 
1.1.1.1 Functions of the nasal cavity 
The nasal cavity has three main functions: filtration, conditioning of air, and olfaction 
(Proctor and Andersen 1982). The structure of the nasal cavity allows for the removal of 
large particles preventing entry to the lower respiratory tract. Inspired air is rapidly warmed 
and humidified by the warm, moist nasal mucosa, to near pulmonary airway conditions 
(within 1°C of body temperature, 97-98% relative humidity) (Guyton and Hall 1996). 
Olfactory nerves are located in the nasal cavity and distinguish odors. 
1.1.1.2 Structure of the human nasal cavity 
The human nasal cavity is located between the floor of the cranium and the roof of 
the mouth (Figure 1) (Taber and Thomas 2001). It is divided bilaterally by the nasal septum, 
with each half having a volume of about 7.5 mL (Mygind and Dahl 1998). The air enters 
through the anterior nares of the nostrils. In the posterior portion of the nostrils, the airways 
narrow to a cross-sectional area of about 0.3 cm2 on each side at a constriction known as the 
nasal valve (Newman, Pitcairn et al. 2004). The region, which is the most constricted section 
of the upper respiratory tract, accounts for up to 80% of nasal resistance and almost half of 
the total respiratory resistance (Proctor and Lundqvist 1973). After the nasal valve, the 
airway bends at a right angle into the opening of the skull and then widens where air comes 
in contact with turbinates or conchae (respiratory region). There are three distinct turbinates 
designated superior, middle, and inferior. These structures increase the total surface area to 
approximately 150 cm2 (Proctor and Andersen 1982). Finally, air passes through the posterior 
nares into the nasopharynx. The nasal cavity is enclosed by four groups of air-filled paranasal 
sinuses (Jones 2001). The olfactory region is located in the superior portion of the nasal 
cavity in an area of approximately 370 mm2, lying partly on the septum and partly on the 
superior and middle turbinates (Jones 2001). 
The anterior portion of the nasal cavity is lined with squamous epithelial cells which 
gradually change to pseudostratified columnar epithelial cells in the respiratory region (Illum 
1999). Approximately 15% to 20% of these cells in the respiratory region are ciliated (Figure 
2) (Ugwoke, Verbeke et al. 2001). Dispersed between the columnar cells are the mucus-
producing, goblet cells (Quraishi, Jones et al. 1998). Below the columnar epithelium are 
“replacement” basal cells, which differentiate into the other cell types (Illum 1999). 
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1.1.1.3 Structure of the rat nasal cavity 
 The rat is an obligate nose breather due to the close proximity of the epiglottis to the 
soft palate (Krinke 2000). The nasal cavity has a total volume of about 0.25 mL and a surface 
area of approximately 13 cm2 (Gross, Swenberg et al. 1982). The olfactory epithelium is 
located on the middle and superior nasal turbinates (ethmoturbinates) and constitutes 
approximately 50% of the total surface area, while the remaining regions are lined with 
respiratory epithelium (Gross, Swenberg et al. 1982). Among all laboratory animals, the rat 
presents the smallest deviation in the nasopharynx which has a bend angle of 15° (Schreider 
and Raabe 1981).  
1.1.1.4 Mucus and mucociliary clearance 
The secretions covering the nasal epithelium form two layers (Figure 3): the gel (or 
mucus) layer (0.5-2.0 µm thick) and the periciliary aqueous layer (7-10 µm thick). The gel 
layer is composed of 95% water, 2-3% glycoproteins, 1% lipid, 1% salts, and 0.02% DNA, 
which is exposed to the inspired air, is highly viscous, has non-Newtonian viscoelastic 
properties, and entraps inhaled particulates (Quraishi, Jones et al. 1998). In humans the 
mucus sheet in the nasal cavity is completely replaced approximately every 15 minutes. The 
periciliary layer is a low viscosity fluid with Newtonian properties which permits ciliary 
beating. The ciliary beat has two components: the effective stroke and the recovery stroke 
(Stannard and O'Callaghan 2006). In the effective stroke, the tip of the cilia penetrates the gel 
layer and the stroke pushes the mucus towards the posterior region of the nasal cavity. In the 
recovery stroke, the cilia move through the low viscosity periciliary fluid to the start position 
for the next stroke. The beat frequency is normally 15-20 Hz or approximately 1000 beats per 
minute (Mygind and Dahl 1998). Particles that deposit on the anterior portion of the nasal 
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cavity are cleared by mucus through the posterior region. In humans, the average rate of 
mucociliary clearance is 5 mm/min, though there is wide variation in mucociliary clearance 
between individuals (Proctor and Lundqvist 1973).  
The range of published mucociliary clearance rates in rats, of 1.1-5.9 mm/min on the 
respiratory epithelium and 0.9 mm/min on the olfactory epithelium, overlaps that of humans 
(Morgan, Patterson et al. 1986). 
1.1.1.5 Nasal-associated lymphoid tissue 
Most infectious diseases are caused by pathogens invading the host through mucosal 
surfaces, which represent a considerably greater surface area of body than the skin surface 
(Mestecky, Moldoveanu et al. 1997). Mucosal immunity, the first line of defense against 
pathogens, is of major importance in preventing infectious diseases. The nasal-associated 
lymphoid tissue (NALT) is the principle mucosal lymphoid tissue in the upper respiratory 
tract (Kuper, Koornstra et al. 1992). The NALT is situated just under the nasal epithelium 
and consists of a reticular network filled with various types of lymphoid and non-lymphoid 
tissue (Roitt and Delves 2001). Particulate antigens may be removed from the nasal mucosa 
by the mucociliary system. However, if the antigen comes in contact with the nasal 
epithelium, it can be taken up by specialized epithelial cells called the microfold (M) cells. 
Alternately, the antigen can be engulfed by a phagocytic cell: the dendritic cell (Tamura and 
Kurata 2004). Portions of the antigen are displayed on the surface following phagocytosis of 
the antigen. M cells and dendritic cells are known as antigen presenting cells (APC). This 
stimulates the recruitment of helper T cells which signal to recruit B cells that evolve into 
plasma cells. The plasma cells, existing in lymphoid tissue, secrete antibodies in great 
amounts. The B cells which do not evolve into plasma cells circulate as memory cells. There 
 4
are five classes or isotypes of antibodies (also called immunoglobulins (Ig)): IgM, IgG, IgA, 
IgD and IgE (Leffell, Donnenberg et al. 1997). When characterizing an immune response 
elicited by a vaccine, IgG and IgA are good descriptors of a systemic and local mucosal 
immune response, respectively. IgE should be monitored as an indicator of a possible 
hypersensitivity reaction. 
In rats, the NALT is located in the anterior portion of the nasal cavity (Spit, 
Hendriksen et al. 1989; Kuper, Hameleers et al. 1990; Kuper, Koornstra et al. 1992). In 
humans, the NALT is generally described as the Waldeyer’s ring and consists of the adenoid 
(nasopharyngeal tonsil), the bilateral pharyngeal lymphoid bands, the bilateral tubal and 
facial (palatine tonsils), and the bilateral lingual tonsils (Kuper, Koornstra et al. 1992). 
Studies in infants have demonstrated that lymphoid tissue is disseminated in the whole nasal 
mucosa (Debertin, Tschernig et al. 2003). This is significant for the targeting of the antigen. 
A vaccine must come in contact with the NALT, wherever it is located, to elicit an immune 
response. The potential for the NALT to exist throughout the nasal cavity, in human infants, 
increases the probability of antigen reaching the target, resulting in a greater immune 
response to intranasal vaccination (Nordqvist 2006). 
1.1.2 Particle Deposition in the Nasal Cavity 
Nearly all particles greater than 50 µm and about half of the particles in the 2-4 µm 
size range are deposited in the nasal cavity (Proctor and Andersen 1982). All particles less 
than 2 µm pass through the human nasal cavity into the lower airways. The predominant 
factor in deposition in the nose is inertial impaction. After passing through the initial bend 
angle, of 90° in humans, the air enters the main region of the nasal cavity, which widens with 
consequent reduction in linear velocity. In the posterior region, prior to the nasopharynx, the 
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airway path bends, resulting in narrowing and an increase in airflow linear velocity in the 
area around the adenoid tissue. This increase in velocity results in higher particle inertia and 
local deposition. In rats, most of the particles larger than 0.5 µm or smaller than 0.05 µm 
deposit in the nasal airways, with the remaining fraction being deposited in the alveolar 
region (Krinke 2000). Ultrafine particle deposition increases with decreasing particle size, 
primarily because of Brownian diffusion, and coarse-particle deposition increases with 
increasing particle size and therefore inertia primarily because of inertial impaction (Kelly, 
Bobbitt et al. 2001). 
1.1.3 Delivery of Drug to the Nasal Cavity 
The nasal route of administration has been utilized for centuries to deliver non-
therapeutic agents and drugs of abuse, for example tobacco or cocaine. The ancient Chinese 
were the first to utilize the nasal route to vaccinate people to prevent small pox infection 
(Voltaire 1961). However, it wasn’t until the second half of the 20th century that the nasal 
delivery of pharmaceuticals and biologicals was widely considered. Early products focused 
on the use of locally acting pharmaceutical agents for chronic sinusitis. In the past 20 years, 
greater emphasis has been placed on the use of nasal delivery for systemic agents (Table 1). 
Delivery to the nasal cavity has advantages compared to conventional oral ingestion of 
systemically acting agents. Compounds, delivered orally, may have poor or unpredictable 
absorption or bioavailability (Illum, Jenkins et al. 1999). The onset of action for substances 
delivered intranasally is significantly shorter than that of oral delivery. Nasal delivery 
circumvents the first pass liver and gastrointestinal metabolism associated with oral 
ingestion. 
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1.1.4 Delivery of Vaccines to the Nasal Cavity 
The nasal mucosa represents a promising route for the delivery of vaccines due to its: 
ease of accessibility; extent of vascularization; relatively large surface area; and the ability to 
induce both local and systemic immune responses. Moreover, immune responses elicited in 
the nasal cavity may induce responses in distant mucosal sites. The phenomenon of 
integration of responses from discrete mucosal sites is known as the “common mucosal 
immune system” (Roitt and Delves 2001). Delivery of vaccines and therapeutic drugs to the 
nasal and pulmonary systems has been studied extensively (Gonda 2000; Singh, Briones et 
al. 2001; Illum 2002; Groneberg, Witt et al. 2003; Roth, Chapnik et al. 2003). These 
approaches represent non-invasive alternatives to needle-based delivery. The nasal route 
facilitates vaccination of large groups of people, without employing large numbers of 
syringes and needles that are viewed as hazardous waste, requiring appropriate and expensive 
disposal (Partidos 2000). 
 Recently, a live, attenuated, cold-adapted trivalent intranasal (IN) influenza vaccine, 
FluMistTM, was approved by the FDA. This vaccine was shown to be safe and well-tolerated 
in certain healthy pediatric and adult populations (Belshe, Mendelman et al. 1998; Nichol, 
Mendelman et al. 1999; Treanor, Kotloff et al. 1999), thus providing a non-invasive 
alternative to needle-based injection of influenza vaccines. However, to maintain potency, 
the product must be stored as a frozen liquid and thawed immediately before use. In addition, 
there have been safety concerns related to the use of a live virus vaccine in populations such 
as children under age 5, the elderly, and the immunocompromised (FluMist Package Insert 
2003).  
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In addition to influenza, vaccination strategies have been developed for a number of 
diseases, including HIV, hepatitis B, measles, anthrax, plague, diphtheria, pertusis, tetanus, 
bacterial meningitis, respiratory syncytial virus and rotavirus (Hirabayashi, Kurata et al. 
1990; Russell, Moldoveanu et al. 1996; Bergquist, Johansson et al. 1997; Muszkat, Friedman 
et al. 2000; Davis 2001; Boyaka, Tafaro et al. 2003). Liquid formulations of these vaccines, 
delivered IN, have been shown to elicit increased local and systemic responses compared to 
parenteral administration. While dry powder vaccines have the potential to overcome the 
costly and limiting cold chain requirements of liquid vaccines, there have been very few 
reported studies of their use in IN delivery systems. Anderson et al. showed that a powder 
form of rinderpest virus elicits protective immune responses in cattle (Anderson, Fishbourne 
et al. 2000). In addition, Illum et al. reported increased serum IgG and nasal IgA titers 
following IN delivery of a pertusis/chitosan powder vaccine to guinea pigs (Illum, Jabbal-
Gill et al. 2001) However, control experiments comparing the results to standard parenteral 
routes were not conducted and the powders employed were not fully characterized (Huang, 
Garmise et al. 2004). 
1.1.5 Mucoadhesive Compounds 
Most IN vaccines do not elicit immune responses without co-administration with 
adjuvant. Concerns about toxicity limit the use of antigens in humans. Therefore, alternative 
strategies to enhance antigenicity are desirable, one of which is increasing the local residence 
time of antigen at the mucosal surface. 
Enterotoxin-based adjuvants, such as cholera toxin or Esherichia coli heat-labile 
enterotoxin, are used commonly as mucosal adjuvants in animal studies. However, their 
potential toxicity in humans is a major concern with respect to their clinical application. 
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Nanoparticles, microspheres, synthetic lipopeptides, cytokines, and CpG-containing 
oligonucleotides have also been studied as potential adjuvants (Hunter, Andracki et al. 2001; 
Staats, Bradney et al. 2001; Debin, Kravtzoff et al. 2002; Mariotti, Teloni et al. 2002; 
Rharbaoui, Drabner et al. 2002). Bioadhesives are compounds that adhere to a biological 
surface. Where the biological surface is mucosal, the compound is referred to as a 
mucoadhesive compound (MA). MAs can interact with the mucus in a number of ways. 
Chitosan, a widely studied cationic polymer, interacts with the negatively charged sialic acid 
group of the mucin glycoprotein (Illum, Jabbal-Gill et al. 2001). Other mechanisms of 
mucoadhesion are hydrophobic interactions, hydrogen bonding, and van der Waal’s 
interactions, depending on the polymer and the pH (Gu, Robinson et al. 1988). Another 
proposed mechanism of mucoadhesion is based on the local dehydration of the mucus; 
namely the water movement to the polymer causes the mucoadhesive interaction (Illum 
1999). Carbopol’s (polyacrylic acid) mucoadhesive properties are thought to be due to the 
entanglement of the chains of the Carbopol and mucin, thus decreasing mucociliary 
clearance. The mucoadhesive function of polymers, such as Carbopol and chitosan, may be 
useful in eliciting mucosal immunity to dry powder influenza vaccine formulations delivered 
IN.  
MAs are used to increase local residence time in the nasal cavity. There is evidence 
that chitosan, a biocompatible and biodegradable polymer from crustacean shell, may be used 
as a mucoadhesive for IN delivery and will boost the mucosal immune response (Jabbal-Gill, 
Fisher et al. 1998; Illum, Jabbal-Gill et al. 2001; van der Lubben, Verhoef et al. 2001; 
Westerink, Smithson et al. 2001; van der Lubben, Kersten et al. 2003). Carbopol, has been 
used to demonstrate enhanced insulin bioavailability in rabbits (Callens and Remon 2000). 
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MAs have been studied in liquid IN influenza vaccine formulations, using purified 
surface antigens (PSA) (Bacon, Makin et al. 2000). Chitosan and gellan (bacterial 
polysaccharide) formulations were administered IN to mice and compared to IN or 
subcutaneous PSA alone. Each group of animals received three sequential doses (vaccination 
and two boosts at the same concentrations). The chitosan formulation elicited significantly 
higher IgG titers than IN PSA after three doses, and significantly higher IgG titers than the 
gellan formulation after the last two doses. Also, the chitosan formulation elicited equivalent 
hemagglutination inhibition (HI) to subcutaneous dosing, while IN PSA alone did not 
generate any HI titers. This is an important observation because the HI assay measures 
functional activity of the antibody and is recognized as a reliable measure of protective 
antibody titer against influenza vaccine (Glueck 2001). 
The effect of chitosan on the mucociliary transport rate (MTR) in human nasal 
turbinates ex vivo has been evaluated (Aspden, Mason et al. 1997). Chitosans of varying salts 
(glutamate and hydrogen chloride) and molecular weights (< 50, 205, and 340 KDa) were 
delivered in a nasal spray. A significant decrease in MTR occurred for each of the three 
chitosans when compared to control. The two highest molecular weight chitosans delivered 
in nasal drops resulted in a significant decrease in the MTR when compared to a nasal spray. 
Thus, chitosan may decrease the MTR through the nasal cavity and increase the residence 
time of a co-administered antigen on the nasal mucosa, potentially increasing its 
immunogenicity. 
The mucoadhesive effects of chitosan have also been evaluated as a function of 
formulation (Soane, Hinchcliffe et al. 2001). Chitosan microspheres and solutions were 
compared with saline control for effects on mucociliary clearance in sheep. Clearance half-
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life (time to clear 50% of a radiolabeled marker, 99mTc) increased by more than 7-fold for the 
chitosan microsphere formulations compared to ~3-fold for chitosan solutions, indicating that 
chitosan powders could effectively increase residence time on the nasal mucosa compared to 
solutions or controls.  
The use of MA in nasal delivery, has been widely described and recently reviewed 
comprehensively (Ugwoke, Agu et al. 2005; Illum 2006). 
1.1.6 Influenza Virus 
Influenza infections occur when the virus invades the host through the thin and 
permeable mucosal surface in the upper respiratory tract (Lamb and Krug 1996). The virus is 
primarily transmitted person to person in liquid droplets generated by talking, coughing or 
sneezing (Dimmock, Easton et al. 2001). Influenza is a highly contagious disease that causes 
high morbidity and mortality worldwide each year (WHO 2006). Although difficult to assess, 
these annual epidemics are thought to result globally in three to five million cases of severe 
illness and between 250,000 and 500,000 deaths. Most deaths ascribed to influenza in 
industrialized countries occur among the elderly, individuals over 65 years of age (WHO 
2006).  
The currently circulating influenza viruses associated with human disease are divided 
into two groups (A and B). Influenza viruses are defined by two different antigens on their 
surface. They are apparently spike-like features identified as hemagglutinin (H) and 
neuraminidase (N) (Lamb and Krug 1996). Hemagglutinin has 16 subtypes (H1 through 
H16), but only the first three, H1, H2, and H3, routinely infect humans (Nicholson, Webster 
et al. 1998). Neuraminidase has 9 subtypes (N1 through N9), but only the first two, N1 and 
N2, routinely infect humans. Influenza A has two subtypes which can infect humans: 
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A(H3N2) and A(H1N1), of which the former is currently associated with most deaths (WHO 
2006).  
Avian influenza, influenza A, is of great global interest due to the potential to mutate 
to a form capable of transmission to humans. Of the hundreds of strains of avian influenza A 
viruses, only four are known to have caused human infections: H5N1, H7N3, H7N7, and 
H9N2. H5N1 virus is of greatest public health concern (WHO 2006). Between 2003 and the 
first half of 2006, the H5N1 virus was responsible for a reported 202 cases, with 113 of these 
resulting in death (WHO 2006). The virus is not yet capable of efficient infection and 
transmission between humans. This may be the only reason that avian influenza has not 
resulted in pandemic disease (Aldhous and Tomlin 2005). From an epidemiological 
perspective it appears inevitable that H5N1, or one of the other strains, will eventually be 
capable of causing worldwide disease. A vaccination strategy that is quick and effective will 
be necessary to prevent such a global pandemic. 
Hemagglutinin has been the subject of considerable study because of its role as the 
major antigen against which a protective immune response is directed (Tsurudome, Glueck et 
al. 1992). Hemagglutinin, which is distributed evenly on the surface of the virus particles, is 
the target for an immune response that results in host protection (Glueck 2001). It is H that 
allows the virus to attach to specific sialic acid receptors on the cell surface and causes 
endosomal fusion of the virion and cell membranes. The surface H units are trimers of H1-H2 
units. The H1 monomer has a globular membrane-distal domain of anti-parallel beta sheets, 
which contain the sialic acid containing receptor-binding site (Tsurudome, Glueck et al. 
1992). Neuraminidase, the other major protein component of the influenza virus, cleaves 
sialic acid from receptors, allowing the replicated virus to bud from the host cell (Nicholson, 
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Webster et al. 1998). Another important physical feature of the influenza virus crucial for 
replication is the M2-proton channel. The proton channel mediates an influx of H+ ions into 
the infecting virion early in the viral replication cycle. This cycle facilitates the dissociation 
of the ribonucleoproteins from the virion interior and allows them to be released into the 
cytoplasm and transported into the cell nucleus (Hayden 2006). Neuraminidase and M2-
proton channel have been drug targets but are not considered as part of a vaccine strategy. 
1.1.7 Influenza Treatment 
There are currently several marketed drug products for prophylaxis and treatment of 
the signs and symptoms of influenza. These medications fall into two classes: the M2 ion-
channel inhibitors (adamantanes) and the neuraminidase inhibitors (NI). The adamantanes, 
amantadine (Symmetrel®) and rimantidine (Flumadine®), are active against influenza A 
viruses, but not influenza B viruses.(Keitel and Piedra 1998). The NI, zanamivir (Relenza®) 
and oseltamivir (Tamiflu®), are active against both influenza A and B viruses. The 
adamantanes can reduce the duration of uncomplicated influenza A illness, and the NI can 
reduce the duration of uncomplicated influenza A and B illness by approximately one day 
when administered within two days of the onset of illness to otherwise healthy adults.(Smith, 
Bresee et al. 2006) Amantadine, rimantadine, and oseltamivir are administered orally. 
Zanamivir is available as a dry powder for pulmonary delivery using the Diskhaler® 
inhalation device. Oseltamivir and zanamivir are not a substitute for vaccination, although 
they can be critical adjuncts in preventing and controlling influenza (Smith, Bresee et al. 
2006). It has recently been suggested that neither amantadine nor rimantadine should be used 
for the treatment or chemoprophylaxis of influenza A in the United States because of recent 
data indicating widespread resistance of this virus to these medications (Bright, Shay et al. 
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2006). The resistant virus has a single amino acid mutation which prevents the adamantanes 
from binding to the M2 ion-channel and exerting its effect.(Hayden 2006)  
1.1.8 Influenza Vaccination 
Vaccination has a major impact on disease prevention and containment of epidemics. 
It is recommended by the World Health Organization (WHO) that the elderly and those of 
any age who are considered high risk (i.e. immunocompromised patients, healthcare workers, 
pregnant women) for influenza-related complications, due to underlying health conditions, 
should be vaccinated (WHO 2006). Among the elderly, vaccination is thought to reduce 
influenza-related morbidity by 60% and influenza-related mortality by 70-80%. Among 
healthy adults, vaccination is effective (70-90%) in reducing influenza morbidity, and has 
substantial health-related and economic benefits (WHO 2006). In addition, vaccination 
reduces both health-care costs and productivity losses associated with influenza illness. 
The strains of influenza virus are designated according to a formula which describes 
their full pedigree. A strain is named by type, sub-type, geographical location of first 
isolation, a laboratory identification number and the year of isolation (Keitel and Piedra 
1998). The strains of influenza utilized for the 2005-06 season were A/California/7/2004 
(H3N2)-like, A/New Caledonia/20/99 (H1N1)-like, and B/Shanghai/361/2002-like antigens. 
For the A/California/7/2004 (H3N2)-like antigen, manufacturers were able to use the 
antigenically equivalent A/New York/55/2004 (H3N2) virus, and for the 
B/Shanghai/361/2002-like antigen, manufacturers were able to use the antigenically 
equivalent B/Jilin/20/2003 virus or B/Jiangsu/10/2003 virus (Smith, Bresee et al. 2006). 
These virus strains were chosen for their growth properties, and also because they were 
representative of the influenza virus strains likely to circulate in the United States during the 
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2005-2006 season. Circulating influenza A (H1N2) viruses are a reassortment of influenza A 
(H1N1) and (H3N2) viruses. Therefore, antibodies directed against influenza A, (H1N1) and 
(H3N2), vaccine strains provide protection against circulating influenza A (H1N2) viruses 
(Smith, Bresee et al. 2006).  
Inactivated influenza vaccines are made by inoculating fertilized chicken eggs with 
virus, harvesting the fluid, and then extensively purifying it. Thus, vaccines contain small 
amounts of residual egg protein which can potentially cause an allergic reaction in certain 
individuals. New technology focuses on the use of  MDCK cell lines for virus production, 
which eliminates this side effect, and allows rapid production of large amounts of vaccine 
(Audsley and Tannock 2004).  
Influenza vaccines currently present antigen in four forms: (1) whole inactivated 
influenza virus (WIIV); (2) subunit vaccine; (3) split vaccine; and (4) live attenuated virus. 
The first three forms require chemical inactivation of the virus, usually with formaldehyde 
(Keitel and Piedra 1998). The WIIV utilizes the whole virion. In a subunit vaccine (also 
referred to as PSA), the H and N proteins of the influenza virus are extensively purified, by 
procedures such as zonal centrifugation, so that the vaccine consists predominantly of only 
these proteins. Split vaccines require that the lipid envelope of the influenza virion is 
digested by detergents, freeing the soluble H and N proteins and internal proteins from the 
whole virus particle which can then be used as the vaccine. The split vaccine was originally 
developed to reduce the side effects caused by the lipid envelope (Keitel and Piedra 1998). 
Early split and subunit vaccines displayed reduced immunogenicity with respect to the WIIV, 
due to the removal of adjuvant associated with the lipid envelope. However, modern versions 
of these vaccines utilize adjuvants such as aluminum phosphate, making the immunogenicity 
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comparable to that of the WIIV. Similarly, modern WIIV vaccines are extensively purified so 
that the incidence of side effects is not significantly different to that of the subunit or split 
vaccines. The advantage of utilization of a live attenuated virus is the induction of mucosal 
and systemic immune responses that more closely resemble those provided by the natural 
infection (Keitel and Piedra 1998). 
1.1.9 Rationale for a Dry Powder Influenza Vaccine 
Current efforts to control influenza are based on the use of neuraminidase inhibitors, 
adamantanes, or annual vaccines. The drug compounds are costly prescription medications 
that must be taken prior to infection and are not effective if symptoms have lasted for more 
than two days. The need for vaccination is of increasing importance with the development of 
resistance to the adamantanes. There are currently four different commercial trivalent vaccine 
formulations: three intramuscular (IM) injections and an intranasal (IN) solution. The IM 
vaccines contain inactivated influenza virus. They must be administered invasively by a 
health care professional, stored refrigerated, kept sterile, and containers, needles and syringes 
must be disposed of as biological waste. The IN vaccine, FluMist®, provides a non-invasive 
alternative to needle-based injection of influenza vaccines and delivers live, attenuated, and 
cold-adapted virus. However, in order to maintain potency, the vaccine must be stored frozen 
and thawed immediately before use. The IN vaccine elicits a systemic immune response (IgG 
production), but, unlike IM administration, the IN vaccine also elicits a local mucosal 
response (IgA production). However, the IN vaccine hasn’t been approved for use in select 
populations such as children, the elderly and the immunocompromised, which are most 
commonly affected by the virus.  
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One option, which is being widely considered to overcome the shortcomings of the 
currently approved products, is the use of nasal dry powder vaccines. There is growing 
interest in the development of stable powder vaccine formulations and delivery technologies 
to overcome refrigerated storage and distribution (i.e., “cold chain”) requirements, associated 
with liquid based vaccine stability and delivery. Dry powder formulations are potentially 
superior to liquid formulations in their sterility and stability, eliminating the necessity of the 
cold chain, thereby facilitating mass vaccination particularly in the developing world 
(LiCalsi, Christensen et al. 1999; Anderson, Fishbourne et al. 2000; Illum, Jabbal-Gill et al. 
2001; LiCalsi, Maniaci et al. 2001; Smith, Bot et al. 2003). There is an urgent need not only 
to overcome cold chain requirements (for improved stability), but also to provide single-use, 
non-refillable delivery technologies that require minimal training. This route of 
administration offers protection from influenza, since the virus uses the nasal route of entry 
into the host and IN vaccine elicits both a local and systemic immune response. This 
approach may ultimately provide a safe and an effective alternative to the currently available 
influenza vaccines.  
A dry powder influenza vaccine system containing WIIV and a high-molecular-
weight ionic polysaccharide extracted and purified from Aloe vera has been studied for 
intranasal delivery (Ni and Yates 2004). The system is capable of in situ gelation, greatly 
increasing the residence time in the nasal cavity. Preclinical studies showed that the vaccine 
induced a strong protective immune response at a low antigen dose after a single nasal 
immunization and a strong boosting effect following a second immunization (Ni, Tian et al. 
2005). A human Phase I safety study showed that this powder system (without an antigen) 
was safe and well tolerated (Yates 2006). 
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Practical considerations for the manufacture of a dry powder IN influenza vaccine 
must be addressed. Powder manufacture and characterization, dispersion properties, and 
methods to assess deposition, clearance and immune response elicited are important 
considerations in determining optimal vaccine characteristics (Figure 1.4). Powder systems 
require hydration/dissolution to occur for the system to be effective (Figure 1.5). Release of 
the active component from a powder to the nasal mucosa must take into account the water 
uptake and dissolution rates and the interaction between the mucoadhesive and mucus (Medi, 
Tian et al. 2006). 
1.1.10  Formulation of Nasal Dry Powders 
The advantages of local mucosal immunity and stability of powder formulations, have 
led to increasing interest in this form of vaccine delivery to the respiratory tract (LiCalsi, 
Christensen et al. 1999; Anderson, Fishbourne et al. 2000; Illum, Jabbal-Gill et al. 2001; 
LiCalsi, Maniaci et al. 2001; Smith, Bot et al. 2003). Processing methods are available for 
producing powder forms of vaccines tailored specifically for delivery to either the nasal 
cavity or lungs. LiCalsi et al. have developed a pulmonary powder delivery device and 
characterized powder formulations of the measles vaccine (LiCalsi, Christensen et al. 1999; 
LiCalsi, Maniaci et al. 2001). However, the vaccine was developed specifically for 
pulmonary rather than IN delivery and in vivo protection or immunogenicity data for such 
formulations have not been published.  
Historically, two methods for the manufacture of multi-component dry powder 
formulations have been employed, spray-drying and freeze-drying. Spray-drying involves the 
transformation of liquid feed through an atomizing nozzle into a dried form by spraying the 
feed into a hot drying medium (Masters 1976). However, the high drying temperature 
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necessary during the process of spray-drying can result in the denaturation of the vaccine 
protein components which is undesirable since this leads to inactivity and therapeutic 
ineffectiveness. Lyophilization and spray-freeze-drying are, arguably, more appropriate 
methods for the manufacture of dry powder particles suitable for nasal delivery, since little 
denaturation is anticipated.  
1.1.10.1 Lyophilization 
Lyophilization (or freeze-drying) occurs when a solution or suspension is crystallized 
at a low temperature, followed by solvent removal from the solid-state through the process of 
sublimation (Gennaro and Remington 1995). The freeze-drying (FD) process is divided into 
two steps as its name suggests. Freezing is most critical to product quality and is influenced 
by a number of factors (Oetjen and Haseley 2004). These factors include freezing rate, 
number and geometry of foreign particles (nuclei), the degree of sub cooling, the rate and 
growth of ice crystals, the presence and amount of unfrozen water, and the crystallization of 
the dissolved substances. These factors are interdependent. For example, the degree of sub 
cooling is strongly influenced by the freezing rate and the number and geometry of foreign 
particles. Both the rate and growth of ice crystals and the crystallization of the dissolved 
substances are influenced by the temperature and the viscosity of the solution (Oetjen and 
Haseley 2004).  
The addition of cryoprotective agents, such as lactose, sucrose, mannitol, or trehalose  
influences the cooling, solidification process and adds to the solid mass of the solution, 
significantly decreasing molecular mobility and, thereby, preventing hydrolytic degradation 
of a protein or peptide (Rey and May 2004). Furthermore, cryoprotectants maintain the 
peptide or protein in its active conformation in the solid state by maintaining favorable H-
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bonding interactions as water is removed. A number of excipients have been studied for their 
cryoprotective properties in maintaining the activity of enzymes (Carpenter, Arakawa et al. 
1992). Lactose, sucrose, and trehalose maintained high levels of enzyme activity after freeze-
drying. Although lactose can maintain protein activity during lyophilization, it is a reducing 
sugar and can degrade proteins by the Maillard reaction during storage, hence, it is not 
considered the cryoprotectant of choice for this category of macromolecules (Hageman 
1992). 
1.1.10.2 Spray-freeze-drying 
A new manufacturing method, spray-freeze-drying (SFD) which combines the 
methods of spray-drying and freeze-drying has been developed recently (Table 1.2) 
(Gombotz, Healy et al.; Maa, Nguyen et al. 1999; Costantino, Firouzabadian et al. 2000; 
Carrasquillo, Carro et al. 2001; Carrasquillo, Stanley et al. 2001; Costantino, Firouzabadian 
et al. 2002). This process is initiated by spraying a liquid feed into liquid nitrogen, thus 
freezing the droplets. The frozen particles are lyophilized at a low temperature and pressure, 
eliminating the possibility of heat damaging or destroying the solute. SFD frequently 
produces large porous particles with different aerodynamic properties than spray-dried 
particles (Maa, Nguyen et al. 1999). Ideally, spray-freeze-dried particles are spherical and in 
a narrow particle size range. They rarely require further particle size reduction (if required 
this is limited to deaggregation), minimizing the potential loss of activity, and rendering them 
suitable for blending with an added mucoadhesive compound. 
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1.1.11 Particle size characterization of dry powders 
Quantitative descriptors of particle size are as numerous as the specific properties 
from which they are derived. The projected area diameter (dp) is obtained from two 
dimensional images of particles and represents the diameter of a disc with the same projected 
area as the particle being examined (Martin and Bustamante 1993). The equivalent volume 
diameter (de) is the diameter of a sphere of the same volume to the particle. While these 
diameters are readily measured by microscopy or laser diffraction techniques, respectively, 
they have limited application to particles deposited in the respiratory tract. The aerodynamic 
diameter (da) is the dimension used to represent airborne particle size. The da of a particle is 
the diameter of a unit density sphere that has the same terminal settling velocity in air as the 
actual particle (Hinds 1999):  
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where VTS is the terminal settling velocity of the unit density sphere, ρ0 is unit density, ρp is 
the particle density, g is the acceleration of gravity, η is the air viscosity, and χ is a factor 
based on the particle shape (χ=1 for spherical particles). This equation states that as the 
particle diameter increases but density is uniform, the terminal settling velocity increases, 
and the larger particle is more likely to deposit by inertial impaction than a small one. 
However, if density can vary, a larger, low density particle can have the same terminal 
settling velocity as a smaller high density particle. This is important because spray-freeze-
drying generally produces porous particles (low-density) which may result in a significant 
difference between the directly observable, geometric diameter and the aerodynamic 
diameter. 
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Powders consisting of particles of similar size (i.e. monodisperse) can be described by 
a single parameter, the diameter. However, most powders consist of a range of particle sizes 
(i.e. polydisperse) that affect their flow and dispersion, and the entire distribution of particle 
sizes must be characterized (Hinds 1999).  A particle size distribution can be represented in 
several ways (Figure 1.6). A frequency distribution is the proportion of the particles of a 
specific size plotted with respect to particle diameter. A plot of the frequency against the 
logarithm of particle size results in a normal or Gaussian distribution, termed lognormal. A 
lognormal distribution can also be plotted on a logarithmic scale against the cumulative 
fraction of particles below that size, termed a cumulative distribution plot. A log-probability 
plot is a linear plot that results from the percent undersize on a logarithmic scale plotted 
against the logarithm of particle size. Finally, a probit frequency scale, a linearized function 
of variance, is employed to plot data with respect to the logarithm of particle size. The 
median diameter, d50, is by definition the geometric mean and is assigned a probit value of 
five, consistent with its function of dividing the distribution into two equal halves, at the 
fiftieth percentile. The diameters at the 16th and 84th percentiles are one standard deviation 
below and above the median and are given values of four and six, respectively. A probit plot 
of a lognormal distribution is linear. Distributions which may not be fitted by a log-normal 
mathematical approximation, e.g. multimodal distributions, will deviate from linearity on a 
log-probability plot. 
 The median diameter is used to represent the 50th percentile of the distribution and 
geometric standard deviation is used to represent the breadth of the particle size distribution. 
The median of a size distribution can be based on the count, mass, or volume and are termed 
count median diameter (CMD), mass median diameter (MMD) and volume median diameter 
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(VMD), respectively. The geometric standard deviation (GSD) for a normal distribution can 
be calculated from the following equation (Hinds 1999): 
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where D84 and D16 represent the diameters at the cumulative percentiles of 84% and 16%, 
respectively, and the median diameter of the distribution is represented by D50. Particle 
distributions with a higher GSD are more polydisperse and represent a greater range of 
deposition characteristics. For an aerodynamic size distribution, the median is identified as 
the mass median aerodynamic diameter (MMAD).  
 The span is an alternative measure of the breadth and uniformity of a distribution, 
which is commonly used to describe nasal formulations where laser diffraction technique has 
been used to collect equivalent volume diameter data (Newman, Pitcairn et al. 2004):  
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where D90% and D10% represent the diameters at the cumulative percentiles of 90% and 10%, 
respectively. Both GSD and span are dimensionless parameters.  
1.1.12 Physico-chemical characterization of dry powders 
The flow properties of a powder reflect the cohesive forces of a powder (Carstensen 
1993; Martin and Bustamante 1993). The ability of a powder to flow is a factor that affects 
the mixing of different materials to form a blend (Martin and Bustamante 1993). This may be 
important for the blending of the virus particle preparation and excipient to achieve a dry 
powder formulation. Nasal delivery also requires fluidization of the powder bed, where the 
flow properties of powders would be anticipated to affect the emitted dose from the device 
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and subsequent deposition in the nasal cavity. Static methods, reflecting particle interactions, 
may be used to predict the potential flow properties of a powder and include bulk/tapped 
density and static angle of repose (Gennaro and Remington 1995). 
The surface area of particles influences particle interactions in a powder due to the 
number of contact points available for these interactions to occur. Surface area for a single 
spherical particle is equivalent to πd2 and, therefore, increases as the diameter, d, of the 
particle increases. However, in a defined mass of powder there are many more small particles 
than large ones. On a population basis, the sum of the surface area of small particles is 
greater than that of large particles in any particular powder.  
Where particles are irregularly shaped their surface area to volume ratios are 
substantially different, and potentially variable across a population, from those of a spherical 
particle hence the estimates of particle diameter based on equivalent spherical sizes may be 
quite different when based on different physical dimensions (e.g. surface and volume). These 
differences may be employed to derive shape factors (Martin and Bustamante 1993). The 
dominant effect of shape is on surface area. The surface area is most commonly measured by 
gas adsorption at the surface of a known mass of powder (Crowder 2003). 
Particles consist of organized structures of molecules the dimensions of which dictate 
the crystal system. The appearance of the each particle is dictated to large extent by the 
nature of the particle manufacturing process and the nature of the growth phenomenon which 
gives rise to a particular crystal habit. Pharmaceutically the underlying molecular structure 
contributes to the stability of the powder system. Thermal analysis is one means of studying 
this structure. The principle underlying thermal analysis is to apply energy, in the form of 
heat, that can be absorbed by the solid  and may contribute to a re-ordering of the system into 
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another form (solid, liquid or gas) or result in dissociation of important elements of the 
stucture (e.g.water). Differential scanning calorimetry (DSC) is the method most frequently 
employed to study these phenomena. 
DSC measures differences in the amount of heat required to increase the temperature 
of a sample with respect to a reference (Craig, Royall et al. 1999). When the sample 
undergoes a physical transformation, such as in phase transitions (thermodynamic or kinetic), 
there will be a difference in heat needed to flow to it than the reference to maintain both at 
the same temperature. Whether more or less heat must flow to the sample depends on 
whether the process is exothermic or endothermic. DSC may be used to measure denaturation 
and unfolding events in peptides and proteins. DSC may also be used to measure kinetic 
phase transitions, such as glass transitions.  
The forces of attraction that can exist between particles include van der Waals forces, 
electrostatic forces, and capillary forces. There are numerous ways to characterize the forces 
of interaction between particles and/or surfaces. Experimental measurements of adhesive 
forces are made by determining the force required to separate a particle from a surface. 
Limited data are available on the adhesion force between micron sized particles and solid 
surfaces (Staniforth 1994). Methods used to evaluate the adhesive force include the variation 
of the slope of a surface, pendulum (Otsuka, Iida et al. 1983), microbalance method, 
centrifuge (Kulvanich and Stewart 1987), aerodynamic or hydrodynamic (Visser 1970), and 
the vibration method (Mullins, Michaels et al. 1992). The only methods applicable to 
particles in the 0.1-50 μm size range are the centrifugal, aerodynamic, and vibrational 
methods. An impact energy apparatus has previously been developed (Concessio 1997; 
Concessio, Van Oort et al. 1998) to enable characterization of particles as small as 1 µm. The 
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purpose of the device was to determine the force required to detach particles from solid 
surfaces. With this apparatus, the detachment of nasal powder from a surface can be studied. 
In addition, the hygroscopicity, capacity to take on moisture, and the ambient relative 
humidity of powders in a dry powder formulation can influence their flow and dispersion. 
Powders with higher moisture contents are more likely to aggregate due to surface tension 
effects and capillary forces, and hygroscopicity can increase the probability of these effects 
occurring (Hickey and Ganderton 2001). A high ambient relative humidity (between 65 and 
100%) presents water to the surfaces (adsorption) of particles leading to large capillary forces 
(Kulvanich and Stewart 1988). Low relative humidity can lead to low equilibrium moisture 
content that results in an increase in electrostatic forces in non-conducting solids. It is 
important to know the capacity of a powder for moisture uptake over a range of relative 
humidities to assess the potential for particle aggregation (Hickey and Ganderton 2001). 
Moisture content is determined by difference, measuring the change in weight of a powder 
before and after heating. 
The cascade impactor is used to separate airborne particles into aerodynamic size 
classes (Lodge and Chan 1986). Cascade impactors operate on the basis of inertial impaction 
(Hinds 1999). These devices consist of a series of stages with orifices that decrease in size 
with each succeeding stage (Figure 1.7). A vacuum drawn at the base of the impactor by a 
pump is adjusted to generate a predesignated volumetric airflow rate. Particles are drawn into 
the impactor on the conveying air stream. Collection surfaces serve to obstruct the path of the 
airflow. Since the orifice size decreases with succeeding stages, the linear velocity of air 
increases at each successive stage. Therefore, the inertia and stopping distance of the 
particles increases at each stage increasing their probability of deposition (Baron and Willeke 
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2001). This allows particles with a range of aerodynamic diameters to be deposited on each 
collection surface with particles having a higher aerodynamic diameter depositing on the 
upper stages. Additionally, the amount of powder dispersed from the delivery device can be 
quantified and an emitted dose can be calculated.  
Cascade impactors must be calibrated or mensurated before operation. Calibration is 
typically performed with aerosols containing particles of the same diameter, monodisperse 
aerosols (Mercer 1963). Impactor efficiency curves can be generated for each stage of the 
impactor during the calibration. The aerodynamic diameter of the particles at which 50% of 
the mass from the air stream impacts on the collection surface, d50, is the effective cut-off 
diameter for that impactor stage. Since the cut-off diameter for each successive stage 
decreases, the aerodynamic diameters of particles that deposit on each successive stage also 
decrease. This allows for the measurement of the aerodynamic diameter distribution of the 
particles after they have been dispersed. Therefore, the size distribution obtained is an 
indication of the particle dispersion. Mensuration involves assumptions regarding 
manufacturing tolerances. A single impactor is calibrated as described above. Other 
impactors are manufactured according to documented specifications, their functional 
dimensions (jet diameters, numbers, and distance to impaction surfaces) are measured 
accurately and sensitive pressure drop measurements are conducted for comparison to the 
calibrated device. These uncalibrated impactors are assigned the same collection efficiency 
curves as the calibrated device, if their measured dimensions are within manufacturers’ 
specifications (USP 2006). 
Mucociliary clearance has been evaluated in vivo (Puchelle, Aug et al. 1981; 
Ugwoke, Exaud et al. 1999; Ugwoke, Agu et al. 2000). Gamma scintigraphy is a non-
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invasive method for studying the deposition and clearance of particles associated with 
radiolabeled materials that have been administered to animals and humans. It allows both 
quantitative and direct visual imaging of distribution and clearance of the radiolabeled 
vaccine formulation. To perform scintigraphic imaging, a γ-radiation emitting tracer, usually 
a form of 99mTc associated with the substance of interest, is placed under a camera and 
imaged using a detector array. Analysis of nasal delivery requires the presence of 
radiolabeled particles in the nasal cavity and acquisition of gamma camera images of the 
lateral side of the head taken at various time points. There are limitations to this approach. 
Imaging of nasal deposition in rodents is difficult to achieve and clearance studies as a 
function of time pose imaging sensitivity questions (Liversidge, Wilson et al. 1988). Nasal 
lavage is a technique that has been used to collect and quantify markers of inflammation in 
the nasal cavity (Foy and Schatz 2004; Wilfong and Dey 2005). Nasal imaging studies allow 
the disposition of labeled formulations to be followed as a function of time following 
administration. However, nasal lavage may be employed to wash the radiolabeled particles 
from the nasal cavity and subsequent scintillation counting of the collected lavage fluid 
allows estimation of residual materials.  
1.2 Problem Statement 
Current efforts to control influenza are based on the use of NI, adamantanes, or 
annual vaccines. NI prevent the budding of replicated influenza from the host cell, thus 
limiting the ability of the influenza virus to proliferate. NI must be taken just prior to 
infection, are not effective if symptoms have lasted for more than 2 days, are prescription 
medications, and are costly. There are currently four different commercial vaccine 
preparations: three IM injections and an IN solution. The IM vaccines contain whole, 
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inactivated influenza virus (WIIV). They require invasive delivery monitored by a health 
care professional, frozen storage, sterility, and their delivery systems (containers, needles and 
syringes) must be disposed of as biological waste. The IN vaccine is a live, attenuated, cold-
adapted trivalent influenza. The IN vaccine provides a non-invasive alternative to needle-
based injection of influenza vaccines. However, to maintain potency, the vaccine must be 
stored frozen and thawed immediately before use. The IN vaccine elicits a systemic immune 
response (IgG production), but, unlike IM delivery, the IN vaccine also elicits a local 
mucosal response (IgA production). However, there have been safety concerns related to the 
use of a live virus vaccine in select populations such as children, the elderly and the 
immunocompromised.  
1.3 Hypothesis and Specific Aims 
A novel integrated approach to the preparation and evaluation of WIIV vaccines is desirable. 
The delivery of nasal dry powder vaccines may ultimately provide a safe, effective, stable, 
and affordable alternative to currently available influenza vaccines. It is proposed that 
maximal mucosal and systemic antibody production will be elicited by a dry powder nasal 
vaccine formulation containing whole inactivated influenza virus in response to increased 
local residence time. This hypothesis was addressed by the following series of specific aims: 
1. To prepare particles containing whole inactivated influenza virions and to 
evaluate the powder properties for nasal delivery.  
Particle Manufacture- Dry powders of suitable size for nasal delivery of WIIV and 
excipients were prepared by FD followed by milling or SFD. Desirable properties for the 
manufactured particles included: a) aerodynamic particle size > 20 µm with a median 
diameter of 30-60 µm; b) suitable for dispersion (good flow properties). (Chapter 2) 
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Powder Characterization- Each manufactured powder was characterized for particle size 
and size distribution, particle morphology, thermal properties (crystallinity, polymorphism), 
moisture content/uptake, bulk/tapped density, static angle of repose, surface area, and 
electrostatic properties. Several delivery devices were employed and the dispersion 
properties of the formulations were examined. Functional stability of the dry powder 
preparation after shelf storage at room temperature was determined using a hemagglutination 
assay. (Chapter 3) 
Novel Methods/Applications- a) Impact force detachment was used to evaluate the 
dispersion properties of heterogeneous particles. b) A modified Andersen cascade impactor 
method was employed to characterize particles with aerodynamic diameters < 20 µm. 
Development of this method allowed accurate estimation of quantities of powder that might 
potentially enter the lungs, an undesirable characteristic as it may be associated with adverse 
effects. Cut-off diameters of stages of the cascade impactor at a reduced flow rate were 
calibrated using a vibrating orifice monodisperse aerosol generator. (Chapter 3) 
Effects of Mucoadhesive Compounds- a) Mucoadhesive compounds exhibiting a range of 
structural and charge properties were evaluated with respect to swelling and viscosity factors 
consistent with retention on the nasal mucosa. Representative compounds were selected 
following designed experiments to identify desirable physico-chemical properties. b) Site of 
deposition was evaluated using scintigraphic imaging.  The effect of mucoadhesive 
compounds on the residence time on the nasal mucosa was evaluated by nasal lavage of 
radiolabeled powder preparations. (Chapter 4) 
2. To demonstrate the effectiveness of the powder vaccine delivered intranasally in 
eliciting a local IgA and systemic IgG immune response in vivo. Dry powder vaccine was 
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delivered to the nasal cavity of rats to determine the magnitude of the immune response 
compared to positive and negative controls, a nasal solution and an IM injection. Production 
of local and systemic antibodies in a rat model was measured after dosing of vaccine 
formulation by conducting nasal lavage and taking blood samples. (Chapter 5) 
 
Figure 1.8 depicts the specific aims and the manner in which they will be addressed in 
the dissertation. 
1.4 Summary 
Drug delivery to the nasal cavity has been achieved using a variety of delivery 
systems. Influenza affects a large number of people annually and invades the host through 
the mucosal membranes in the upper respiratory tract. An intranasal influenza vaccine can 
elicit both a local and systemic immune response. Dry powder vaccines offer the advantages 
of thermal and physical stability over liquid formulations. Freeze-drying followed by milling 
and spray-freeze-drying are manufacturing processes used to formulate dry powder vaccines. 
Particle size is the most important physico-chemical property of nasal delivery dictating the 
site of deposition in the nasal cavity. Mucoadhesive compounds, such as chitosan and gellan, 
extend the residence time for powder formulations in the nasal cavity, increasing the elicited 
immune response.  
With respect to: (specific aim 1) the manufacture and size characterization of particles 
suitable for the formulation of a WIIV dry powder intranasal vaccine are discussed in the 
following chapter.
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Table 1.1– Nasal drug products approved currently in the United States. 
 
INGREDIENT NAME TRADENAME DOSE UNIT DOSAGE FORM FIRM NAME 
AZELASTINE 
HYDROCHLORIDE ASTELIN NASAL SPRAY 137 MCG SPRAY 
ALLSCRIPTS HEALTHCARE SOLUTIONS, PHYSICIANS TOTAL CARE 
INC, MEDPOINTE PHARMACEUTICALS 
VANCENASE INHALER NASAL 42 MCG SPRAY DRX PHARMACEUTICAL CONSULTANTS BECLOMETHASONE 
DIPROPIONATE BECONASE AQ NASAL SPRAY 42 MCG SPRAY DRX PHARMACEUTICAL CONSULTANTS INC, GLAXOSMITHKLINE CORP, PHYSICIANS TOTAL CARE 
BUDESONIDE RHINOCORT AQUA NASAL SPRAY 32 MCG SPRAY PHYSICIANS TOTAL CARE INC, ALLSCRIPTS HEALTHCARE SOLUTIONS, ASTRA ZENECA 
CALCITONIN MIACALCIN NASAL SPRAY 200 UNT SPRAY NOVARTIS PHARMACEUTICALS CORP, SANDOZ INC, UNIGENE LABORATORY, UPSHER SMITH LABORATORIES 
CROMOLYN SODIUM NASALCROM 40 MG SPRAY PHARMACIA, PHARMEDIX 
CYANOCOBALAMIN NASCOBAL GEL 0.5 %WV GEL SCHWARZ PHARMA, NASTECH PHARMACEUTICAL 
DDAVP SPRAY NASAL 0.1 MG/ML SPRAY 
AVENTIS PHARMACEUTICAL PRODUCTS INC, FERRING 
PHARMACEUTICALS, ARCOLA LABORATORIES, BAUSCH AND 
LOMB, APOTEX, SUN PHARMACEUTICAL 
MINIRIN NASAL SPRAY 0.1 MG/ML SPRAY FERRING PHARMACEUTICALS 
DESMOPRESSIN 
ACETATE 
STIMATE NASAL SPRAY 1.5 MG SPRAY ZLB BEHRING, FERRING PHARMACEUTICALS 
DIHYDROERGOTAMINE 
MESYLATE MIGRANAL NASAL SPRAY 0.5 MG SPRAY NOVARTIS PHARMA AG, VALEANT PHARMACEUTICALS 
EPINEPHRINE ADRENALIN CHLORIDE SOLUTION 1 MG SPRAY MONARCH PHARMACEUTICALS, PARKEDALE PHARMACEUTICALS 
FLUNISOLIDE FLUNISOLIDE NASAL SOLUTION 0.3 MG SPRAY, METERED BAUSCH AND LOMB 
NASALIDE SOLUTION 0.3 MG AEROSOL, SPRAY DRX PHARMACEUTICAL CONSULTANTS, OREAD 
NASAREL SOLUTION NASAL 0.3 MG SOLUTION ELAN BIOPHARMACEUTICALS, PATHEON, IVAX LABORATORIES  FLUTICASONE 
PROPIONATE FLONASE NASAL SPRAY 0.1 %WW SUSPENSION PHYSICIANS TOTAL CARE, GLAXOSMITHKLINE INC, PAR PHARMACEUTICAL 
ATROVENT NASAL SPRAY 21, 42 MCG SPRAY, METERED BOEHRINGER INGELHEIM PHARMACEUTICALS, ROXANE LABORATORIES, APOTEX CORP IPRATROPIUM BROMIDE 
IPRATROPIUM BROMIDE 0.1 %WW SOLUTION APOTEX CORP, BAUSCH AND LOMB, PHYSICIANS TOTAL CARE, ROXANE LABORATORIES, NOVEX PHARMA 
MOMETASONE 
FUROATE NASONEX NASAL SPRAY 50 MCG SPRAY, METERED SCHERING-PLOUGH CORP, PHYSICIANS TOTAL CARE 
MIPIROCIN CALCIUM BACTROBAN NASAL OINTMENT 21.5 MG OINTMENT PHYSICIANS TOTAL CARE 
NAFARELIN ACETATE SYNAREL SOLUTION NASAL  2 MG SOLUTION GD SEARLE LLC, OREAD 
NICOTINE NICOTROL NS SPRAY 10 MG LIQUID ECR PHARMACEUTICALS, PFIZER CONSUMER HEALTHCARE, PHARMACIA AND UPJOHN 
PIRBUTEROL ACETATE MAXAIR INHALER 0.2 MG AEROSOL 3M PHARMACEUTICALS, PHARMEDIX 
SUMATRIPTAN IMITREX NASAL SPRAY 5, 20 MG SPRAY ALLSCRIPTS HEALTHCARE SOLUTIONS, GLAXOSMITHKLINE 
TETRAHYDROZOLINE 
HYDROCHLORIDE TYZINE NASAL SOLUTION 0.5, 1 MG SOLUTION DENISON PHARMACEUTICALS, BRADLEY PHARMACEUTICALS 
TRIAMCINOLONE 
ACETONIDE NASACORT INHALER NASAL 55 MCG SPRAY, METERED ARMSTRONG PHARMACEUTICALS, AVENTIS, GROUP HEALTH 
ZOLMITRIPTAN ZOMIG NASAL SPRAY 5 MG SPRAY ASTRAZENECA PHARMACEUTICALS , MEDPOINTE PHARMACEUTICALS 
Table 1.2– Literature review of therapeutic powders manufactured utilizing a spray-freeze-drying (SFD) process. 
 
ACTIVE INGREDIENT EXCIPIENT(S) NOZZLE TYPE SOLUTION FEED RATE 
ATOMIZATION 
AIR FLOW 
SOLUTION 
CONC 
PARTICLE 
SIZE REF 
Bovine pancreas trypsinogen Mannitol, trehalose, dextran 37500, polysorbate 80 Ultrasonic 3 mL/min Not Available 20% 20-90 µm 
(SONNER, MAA 
ET AL. 2002) 
Poly (lactide-co-glycolide), Zn Two fluid 33-857 L/min 20-331 L/min 20-25 mg/mL 0.2-12.6 µm 
(COSTANTINO, 
FIROUZABADIAN 
ET AL. 2000) 
Poly (lactide-co-glycolide), Zn Two fluid 33-857 L/min 20-331 L/min 20 mg/mL 0.2 µm 
(COSTANTINO, 
FIROUZABADIAN 
ET AL. 2002) 
Poly (lactide-co-glycolide), poloxamer 
188 (Pluronic F68), trehalose Two fluid 33-857 L/min 20-331 L/min 20-25 mg/mL Not Available 
(CARRASQUILLO, 
STANLEY ET AL. 
2001) 
Bovine serum albumin 
 
Trehalose Two fluid 10-15 psi 20-331 L/min 10 mg/mL Not Available 
(CARRASQUILLO, 
CARRO ET AL. 
2001) 
Cetrorelix acetate Lactose Two fluid (d=0.5mm) Not Available 800 L/hr Not Available 2.13-2.32 µm 
(ZIJLSTRA, 
HINRICHS ET AL. 
2004) 
Trehalose dihydrate, sodium phosphate Ultrasonic  (2 W) 3 mL/min Not Available 0.2 µm 3.2-5.2 µm 
(NGUYEN, 
HERBERGER ET 
AL. 2004) Darbopoetin alfa 
Trehalose dihydrate, poly (lactide-co-
glycolide) 50:50 
Ultrasonic  
(2 W) 1.5 mL/min Not Available 0.2 µm 29 µm 
(BURKE, KLUMB 
ET AL. 2004) 
Diphtheria toxoid, tetanus toxoid, hepatitis 
B surface antigen 
Dextran, mannitol, trehalose dihydrate, 
glycine, aluminum phosphate, AlOH Ultrasonic 2 mL/min Not Available Not Available 38-53 µm 
(MAA, ZHAO ET 
AL. 2003) 
Goat anti-human IgG, goat anti-human IgG 
peroxidase 
Poly (DL-lactide-co-glycolide) 50/50,  
PVA, Tween 80, mannitol, trehalose, Zn Ultrasonic 5 ml/min Not Available 8.3% 110-190 µm  
(WANG, CHUA ET 
AL. 2004) 
Influenza subunit or split-virion 
Dextran, mannitol, poloxamer 188 
(Pluronic F68), polysorbate 20, trehalose 
dihydrate 
Ultrasonic  1.5 mL/min Not Available 20-35% 30-60 µm (MAA, AMERI ET AL. 2004) 
Recombinant hemoglobin 
PEG 3350, dextran T500, trehalose, 
mannitol, sucrose. All solutions are in 5 
mM potassium phosphate, 
150 mM NaCl (pH 7.4). 
Ultrasonic (120 
kHz, 2 W) Not Available Not Available Not Available Not Available 
(HELLER, 
CARPENTER ET 
AL. 1999) 
Recombinant human growth hormone Poly (lactide-co-glycolide), Zn Two fluid 217-480 mL/min 24-121 L/min 5 or 20 mg/mL 0.2-4.5 µm 
(Costantino, Johnson 
et al. 2004) 
Recombinant human nerve growth factor Histidine, sodium bicarb, Zn, trehalose, sucrose, mannitol, lactose, pluronic Ultrasonic 5 mL/min Not Available Not Available Not Available 
(Lam, Duenas et al. 
2001) 
Recombinant-derived humanized anti-IgE 
monoclonal antibody, recombinant human 
deoxyribonuclease 
Mannitol, trehalose, sucrose a) Ultrasonic b) Two fluid 
a) 5 mL/min 
b) 15 mL/min 
a) Not Available 
b) 1050 L/hr Not Available 3.3-32 µm 
(Maa, Nguyen et al. 
1999) 
Figure 1.1– Schematic diagram of the nasal cavity showing the location of: A) nostril; B) 
nasal valve; C) olfactory region; D) superior turbinate; E) middle turbinate; F) inferior 
turbinate; and G) adenoids and tonsils. 
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Figure 1.2– Schematic diagram of the nasal epithelium showing location and features of: A) 
ciliated cell; B) non-ciliated cell; C) goblet cell; D) mucus layer; E) periciliary layer; F) basal 
cell; and G) basement membrane. Adapted from (Ugwoke, Verbeke et al. 2001). 
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Figure 1.3– Schematic diagram depicting mucus and periciliary fluid forming a double layer. 
Adapted from (Quraishi, Jones et al. 1998). 
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Figure 1.4– Formulation, droplet/particle and biological factors that affect nasal delivery. 
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Figure 1.5– Factors that affect powder interaction with the nasal mucosa. 
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Figure 1.6– Particle size distributions shown as: a) frequency with respect to particle size, b) 
frequency with respect to the logarithm of particle size, c) probability with respect to the 
logarithm of particle size, and d) probits with respect to the logarithm of particle size. These 
figures illustrate transformations that may be employed to derive statistical descriptors of 
particle size and distribution. 
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Figure 1.7– Schematic diagrams of a) the Andersen eight stage non-viable cascade impactor 
and b) streamline airflow (indicated by arrows) through an orifice impinging on a collection 
surface. 
a) 
      
b) 
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Figure 1.8– Flow diagram of specific aims and their presentation in the dissertation. 
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 2 PARTICLE MANUFACTURE  
2.1 Introduction 
In order to deliver antigen to the nasal mucosa in the form of dry particles, specific 
manufacturing and characterization approaches must be selected. The importance of these 
methods is that they: (a) achieve the desired particle size for nasal delivery; (b) avoid particle 
penetration into the deep lung; (c) result in measurable and reproducible properties, most 
significantly of morphology (shape and surface roughness), size and distribution, and 
stability. To prepare powder for nasal delivery several techniques may be considered. Freeze-
drying (lyophilization), a conventional method for the production of dry powders containing 
materials of biological origin, has been used for the preparation of vaccines for parenteral 
delivery. Spray-freeze-drying (SFD) is a new and, as yet, commercially unproven technique 
for pharmaceutical particle manufacture. The following sections describe each of these 
methods in general and indicate the nature of their adoption for the following experimental 
sections. 
Lyophilization requires two sequential processes to occur, freezing of components in 
solution that will become elements of the final solid product and drying to remove the 
solvent. As mentioned in Section 1.1.10.1, the freezing process greatly affects the outcome of 
the final lyophilized product. A variety of factors that influence the final product 
characteristics can be noted. The effect of freezing rate on a solution has been reported 
(Dawson and Hockley 1992). These studies demonstrated that a solution frozen too slowly 
develops a concentrate that can cause the surface to collapse, and thus, reduce the drying 
speed. In addition to collapsing, rapid freezing causes the sample to be amorphous and 
fibrous. Solute concentration also affects drying time. At higher solute concentration (i.e., 
>10 % solids in solution), the dry product has smaller specific area, and it is more difficult to 
remove the water. Thus, longer times and/or higher temperatures are needed to finish 
secondary drying , which can adversely affect protein stability (Tang and Pikal 2004). 
Annealing has been used to elicit a phase transition in water from amorphous to crystalline as 
a means of controlling the final product morphology (Gatlin 1992). It entails the freezing of a 
solution at a low temperature below the Tg’, or glass transition temperature if all freezable 
water crystallized, followed by slow temperature elevation to just below the melting point 
and holding for a period of time (Oetjen and Haseley 2004). Lyophilization was the first 
manufacturing technique used, in the experiments described in this chapter, to produce dry 
powder particles suitable for nasal delivery. Factors of freezing rate, annealing and solute 
concentration were evaluated in the experimental design. 
Ball milling of powders is a common size reduction method in which particles are 
fractured by the repetitive collision with stainless-steel or ceramic balls or cylinders (milling 
media) (Gennaro and Remington 1995). Total milling time, speed, powder mass, size of mill, 
and number of milling media elements are all important variables for milling and must be 
determined separately for each formulation (Hickey and Ganderton 2001). A faster milling 
speed corresponds to rapid particle size reduction. Typically, the degree of milling reaches a 
plateau and then may decrease due to the creation of aggregates (Hickey and Ganderton 
2001). Milling occurs more slowly for a higher proportion of powder with respect to milling 
media. The media experiences reduced freedom of motion which reduces the energy 
expended in the milling process. The combined effect of milling time and powder load also 
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may be explained by speed of milling since more time is required to mill a larger load of 
powder. Freeze dried powders were milled to produce particles suitable for nasal delivery 
and optimal milling conditions, of time, mass of powder and quantity of milling media, were 
assessed.  
Sieving is a method of obtaining particles of a desired size range from a powder with 
a wide range of particle sizes (Fonner, Banker et al. 1966). Sieves may be used to remove 
smaller particles (<25 um) that may impact negatively the performance of the powder (i.e. 
results in poor flow and mixing properties). It is also used in the separation of large excipient 
particles in designated size ranges that have a variety of flow properties, where larger particle 
size fractions flow well due to decreased particle interactions. In the context of nasal 
delivery, the removal of small particles prevents entry and deposition of particles in the lower 
respiratory tract. Sieving was used to select particles of antigen preparation and excipient in 
sizes suitable for dispersion and deposition in the nose. 
The SFD process requires atomization of droplets which can be achieved by forcing a 
liquid through a nozzle. The liquid and accompanying air pressures, along with the nozzle 
geometry, causes the liquid stream to break into ligaments, which are then further broken 
down into droplets. The size of the droplets formed depends on the liquid flow rate, air 
pressure, spray angle, and liquid properties (surface tension and viscosity). Low liquid or 
high airflow rates and smaller nozzle dimensions generally result in the production of small 
droplets and particles (Masters 1976). SFD was employed in the present studies and each of 
the above factors was studied. 
Effectiveness of particle manufacture is assessed by measuring important 
characteristics of the powder product. Techniques that may be employed include microscopy 
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and optical methods for specifying morphology, particle size and distribution. Moreover, 
these methods can be designated as endpoint measures (responses) in statistically controlled 
experimental designs to allow optimization of the factors in the manufacturing process. 
Methods of representing data from such experiments (half-normal probability plots, 
ANOVA, residual, interaction and cube plots) are described below. 
Scanning electron microscopy (SEM) is a technique capable of producing high-
resolution images of a sample (Martin and Bustamante 1993). SEM images have a 
characteristic three-dimensional appearance and are useful for judging the surface structure 
of particles. SEM can also be utilized to show morphological differences between FD cakes 
manufactured under various conditions (Dawson and Hockley 1992).  
Laser diffraction is one of the most commonly used light scattering methods of 
particle sizing. Particles are passed through a laser (frequently Helium-Neon, 682.3 nm) 
creating a diffraction pattern on a detector array. An algorithm can be used to calculate the 
particle size distribution from this diffraction pattern (Ranucci 1992). It is notable that the 
geometry of the detector array and the algorithm for data presentation vary for each 
instrument manufacturer. The algorithms themselves, which are based on Fraunhofer or Mie 
theory, are considered proprietary. 
The design of experiments is commonly used in the pharmaceutical industry for a 
wide range of applications including the development of solid dosage forms and dispersed 
systems (Gohel and Amin 1998; Deaton, Jones et al. 2002; Smyth, Brace et al. 2006). 
Factorial designs are among the most frequently utilized statistical designs in industry. A 
general factorial design is performed by selecting a fixed number of levels for each of the 
variables (or factors) and running experiments to determine responses for all possible 
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combinations of factors (Box, Hunter et al. 2005). A response is a variable which is measured 
during an experiment and is dependent on the factors in the study. A full or complete 
factorial design, in which the factors are examined in all possible combinations, are best 
suited for studies where the number of factors is not too large. Full factorial designs at two 
levels are the most commonly used designs in the pharmaceutical literature (Box, Hunter et 
al. 2005). 
The target particle morphology, size, and distribution for dry powders for potential 
delivery of whole inactivated influenza virus to humans was spherical (or regular polygonal) 
40µm median diameter with limited quantities of powder below 10 µm (See 1.1.2). The 
target properties for powders to deliver to rats were 25 µm median diameter spherical 
particles. The size was smaller than that for humans because of delivery device limitations. 
Two manufacturing processes were evaluated for their potential to produce particles of 
suitable size and morphology for nasal delivery. The factors affecting freeze-drying (freezing 
rate, solute concentration, and annealing) and spray-freeze-drying (solution feed rate, airflow 
rate, and solute concentration) were optimized using designed experiments. The morphology 
of manufactured cakes and powders and mucoadhesive compounds (MA) were observed 
using scanning electron microscopy and particle size analysis was performed using laser 
diffraction (Figure 2.1).  
Selection of Materials 
Whole inactivated Influenza virus (WIIV) of the H1N1 strain, A/PR/8/34, purchased 
from Charles River SPAFAS (North Franklin, Connecticut; Lot#4PRI000901, 2 mg/ml), was 
used as a liquid preparation as provided by the vendor or prepared as a powder. WIIV was 
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propagated in the allantoic fluid of chicken eggs, purified from a sucrose gradient, 
inactivated by buffered formalin, and re-suspended in HEPES saline.  
D-(+)-trehalose dihydrate (referred to as trehalose, Sigma Chemical Co., St. Louis, 
MO) was used as a cryoprotective agent. Trehalose is a non-reducing sugar formed from two 
glucose units joined by a 1-1 alpha bond. This bonding makes trehalose very resistant to acid 
hydrolysis, and, therefore, stable in solution at high temperatures even under acidic 
conditions. The bonding also keeps non-reducing sugars in closed-ring form, such that the 
aldehyde or ketone end-groups do not bind to the lysine or arginine residues of proteins, 
known as glycation.  
Hydroxypropyl methylcellulose (MW= 10 kD, HPMC LMW or MW= 90 kD, HPMC 
HMW, Sigma), is a cellulose ether as shown in Figure 2.2A. The functional properties of 
HPMC depend on the degree of substitution of the cellulose structure, and on the chain 
length of the cellulose backbone. HPMC is used as an emulsifier, thickening agent, stabilizer, 
and suspending agent. It is a white to off-white fibrous powder which swells in water to 
produce a viscous colloidal solution, non-ionic. HPMC dissolves slowly in cold water and is 
insoluble in hot water. 
Carboxymethylcellulose sodium (MW= 90 kD, CMC LMW or MW= 700 kD, CMC 
HMW, Sigma) is a cellulose derivative with carboxymethyl groups bound to some of the 
hydroxyl groups of the glucopyranose monomers that make up the cellulose backbone as 
shown in Figure 2.2B. The polar carboxyl groups enhance the solubility of the cellulose and 
contribute to chemical reactivity. The functional properties of CMC depend on the degree of 
substitution of the cellulose structure, and on the chain length of the cellulose backbone. 
CMC is used in food science as a viscosity modifier (thickener) and to stabilize emulsions. 
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Sodium alginate (SA, Sigma, 200-400 cps) is the sodium salt of alginic acid (Gennaro 
and Remington 1995) as shown in Figure 2.2C. It is an extract of seaweed and is used as a 
thickener in the food industry and as a gelling agent and emulsifier.  
Chitosan (MW= 161 kD, degree of deacetylation= 92%, donated by Vansen) is a 
linear polysaccharide composed of randomly distributed β-(1-4)-linked D-glucosamine 
(deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit) as shown in Figure 2.2D. 
Chitosan is produced commercially by deacetylation of chitin, which is the structural element 
in the exoskeleton of crustaceans (crabs, shrimp, etc.). The amino group in chitosan has a 
pKa value of ~6.5, thus, chitosan is positively charged and soluble in acidic to neutral 
solution with a charge density dependent on pH and the degree of deacetylation. Chitosan is 
bioadhesive and readily binds to negatively charged surfaces such as mucosal membranes. 
Chitosan enhances the transport of polar compounds across epithelial membranes by opening 
of tight junctions (Artursson, Lindmark et al. 1994) and is biocompatible and biodegradable. 
2.2  Methods 
2.2.1 Particle Manufacture and Powder Preparation 
2.2.1.1 Freeze-Drying Followed By Milling 
Freeze-drying. The factors affecting the FD process were examined using the principles of 
statistical factorial design. Changes in the concentration of the solution (1 and 10%), the 
freezing rate of the solution (slow and fast), and thermal treatment (yes or no) were all 
optimized for the formulation used. Effective initial designed experiments examine a very 
broad range of factors, ensuring capture of the desired response (Wu and Hamada 2000). 
With this in mind, the concentration range was dictated by the upper limit, as previously 
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stated, of 10% solids. The lower limit was set one order of magnitude lower than the upper 
limit. Solutions of the designated concentrations of trehalose in water were prepared. Five 
milliliters of each solution was placed in a 20 mL lyophilization vial. Freezing rates were 
determined by exposing the solutions to different low-temperature conditions. Liquid 
nitrogen was chosen because of its low boiling point (~ -180°C), while the lower limit of 
freezing rate was determined by freezing a solution below its Tg’, which for trehalose is -
30°C. For fast freezing, the lyophilization vials were placed in a tray of liquid nitrogen and 
then transferred to a freeze-dryer (Dura-Stop/Dura-Dry, FTS Systems, Stonebridge, NY) pre-
cooled to -40°C shelf temperature. For the slow freezing, the vials were located on the pre-
cooled shelf for 2 hours. Empty vials were placed around the edge of the shelf and aluminum 
foil was placed over the glass door to reduce thermal effects by radiant energy and heat 
transfer from chamber walls. Annealed samples were prepared by gradually elevating the 
shelf temperature over 6 h to -10°C. Samples underwent a lyophilization cycle in which 
drying was performed at -10°C shelf temperature for 6 h, 0°C shelf temperature for 6 h, 10°C 
shelf temperature for 6 h, 15°C shelf temperature for 6 h, and 20°C for 24 h. The vials were 
stoppered under dry nitrogen at atmospheric pressure, to reduce the potential for oxidation or 
hydrolysis that might impact product stability.  
Particle size reduction. A micro-ball mill (SPEX Certiprep #3117 Metuchen, NJ) was used 
to reduce particle size for small quantities of powder (<300 mg). The mill consists of a 
stainless steel vessel containing a 1/4” steel ball. Optimization of the milling process was 
performed previously (Garmise, Mar et al. 2006). A milling time of 30 minutes with a 
powder load of 150 mg was used. The mini-mill was sealed and mounted on an oscillating 
motor (Variable Speed Jig Saw, Black & Decker Inc., Towson, MD) to provide agitation at 
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200 rpms. To minimize moisture effects, work was completed in a dry box (<20% RH, 22.0 
± 2°C). 
Sieving. Milled powders were sieved with sieve mesh sizes of 45, 75, 125, 180, and 300 μm 
using a 3-inch sieve shaker (Model No. SS-5, Gilson Company Inc., Worthington, OH). The 
sieves were arranged in descending order of mesh size with the 300 μm sieve on top and the 
45 μm sieve on the bottom. A mass ≤10 g of powder was placed on the top sieve and the 
sieve shaker was operated in the tap mode for two hours. Milled FD and bulk MA powders 
were sieved and particles in the 45-125 μm size range were collected. Similar to milling, 
relative humidity was controlled during the sieving runs (<20% RH, 22.0 ± 2°C). 
2.2.1.2 Spray-Freeze-Drying 
The factors affecting the SFD process were examined using the principles of factorial 
design, similar to those employed to develop the FD process. The concentration of the 
solution, the flow rate of the solution, and the atomizing airflow rate were all optimized to 
achieve the desired properties. Similar to FD experiments, the upper limit for solute 
concentration was 10%, while the lower limit was 1%. The maximum rate of solution flow 
for this system was 25 mL/min. The lower level was set at 3 mL/min. Powders produced by 
SFD in the literature were produced utilizing two-fluid nozzles with high airflow rates 
(~1000 L/hr), while producing particles < 10 μm (Costantino, Firouzabadian et al. 2002; 
Costantino, Johnson et al. 2004). The upper limit of the experimental design was set at 500 
L/hr, while the lower limit was set at 250 L/hr to produce larger particles. Aqueous solutions 
containing trehalose were prepared and passed through a spray nozzle (7 mm diameter) from 
a bench top spray-dryer (Büchi Mini Spray-Dryer, B-191, Switzerland) at the desired flow 
rate. Atomizing nitrogen gas, with a fixed back pressure of 1 atm was used to deliver the 
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suspension. When spraying was complete, the frozen droplets in the liquid nitrogen were 
transferred to a glass container to be lyophilized at a fixed manifold temperature (-55°C) and 
pressure (25 mtorr) for 72 hours.  
2.2.2 Particle Morphology of Powders 
Scanning electron microscopy. The powders were adhered to double-sided adhesive carbon 
tabs (Ted Pella Inc., Redding, CA) on aluminum stubs (Ernest F. Fullam, Inc., Latham, NY) 
scanning electron microscopy (SEM). A Polaron sputter coater (model E-5200, Electron 
Beam Services (EBS), Agawan, MA) was used to coat the samples with gold-palladium. A 
scanning electron microscope (JEOL 6300, JEOL Corp., Peabody, MA) was used with an 
electron beam at an acceleration voltage of 15 kV and a working distance of ~25 mm. 
Representative areas of the stub were photographed (n=3). 
2.2.3 Particle Size and Size Distribution of Powders 
Laser diffraction. Each powder was subjected to laser diffraction (Malvern 2600 Series, 
Worcestershire, UK) particle size analysis by a suspension method using a small liquid 
dispersion sample cell. The sample cell has an integral stir bar and a volume of ~15 ml. The 
cuvette was filled with 1% w/w Span 80 (Sigma) in light, white mineral oil (Sigma). Powder 
samples of ~10 mg were dispersed in 2 ml of 1% w/w Span 80 in light, white mineral oil, 
sonicated for five minutes and then placed into the sample cell one drop at a time until a laser 
obscuration between 2 and 30% was achieved (n=3), as recommended by the manufacturer 
for optimal data collection. 
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2.2.4 Experimental Design 
Factorial designs maximize the information gained while minimizing the resources 
used and offer the advantage of exhibiting a high degree of “hidden” replication. Factorial 
designs also provide estimates of possible interactions between each of the factors. With a 
factorial approach, the effects of a single factor are examined for every possible combination 
of the other factors included in the experiment. This effectively maximizes the information 
regarding the influence of various factors in the design and their inter-relationships on the 
designated response(s).  
 Normal and half-normal plots are graphical tools for determining effects in the model 
that are significant. These graphical techniques are not used alone in deciding significant 
effects, but rather are used in conjunction with analysis of variance. A sigmoidal cumulative 
normal curve is generated for a normal distribution by plotting P versus X (an effect), where 
P represents the percentage probability of the occurrence of X (Box, Hunter et al. 2005). 
Plotting the same data on normal probability paper yields a straight line. Data that may be 
explained by random variation around a mean (a near normal distribution) falls on a straight 
line when plotted on a normal probability scale. Points that do not fall on the straight line are 
effects that are not easily explained as chance occurrences, and are considered significant. 
The half-normal plot is employed to make decisions regarding of the observed effects. 
Plotting the cumulative distribution of the set of effects from a 2 factorial experiment on a 
half-normal plot assists in the interpretation of the data by highlighting outliers, 
heteroscedasticity (different variances), dependence of the variance on mean and defective 
randomization with a greater degree of accuracy than a normal plot. In a half-normal plot the 
points of the modified distribution fall on a straight line that passes through the origin. Points 
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that fall off the line are considered large, and their effects distinguished from the rest as 
significant. 
Data from experimental designs employ an analysis of variance (ANOVA). The 
variance associated with a specific independent variable or interactions between independent 
variables is compared with the variance associated with the random error occurring in the 
experiment (Box, Hunter et al. 2005). A variable is considered to have a statistically 
significant effect on the measured response if a difference exists between the treatment and 
error variance. For these experiments, the criterion for significance was P<0.05.  
Plots of residuals (the difference between the observed value and the predicted value 
for the model used) versus predicted values should appear as points randomly scattered 
around a horizontal line, provided the residuals have a mean zero, a constant variance, are 
independent and normally distributed (Box, Hunter et al. 2005). An inadequate model or 
variances that are not constant lead to abnormalities in the scatter pattern, which may be 
corrected by transforming the independent or dependent variable, or by adding additional 
terms to the model. 
Interactions graphs reveal trends in the measured response as the factor varies from 
the lower level to the higher. These graphs plot individual responses as a function of factors 
that have a statistically significant effect on the specified measured response.  
Cuboidal plots are utilized to reveal trends in the data by comparing the lower level 
and higher level factors simultaneously. Factors are plotted on an axis in the x, y, or z 
direction. These plots facilitate data interpretation in identifying significant factors in 
designed experiments. 
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The specific experimental designs for each manufacturing method are shown in 
Tables 2.1 and 2.2. A full 23 factorial design was employed for each of the two methods, FD 
followed by milling and sieving, and SFD. Three replicate batches for each of the conditions 
were prepared. The latter replicates were performed to account for inherent variability. 
2.3 Results and Discussion 
2.3.1 Particle Manufacture and Powder Preparation 
2.3.1.1 Lyophilization Followed by Milling and Sieving 
The freeze-dried material formed white, porous cakes showing slight shrinkage 
(detachment from container walls), but no large-scale collapse was observed.  
2.3.1.2 Spray-freeze-drying 
 The spray-freeze-dried material formed a white, low density, porous powder that 
seemed to flow very easily. 
2.3.2 Particle Morphology of Powders 
Scanning electron micrographs (SEMs) of bulk trehalose fractions are shown at 
various magnifications (Figure 2.3).  Bulk trehalose particles are orthorhombic crystals that 
are heterogeneous in size and cuboidal or needle-like in shape. SEMs of 45-75 µm sieved 
trehalose fractions are shown at various magnifications (Figure 2.4). The sieved trehalose 
particles are polyhedral crystals, rhomboidal in shape, that exhibit a fairly narrow size 
distribution.  
SEMs of mucoadhesive compounds were taken at 60X (Figure 2.5) and 150X (Figure 
2.6) of sieved fractions of HPMC LMW, HPMC HMW, CMC LMW, CMC HMW, chitosan 
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(all 45-75 µm), and SA (45-125 µm). HPMC LMW is a white to off-white powder consisting 
of a mixture of fibrous and granular particles that are heterogeneous in size and shape. 
HPMC HMW, CMC LMW, and CMC HMW are white to off-white powders with fibrous-
shaped particles. Chitosan is an off-white colored powder with granular and needle-like 
particles. SA is a yellow-brown powder consisting of granular particles. Because of the low 
yield of SA particles in the 45-75 µm size range, 45-125 µm sieved fractions were used. 
SEM of lyophilized cakes of 10% trehalose in deionized water are shown at 40X 
(Figure 2.7) and 100X (Figure 2.8) magnification. The pore sizes of the channels through 
which water was removed appear to be larger in the cakes prepared at a slower freezing rate 
than those frozen rapidly.  This is consistent with the literature (Thijssen 1969). The freezing 
rate determines the size of the ice crystals. When the temperature of a solution is decreasing 
at a slow rate, ice crystals will grow first, effectively concentrating the dissolved solute in a 
small volume of solvent. This is termed the freeze concentrate. The size of the ice crystals 
can be estimated from the size of the pores in the dried cake. As the freezing rate is 
increased, a decrease in the mean pore diameter occurs (Thijssen 1969). This is an important 
phenomenon because the pore size dictates the drying rate of the frozen product. When large 
ice crystals are sublimed, the resultant pores in the cake are necessarily large.  
Factors such as concentration of the solution and freezing rate give rise to a highly 
viscous concentrate on freezing. The consequent lowering of the freezing point hinders the 
transition causing an amorphous state representing disorder between the water and the solids 
(Dawson and Hockley 1992). Rapidly frozen samples did not appear to exhibit this 
phenomenon on visual inspection. If a product is frozen too quickly, the concentrated liquid 
is located at the center of the mass, forming an uneven surface and causing a partially 
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collapsed channel during drying. Visual inspection has also verified that the drying time of 
48 hours was sufficient for all of the freeze-dried cakes. 
SEMs of trehalose powder after milling and sieving are shown at 60X (Figure 2.9), 
150X (Figure 2.10), and 600X (Figure 2.11) magnifications of four different FD runs. FD 
followed by milling and sieving produced polydisperse, irregularly shaped particles. These 
particles tended to aggregate after milling. Milling methods generally result in non-spherical 
solid particles with a wider size distribution than spray-drying (Hickey and Ganderton 2001). 
The stability of the points of contact between the particles, which depends on the shape of the 
particles, will influence the blending and dispersion (Podczeck, Newton et al. 1997). 
Elongated particles, such as trehalose, have larger areas of contact and will flow poorly. In 
addition, surface irregularities may increase the amount of mechanical interlocking between 
particles making dispersion more difficult. Frictional heating during the milling must also be 
controlled as it can potentially cause a reduction in the activity of the thermolabile materials 
such as macromolecules or structural components of micro-organisms present in vaccines. A 
slow milling speed was used to minimize the potential for milling to reduce vaccine potency 
(Garmise, Mar et al. 2006).  
SEMs of trehalose powder after SFD are shown at 60X (Figure 2.12) and 150X 
(Figure 2.13) magnifications for four different SFD runs. Particles are spherical and fairly 
homogeneous in size and shape for powders produced by the slower solution feed rate. 
However, the faster solution feed rate produced particles of heterogeneous size and shape. 
Some of the particles were spherical while others were fibrous. As the shape of the particles 
becomes more irregular, the ability of a powder to flow decreases due to increased particle-
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particle interactions correlated with large planar surfaces and increased specific surface areas 
(Ridgway and Rupp 1969).  
2.3.3 Particle Size and Size Distribution of Powders 
Mucoadhesive Compounds 
 Particle sizes of bulk and sieved 45-125 µm sieved fractions of HPMC, CMC, 
chitosan, and SA are shown (Figure 2.14). A sieving step was utilized to remove very large 
(>125 µm) and fine particles (<45 µm) to prevent potential deposition in the lower 
respiratory and enable blending with the manufactured trehalose particles. The bulk HPMC 
powders were composed of predominantly large particles and bulk CMC and SA powders 
contained significant fine particles content that was removed by sieving (Table 2.3). 
Freeze-Drying 
A designed experiment was utilized to evaluate the effect of three selected factors: 
freezing rate; concentration; and annealing on the production of particles of suitable size for 
nasal delivery. The four responses measured, by laser diffraction, were median diameter 
(D50), 90% diameter (D90), 10% diameter (D10), and span ((D90-D10)/D50). The matrix of the 
three factors evaluated, each at two levels with three replicates, is shown (Table 2.1). Values 
of D50 ranged from 10.70 to 28.65 µm, D90 ranged from 22.97 to 89.94 µm, D10 ranged from 
0.97 to 6.95 µm, and span ranged from 1.77 to 3.94 of milled, sieved powders. Particle sizes 
of powders grouped by manufacturing parameters are shown (Table 2.4).  
a) Median Diameter 
The half normal % probability as a function of effect for the D50 of particles produced 
by FD followed by milling and sieving is shown (Figure 2.15). The effects of primary 
variables of freezing rate (A), concentration (B), annealing (C), freezing rate-concentration 
 57
interaction (AB), and confounded variables of freezing rate-annealing interaction (AC), 
concentration-annealing interaction (BC), and freezing rate-concentration-annealing 
interaction (ABC) had a significant effect on D50, as indicated by points deviating from the 
straight line. 
ANOVA confirmed the conclusions drawn from the half normal plots. All of the 
above factors had a statistically significant effect (P<0.05) on D50, with p-values listed below 
(ANOVA tables in Appendix A). 
Factor A B C AB AC BC ABC 
p-value <0.0001 0.0482 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
The residuals plotted versus predicted values for the model describing the effect of 
various factors on median diameter (D50) of powders manufactured by FD followed by 
milling and sieving were randomly distributed (Figure 2.16). The model exhibited a good fit 
with an R2 of 0.99. 
Interaction graphs indicating the effects of a) solute concentration (B-=1%, B+=10%) 
and freezing rate (A-=Slow, A+=Fast), and b) annealing (C-=No, C+=Yes) and freezing rate 
(A-=Slow, A+=Fast) on median diameter (D50) of particles produced by FD followed by 
milling and sieving are shown (Figure 2.17). The effect of solute concentration was 
dependent on freezing rate. At slower freezing rates, a lower concentration of solute 
produced larger median diameters, while at faster freezing rates, a higher concentration of 
solute produced larger median diameters (Figure 2.17a). In the absence of annealing, larger 
median diameters were produced compared to annealed samples, regardless of the freezing 
rate. However, larger particles were produced with a lower freezing rate (Figure 2.17b). 
Interaction graphs indicating the effects of annealing and solute concentration on D50 of 
 58
particles produced by FD followed by milling and sieving show that without annealing 
particles with larger median diameters were produced compared to annealed samples, 
regardless of the concentration. However, larger particles were produced with a lower 
concentration (Figure 2.18). 
A cuboidal plot indicating the effects of freezing rate, solute concentration, and 
annealing on D50 of particles produced by FD followed by milling and sieving is shown 
(Figure 2.19). This plot indicates that to maximize the median diameter within the conditions 
of the experiment, a 1% trehalose solution should be frozen at a slow freezing rate with no 
annealing. 
b) 90% Diameter 
The half normal % probability as a function of effect for the D90 of particles produced 
by FD followed by milling and sieving is shown (Figure 2.20). The effects of freezing rate, 
concentration, annealing, and concentration-annealing interaction had a significant effect on 
D90. 
ANOVA confirmed the conclusions drawn from the half normal plots. All of the 
above factors had a statistically significant effect (P<0.05) on D90, except concentration with 
p-values listed below (ANOVA tables in Appendix A). Concentration was treated as a 
significant effect because it was a factor in an interaction. 
Factor A B C BC 
p-value <0.0001 0.9486 <0.0001 <0.0001 
The residuals plotted versus predicted values for the model describing the effect of 
various factors on D90 of powders manufactured by FD followed by milling and sieving were 
randomly distributed (Figure 2.21). The model exhibited a reasonable fit with an R2 of 0.90. 
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The interaction graph exhibiting the effects of annealing and solute concentration on 
D90 of particles produced by FD followed by milling and sieving show that annealing 
produced smaller D90 compared to samples that are not annealed, regardless of the 
concentration, but smaller D90 were produced with a lower concentration (Figure 2.22). 
A cuboidal plot indicating the effects of freezing rate, solute concentration, and 
annealing on D90 of particles produced by FD followed by milling and sieving is shown 
(Figure 2.23). To minimize the 90% diameter within the conditions of the experiment, a 1% 
trehalose solution should be frozen at a slow freezing rate with annealing. 
c) 10% Diameter 
The half normal % probability as a function of effect for the D10 of particles produced 
by FD followed by milling and sieving is shown (Figure 2.24). The effects of freezing rate, 
concentration, annealing, freezing rate-concentration interaction(AB), freezing rate-annealing 
interaction (AC), concentration-annealing interaction (BC), and freezing rate-concentration-
annealing interaction (ABC) had a significant effect on D10. 
ANOVA confirmed the conclusions drawn from the half normal plots. All of the 
above factors had a statistically significant effect (P<0.05) on D50, with p-values listed below 
(ANOVA tables in Appendix A). 
Factor A B C AB AC BC ABC 
p-value 0.0213 0.0435 <0.0001 <0.0001 <0.0001 0.0026 <0.0001 
The residuals plotted versus predicted values for the model describing the effect of 
various factors on D10 of powders manufactured by FD followed by milling and sieving were 
randomly distributed (Figure 2.25). The model exhibited a good fit with an R2 of 0.96.  
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Interaction graphs indicating the effects of a) solute concentration and freezing rate 
and b) annealing and freezing rate on D10 of particles produced by FD followed by milling 
and sieving are shown (Figure 2.26). The effects of solute concentration was dependent on 
freezing rate. At slower freezing rates, a lower concentration of solute produced a larger D10, 
while at faster freezing rates, a higher concentration of solute produced a larger D10 (Figure 
2.26a). Annealing produced larger D10 compared to unannealed samples, regardless of the 
freezing rate. However, larger particles were produced with a lower freezing rate (Figure 
2.26b). Interaction graphs indicating the effects of annealing and solute concentration on D10 
of particles produced by FD followed by milling and sieving show that no annealing 
produced larger median diameters compared to annealed samples, regardless of the 
concentration (Figure 2.27).  
A cuboidal plot indicating the effects of freezing rate, solute concentration, and 
annealing on D10 of particles produced by FD followed by milling and sieving is shown 
(Figure 2.28). To maximize the 10% diameter within the conditions of the experiment, a 1% 
trehalose solution should be frozen at a slow freezing rate without annealing. 
d) Span
The half normal % probability as a function of effect for the span of particles 
produced by FD followed by milling and sieving is shown (Figure 2.29). The effects of 
freezing rate (A), concentration (B), annealing (C), freezing rate-concentration interaction 
(AB), freezing rate-annealing interaction (AC), concentration-annealing interaction (BC), 
and freezing rate-concentration-annealing interaction (ABC) had a significant effect on span. 
ANOVA confirmed the conclusions drawn from the half normal plots. All of the 
above factors, except concentration, annealing, and concentration-annealing interaction had a 
 61
statistically significant effect (P<0.05) on span, with p-values listed below (ANOVA tables 
in Appendix A). Because concentration, annealing, and concentration-annealing interaction 
were involved in other interations, they were treated as significant effects. 
Factor A B C AB AC BC ABC 
p-value <0.0001 0.4560 0.2080 <0.0001 0.0055 0.3831 <0.0001 
The residuals plotted versus predicted values for the model describing the effect of 
various factors on span of powders manufactured by FD followed by milling and sieving 
were randomly distributed (Figure 2.30). The model exhibited a reasonable fit with an R2 of 
0.92.  
Interaction graphs indicating the effects of a) solute concentration and freezing rate 
and b) annealing and freezing rate on span of particles produced by FD followed by milling 
and sieving are shown (Figure 2.31). The effect of solute concentration is dependent on 
freezing rate. While a higher concentration of solute doesn’t change the span at different 
freezing rates, a lower concentration of solute produces a smaller span at slower freezing 
rates (Figure 2.31a). The effect of annealing is dependent on freezing rate. No annealing 
produced smaller spans compared to annealed samples at the lower freezing rate. However, 
smaller spans were produced with annealing at a faster freezing rate (Figure 2.31b). An 
interaction graph indicating the effects of annealing and solute concentration on the span of 
particles produced by FD followed by milling and sieving show that annealing and 
concentration do not affect each other (Figure 2.32). 
A cuboidal plot indicating the effects of freezing rate, solute concentration, and 
annealing on D50 of particles produced by FD followed by milling and sieving is shown 
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(Figure 2.33). To maximize the span within the conditions of the experiment, a 1% trehalose 
solution should be frozen at a slow freezing rate with annealing. 
Optimization 
The SEM images of the freeze-dried and milled particles indicate that they are not 
spherical. While some are have multiple planes of symmetry (may be considered regular 
polygonal) many are elongated and exhibit surface asperities. 
 The target median diameter of a human formulation was 40 µm. However, based on 
the factors examined in these experiments and the milling method previously optimized, the 
D50 ranged from 10.70 to 28.65 µm, which is well below the targeted particle size. Also, the 
D10 ranged from 0.97 to 6.95 µm, which is well below 10 µm, indicating that a significant 
percentage of the powder could potentially deposit in the lower respiratory tract. 
Additionally, the heterogeneous shape of the milled particles is unsuitable for blending with 
MA.  
The factors that must be taken into account for the FD process are shown (Figure 
2.34). The correlation coefficients of the D50, D90, D10, and span were all above 0.90, 
indicating at least a reasonable fit, with the D50 and D10 exhibiting a very good fit. This is 
indicative that all factors were taken into account in the production of these particles. 
Because the process space is limited by the categorical variables (freezing rate and 
annealing) and the continuous variable has been maximized to prevent protein degradation, it 
would not be practical to produce nasal particles, with the defined specification above, for 
delivery to humans by this method.  
From the known deposition characteristics for particles in the rat nasal cavity the 
particles were required to be larger than 5 µm. It is important that little or none of the powder 
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is smaller than 5 µm, since lung deposition might be possible. It is known that particles 
smaller than 10 µm tend to aggregate which results in poor flow and non-uniform dispersion 
(Hickey 2003). Consequently, to take advantage of the opportunity to deposit smaller 
particles in the nose of rats than would be suitable for humans the target range is 10 – 40 µm. 
Therefore, the target median diameter of a powder for delivery to rats was 25 µm. Based on 
the factors examined in these experiments, the optimized run conditions to produce the target 
particles was 10% trehalose solution, frozen at the slow freezing rate, without annealing, 
lyophilized, milled at 200 rpms for 30 minutes, and sieved in tap mode for 2 hours. 
Spray-Freeze-Drying 
A designed experiment was utilized to evaluate the effect of three selected factors 
defined as, solution flow rate, atomization airflow rate, and solute concentration on the 
production of particles of suitable size for nasal delivery. The four responses measured were 
D50, D90, D10, and span. These sizes were determined by laser diffraction. The matrix of the 
three factors evaluated, each at two levels with three replicates, is shown in Table 2.2. Values 
of D50 ranged from 15.76 to 50.92 µm, D90 ranged from 24.42 to 181.67 µm, D10 ranged 
from 4.13 to 13.63 µm, and span ranged from 1.28 to 3.39 of milled, sieved powders. Particle 
sizes of powders grouped by run parameters are shown (Table 2.5). The D50, D90, and D10 are 
directly proportional to the solution feed rate.  This is consistent with the literature (Masters 
1976). An increase in the flow rate of the liquid through the nozzle will increase the droplet 
size produced. An increase in spraying pressure will reduce droplet size. An increase in the 
spray angle will reduce droplet size. Greater energy is required to break up high viscosity and 
surface tension liquids, resulting in the formation of a larger droplet size. 
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a) Median Diameter
The half normal % probability as a function of effect for the D50 of particles produced 
by SFD is shown (Figure 2.35). The effects of solution feed rate (A) and airflow (B) had a 
significant effect on D50 as indicated by points deviating from the straight line. 
ANOVA confirmed the conclusions drawn from the half normal plots. All of the 
above factors had a statistically significant effect (P<0.05) on D50, with p-values listed below 
(ANOVA tables in Appendix A). 
Factor A B 
p-value <0.0001 0.0100 
The residuals plotted versus predicted values for the model describing the effect of 
various factors on D50 of powders manufactured by SFD were randomly distributed (Figure 
2.36). The model exhibited a fit of R2 of 0.85.  
A cuboidal plot indicating the effects of solution feed rate (A-=3 mL/min, A+=25 
mL/min), airflow rate (B-=250 L/hr, B+=500 L/hr), and solute concentration (C-=1%, 
C+=10%) on D50 of particles produced by SFD is shown (Figure 2.37). To maximize the 
median diameter within the conditions of the experiment, a solution should be pumped at a 
high solution feed rate and atomized with a low airflow. 
b) 90% Diameter
The half normal % probability as a function of effect for the D90 of particles produced 
by SFD is shown (Figure 2.38). The effects of solution feed rate (A) and airflow (B) had a 
significant effect on D90. 
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ANOVA confirmed the conclusions drawn from the half normal plots. All of the 
above factors had a statistically significant effect (P<0.05) on D90, with p-values listed below 
(ANOVA tables in Appendix A). 
Factor A B 
p-value <0.0001 0.0036 
The residuals plotted versus predicted values for the model describing the effect of 
various factors on D90 of powders manufactured by SFD were randomly distributed (Figure 
2.39). The model exhibited a fit of R2=0.78. 
 A cuboidal plot indicating the effects of solution feed rate, airflow rate, and solute 
concentration on D90 of particles produced by SFD is shown (Figure 2.40). To minimize D90 
within the conditions of this experiment, use a 10% solution of trehalose at 3 mL/min with an 
airflow rate of 500 L/hr. 
c) 10% Diameter
The half normal % probability as a function of effect for the D10 of particles produced 
by SFD is shown (Figure 2.41). The effects of solution feed rate (A), airflow (B), solute 
concentration (C), and the solution feed rate-airflow interaction (AB) had a significant effect 
on D10. 
ANOVA confirmed the conclusions drawn from the half normal plots. All of the 
above factors had a statistically significant effect (P<0.05) on D10, with p-values listed below 
(ANOVA tables in Appendix A). 
Factor A B C AB 
p-value <0.0001 0.4560 0.2080 <0.0001 
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The residuals plotted versus predicted values for the model describing the effect of 
various factors on D10 of powders manufactured by SFD were randomly distributed (Figure 
2.42). The model exhibited a fit of R2 of 0.81.  
An interaction graph indicating the effect of solute concentration and freezing rate on 
D10 of particles produced by SFD is shown (Figure 2.43). Both the lower and higher solute 
concentrations produce larger D10 at the faster solution feed rate than the slower solution feed 
rate, but the D10 of the higher solute concentration is larger.  
A cuboidal plot indicating the effects of solution feed rate, airflow rate, and solute 
concentration on D10 of particles produced by SFD is shown (Figure 2.44). To maximize D10 
within the conditions of this experiment, use a 10% solution of trehalose at 25 mL/min with 
an airflow rate of 500 L/hr. 
d) Span
The half normal % probability as a function of effect for the span of particles 
produced by SFD is shown (Figure 2.45). The effects of solution feed rate (A), airflow (B), 
solute concentration (C), and the solution feed rate-airflow interaction (AB) had a significant 
effect on span. 
ANOVA confirmed the conclusions drawn from the half normal plots. All of the 
above factors had a statistically significant effect (P<0.05) on span, with p-values listed 
below (ANOVA tables in Appendix A). 
Factor A B C AB 
p-value <0.0001 <0.0001 0.0002 0.0078 
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The residuals plotted versus predicted values for the model describing the effect of 
various factors on span of powders manufactured by SFD were randomly distributed (Figure 
2.46). The model exhibited a fit of R2 of 0.84.  
An interaction graph indicating the effects of solute concentration and freezing rate 
on the span of particles produced by SFD is shown (Figure 2.47). Both the lower and higher 
solute concentrations produce a smaller span at the slower solution feed rate than the faster 
solution feed rate, but there is no difference at the lower flow rate between the two solute 
concentrations.  
A cuboidal plot indication the effects of solution feed rate, airflow rate, and solute 
concentration on the span of particles produced by SFD is shown (Figure 2.48). To minimize 
span within the conditions of this experiment, use a 10% solution of trehalose at 3 mL/min 
with an airflow rate of 500 L/hr.
Optimization 
The target D50, of 40 µm particles for human application, falls within the limits 
determined by these experiments, the factors needed to produce the target powder can be 
determined statistically. Based on the factors examined in these experiments, the optimized 
run conditions to produce the target particles is a 4.96% trehalose solution, pumped at 20.60 
mL/min, with an atomization airflow rate of 296.29 L/hr, and lyophilized (Figure 2.49). 
Because the solute concentration did not have a significant effect on D50, 10% solute 
concentration was used to maximize the cryoprotective properties of trehalose. Also, because 
of the lack of sensitivity of the equipment, a 20 mL/min solution feed rate and an atomization 
airflow rate of 300 L/hr were used. The predicted responses of these conditions and the actual 
data from three separate runs performed under these conditions are shown (Table 2.6a). 
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There is good agreement between the predicted and actual parameters. SEMs of the 40 µm 
SFD for human use formulation at 60X, 150X, and 600X magnification are shown (Figure 
2.50). Spherical, porous particles were produced. The 40 µm SFD trehalose particles had 
regions of porosity and surface coating. The surface coating is a result of solvent evaporation 
during the atomization process and removal of solvent during the lyophilization process. 
Small particles can be seen on the surfaces of the larger particles that could potentially enter 
the lower respiratory tract, if inhaled. A particle size distribution, plotted as the relative 
frequency as a function of particle size is shown (Figure 2.51). A mode is present at ~40 µm. 
This plot also indicates the presence of particles <10 µm. Particles with a low density, such 
as porous particles, are more easily fluidized than solid particles of the same diameter 
(Dunbar, Hickey et al. 1998). Therefore, porous particles with geometric diameters suitable 
for nasal delivery may, with suitably low density, enter the lungs. A sieving step may be 
necessary to remove these particles for clinical purposes. 
SEMs of SFD particles show that spherical, porous particles were produced (Figure 
2.52). Similar to the 40 µm SFD trehalose particles, the 25 µm SFD trehalose particles 
exhibited areas of surface coating. The optimized run conditions to produce the target particle 
size, of 25 µm for delivery to rats, was a 6.05% trehalose solution, pumped at 8.33 mL/min, 
with an atomization airflow rate of 485.58 L/hr, and lyophilized (Figure 2.53). Ten percent 
solute concentration was used to maximize the cryoprotective properties of trehalose because 
the solute concentration did not have a significant effect on D50. Also, because of the lack of 
sensitivity of the equipment, a 10 mL/min solution feed rate and an atomization airflow rate 
of 500 L/hr were used. The predicted responses of these conditions and the actual data from 
three separate batches performed under these conditions are shown (Table 2.6b). There is 
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good agreement between the predicted and actual parameters. A particle size distribution, 
plotted as the relative frequency as a function of particle size is shown (Figure 2.54). Modes 
are present at about 4, 10, 20, and 40 µm.  
Powders containing WIIV were produced under the conditions for the 25 µm SFD 
powders for use in rats. Particle size analysis, performed by laser diffraction, was performed 
to determine if the addition of the WIIV had an effect on the size of the particles. The particle 
size of the 25 µm SFD powder was 24.92 µm, with a standard deviation of 3.24 µm. This 
was not significantly different than the particles produced under the same conditions with 
trehalose alone.  
One area of concern is the values and range of the coefficient of variations (R2, ~0.78 
– 0.85) for the SFD designed experiments. These modest fits suggest that not all variables 
were taken into account when describing the process space of the system (Figure 2.55). Some 
variables were not addressed in these experiments as they were presumed to be constant. 
They include: tubing used in the peristaltic pump, pump rate, nozzle diameter, height of 
nozzle above liquid nitrogen, freeze-drying and ambient conditions. While the nozzle 
diameter was not altered (and might be assumed constant under ambient conditions), there 
were limitations on accuracy and precision associated with holding other variables constant. 
For example, since the tubing diameter of the peristaltic pump is fixed, variable flow rate is 
achieved by increasing the linear velocity of the fluid which requires variable rotation speed 
of the pump. It is not clear that the efficiency of the pump is consistent at all flow rates due to 
potential responses of changes in tubing properties and pump characteristics under different 
conditions. The nozzle height was determined based on its proximity to the liquid nitrogen 
avoiding freezing solution and blocking the nozzle. At heights higher than the one utilized, 
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the loss of material was substantial. Clearly, this qualitative estimate of height to the surface 
is subject to variability. The FD conditions are controlled but will be susceptible to some 
variability based on actual control and accuracy and precision of temperature gauges 
(manufacturer’s specification unavailable). Ambient conditions were monitored (T= 23 ± 
2°C, 40 ± 5%RH) but not controlled. 
2.4  Summary 
 Designed experiments examining three factors (freezing rate, solute concentration, 
and annealing for freeze-drying and solution feed rate, atomization airflow rate, and solute 
concentration for spray-freeze-drying) in a full 23 factorial design were used to produce 
particles suitable for nasal delivery. The four responses measured, by laser diffraction, were 
median diameter (D50), 90% diameter (D90), 10% diameter (D10), and span. The goal of these 
experiments was the production of particles for potential human use (target D50=40 µm, all 
particles greater than 10 µm) and particles to be used in rat studies (target D50=25 µm). 
Freeze-drying followed by milling and sieving produced particles below the targeted 
particle size for human delivery. Also, a significant percentage of the powder was in a size 
range that could potentially deposit in the lower respiratory tract. The heterogeneous shape of 
the milled particles was not ideal for blending. Subsequent blending with MA particles was 
intended. Particles prepared for delivery to rats, were produced with appropriate size 
characteristics under conditions of 10% trehalose solution, freezing at the slow freezing rate, 
without annealing, lyophilized, milled at 200 rpms for 30 minutes, and sieved in tap mode for 
two hours. However, the irregular shape and likelihood of poor blending properties resulted 
in this method being discarded in favor of the SFD method. 
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An optimized SFD run of 10% trehalose, a 20 mL/min solution feed rate and an 
atomization airflow rate of 300 L/hr was used to produce particles for human delivery with a 
D50=38.5 µm. Also, an optimized spray-freeze-drying run of 10% trehalose, a 10 mL/min 
solution feed rate and an atomization airflow rate of 500 L/hr was used to produce particles 
for rat delivery with a D50=26.9 µm. These powders were further characterized with respect 
to: (specific aim 1) in vitro, physico-chemical and dispersion properties (Chapter 3); (specific 
aim 1) the physico-chemical properties of MA and their influence on residence time in the 
nasal cavity of the rat (Chapter 4) and; (specific aim 2) immunogenicity of a dry powder 
whole inactivated influenza virus (WIIV) vaccine following nasal delivery to rats (Chapter 
5).  
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Table 2.1– Median diameter (D50), 90% diameter (D90), 10% diameter (D10), and span values 
obtained by laser diffraction for each freeze-drying (FD) run evaluating the effects of three 
factors: freeze rate, solute concentration, and annealing. 
 
Std 
Order 
Run 
Order 
Freeze 
Rate 
Solute 
Concen. 
(g/100mL)
Annealing D50(µm) 
D90 
(µm) 
D10 
(µm) Span 
10 1 Fast 10.00 No 19.84 59.73 5.78 2.72 
23 2 Fast 10.00 Yes 22.95 59.15 6.49 2.29 
6 3 Fast 1.00 No 23.35 87.42 5.67 3.50 
9 4 Slow 10.00 No 19.92 47.00 6.00 2.06 
1 5 Slow 1.00 No 27.78 66.74 6.66 2.16 
15 6 Slow 1.00 Yes 10.67 22.97 3.97 1.78 
20 7 Slow 10.00 Yes 11.01 38.68 0.97 3.24 
18 8 Fast 1.00 Yes 10.74 45.12 2.76 3.94 
24 9 Fast 10.00 Yes 23.46 56.24 6.38 2.39 
4 10 Fast 1.00 No 22.29 75.13 5.54 3.27 
8 11 Slow 10.00 No 19.69 44.89 5.86 1.98 
19 12 Slow 10.00 Yes 11.06 40.36 2.94 3.28 
16 13 Fast 1.00 Yes 12.06 48.91 2.81 3.82 
11 14 Fast 10.00 No 20.49 63.23 5.90 3.86 
2 15 Slow 1.00 No 28.49 65.57 6.95 2.06 
12 16 Fast 10.00 No 21.79 89.94 5.83 2.80 
13 17 Slow 1.00 Yes 10.81 23.24 4.05 1.77 
7 18 Slow 10.00 No 19.92 45.89 5.92 2.01 
17 19 Fast 1.00 Yes 10.97 42.18 2.73 3.60 
21 20 Slow 10.00 Yes 11.04 39.15 2.94 3.38 
14 21 Slow 1.00 Yes 10.70 22.97 4.06 1.77 
3 22 Slow 1.00 No 28.65 70.28 6.38 2.23 
5 23 Fast 1.00 No 21.67 78.41 5.49 3.21 
22 24 Fast 10.00 Yes 22.91 62.59 6.56 2.18 
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Table 2.2– Median diameter (D50), 90% diameter (D90), 10% diameter (D10), and span ((D90 
D10)/D50) values obtained by laser diffraction for each spray-freeze-drying (SFD) run 
evaluating the effects of three factors: solution feed rate, airflow, and solute concentration. 
 
Std 
Order 
Run 
Order 
Solution 
Feed Rate 
(mL/min) 
Atomiz. 
Flow 
(L/hr) 
Solute 
Concen 
(g/100 mL) 
D50
(µm) 
D90 
(µm) 
D10 
(µm) Span 
7 1 3.00 500.00 1.00 15.82 33.55 4.13 1.85 
10 2 25.00 500.00 1.00 39.72 90.08 10.8 2.00 
2 3 3.00 250.00 1.00 21.60 46.37 4.96 1.92 
22 4 25.00 500.00 10.00 38.63 85.29 13.63 1.85 
3 5 3.00 250.00 1.00 20.72 43.44 4.99 1.86 
4 6 25.00 250.00 1.00 44.97 115.37 8.34 2.38 
1 7 3.00 250.00 1.00 20.63 44.01 4.85 1.90 
12 8 25.00 500.00 1.00 39.43 90.84 10.71 2.03 
14 9 3.00 250.00 10.00 20.80 37.91 5.21 1.57 
16 10 25.00 250.00 10.00 42.79 102.73 9.51 2.18 
9 11 3.00 500.00 1.00 16.95 34.46 4.47 1.78 
23 12 25.00 500.00 10.00 38.62 80.65 13.47 1.74 
17 13 25.00 250.00 10.00 42.22 98.50 9.05 2.12 
5 14 25.00 250.00 1.00 50.92 181.67 9.10 3.39 
13 15 3.00 250.00 10.00 37.78 72.04 9.83 1.65 
6 16 25.00 250.00 1.00 50.44 158.58 9.23 2.96 
15 17 3.00 250.00 10.00 26.39 48.94 9.08 1.51 
11 18 25.00 500.00 1.00 40.19 89.36 10.81 1.95 
20 19 3.00 500.00 10.00 22.12 39.99 8.95 1.40 
19 20 3.00 500.00 10.00 15.76 24.42 4.26 1.28 
18 21 25.00 250.00 10.00 43.54 115.55 9.74 2.43 
21 22 3.00 500.00 10.00 29.26 53.10 10.05 1.47 
8 23 3.00 500.00 1.00 22.46 40.25 5.71 1.55 
24 24 25.00 500.00 10.00 39.22 82.46 13.52 1.76 
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Table 2.3– Particle sizes of bulk and sieved 45-125 µm sieved fractions of hydroxypropyl 
methylcellulose (HPMC), carboxymethylcellulose sodium (CMC), sodium alginate (SA), and 
chitosan (Mean (SD), n=3). 
 
Powder D50 (µm) D90 (µm) D10 (µm) Span 
Bulk 69.66 (1.53) 149.27 (1.93) 15.54 (0.23) 1.92 (0.06) HPMC LMW 
Sieved 61.63 (0.73) 137.48 (6.43) 14.57 (0.24) 1.99 (0.08) 
Bulk 78.82 (3.97) 184.60 (15.13) 17.57 (0.88) 2.12 (0.08) HPMC HMW 
Sieved 63.82 (1.37) 146.09 (8.07) 15.13 (0.20) 2.05 (0.09) 
Bulk 39.01 (0.28) 63.28 (2.04) 8.59 (0.12) 1.40 (0.04) CMC LMW 
Sieved 60.87 (2.71) 152.31 (73.58) 20.72 (0.83) 2.13 (1.07) 
Bulk 23.31 (2.11) 36.75 (3.47) 5.29 (0.20) 1.35 (0.03) CMC HMW 
Sieved 63.94 (2.49) 185.34 (6.30) 19.96 (0.31) 2.59 (0.11) 
Bulk 32.90 (1.10) 50.01 (4.07) 5.61 (1.47) 1.29 (0.05) SA 
Sieved 124.25 (6.35) 214.76 (7.77) 53.69 (1.90) 1.30 (0.15) 
Bulk 62.60 (1.37) 104.64 (0.69) 19.94 (0.29) 1.36 (0.02) Chitosan 
Sieved 108.24 (2.03) 198.92 (15.24) 35.39 (0.31) 1.51 (0.14) 
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Table 2.4– Particle sizes of milled and sieved freeze-dried (FD) trehalose by laser diffraction 
(Mean (SD), n=3). 
 
Freezing 
Rate Annealing 
Solute 
Concen. 
(g/100mL) 
D50 (µm) D90 (µm) D10 (µm) Span 
Slow No 10 19.84 (0.13) 45.93 (1.06) 5.93 (0.07) 2.02 (0.04) 
Slow Yes 1 10.73 (0.07) 23.06 (0.16) 4.03 (0.05) 1.77 (0.01) 
Slow No 1 28.31 (0.46) 67.53 (2.45) 6.66 (0.29) 2.15 (0.09) 
Slow Yes 10 11.04 (0.03) 39.40 (0.87) 2.28 (1.14) 3.30 (0.07) 
Fast No 1 22.44 (0.85) 80.32 (6.36) 5.57 (0.09) 3.33 (0.15) 
Fast Yes 10 23.11 (0.31) 59.33 (3.18) 6.48 (0.09) 2.29 (0.11) 
Fast No 10 20.71 (0.99) 70.97(16.52) 5.84 (0.06) 3.13 (0.64) 
Fast Yes 1 11.26 (0.71) 45.40 (3.37) 2.77 (0.04) 3.79 (0.17) 
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Table 2.5– Particle sizes of spray-freeze-dried (SFD) trehalose by laser diffraction (Mean 
(SD), n=3). 
 
Flow Rate 
(mL/min) 
Atomization 
Flow Rate 
(L/hr) 
Solute 
Conc. 
(g/100 
mL) 
D50 (µm) D90 (µm) D10 (µm) Span 
3 250 1 21.41 (2.46) 44.56 (5.57) 5.44 (1.01) 1.83 (0.06) 
3 250 10 28.32 (8.66) 52.96 (17.42) 8.04 (2.48) 1.58 (0.07) 
3 500 1 18.41 (3.55) 36.09 (3.64) 4.77 (0.83) 1.72 (0.16) 
3 500 10 22.38 (6.75) 39.17 (14.36) 7.75 (3.07) 1.38 (0.10) 
25 250 1 48.78 (3.31) 151.87 (33.65) 8.89 (0.48) 2.91 (0.51) 
25 250 10 42.85 (0.66) 105.59 (8.88) 9.43 (0.35) 2.24 (0.16) 
25 500 1 39.78 (0.38) 90.09 (0.74) 10.77 (0.06) 1.99 (0.04) 
25 500 10 38.82 (0.34) 82.80 (2.34) 13.54 (0.08) 1.78 (0.06) 
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Table 2.6– Comparison of predicted parameters and data (n=3) of a) human formulation 
(target D50= 45 µm) and b) rat formulation (target D50= 25 µm) using conditions determined 
by design of experiment software. 
 
a) Predicted formulation for human use parameters 
Factor Name Level 
A Sol.Feed Rate 20.00 
B Airflow 300.00 
C Sol. Conc 10.00 
 
Parameter Predicted Value 
Actual Value 
(Mean) 
Actual Value 
(Std. Dev) 
D50 39.62 38.5 2.3 
D90 100.97 93.7 11.5 
D10 10.18 10.7 0.8 
Span 2.08 2.2 0.20 
 
 
b) Predicted formulation for rat use parameters 
 
Factor Name Level 
A Sol. Feed 10.00 
B Airflow 500.00 
C Sol. Conc. 10.00 
 
Parameter Predicted Value 
Actual Value 
(Mean) 
Actual Value 
(Std. Dev) 
D50 26.21 26.9 2.9 
D90 50.33 44.5 2.1 
D10 9.31 11.1 2.2 
Span 1.47 1.3 0.16 
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Figure 2.1– The process flow for the manufacture of freeze-dried (FD) and spray-freeze-
dried (SFD) powders. 
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Figure 2.2– The structures of A) hydroxypropyl methylcellulose (HPMC), B) 
carboxymethylcellulose sodium (CMC), C) chitosan (Chit), and D) sodium alginate (SA). 
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Figure 2.3– Scanning electron micrographs of bulk trehalose at A) 60X magnification, B) 
150X magnification, C) 600X magnification, and D) 1500X magnification. 
 
 
 
 81
Figure 2.4– Scanning electron micrographs of 45-75 µm sieved trehalose at A) 60X 
magnification, B) 150X magnification, C) 600X magnification, and D) 1500X magnification. 
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Figure 2.5– Scanning electron micrographs (60X magnification) of 45-75 µm sieved 
fractions of A) HPMC LMW, B) HPMC HMW, C) CMC LMW, D) CMC HMW, and E) 
Chit  and 45-125 µm sieved fraction of F) SA. 
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Figure 2.6– Scanning electron micrographs (150X magnification) of 45-75 µm sieved 
fractions of A) HPMC LMW, B) HPMC HMW, C) CMC LMW, D) CMC HMW, and E) 
Chit and 45-125 µm sieved fraction of F) SA. 
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Figure 2.7– Scanning electron micrographs (40X magnification) of lyophilized cakes of 10% 
trehalose in deionized water by A) slow freeze, no annealing, B) fast freeze, annealing, C) 
fast freeze, no annealing, and D) slow freeze, annealing. 
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Figure 2.8– Scanning electron micrographs (100X magnification) of lyophilized cakes of 
10% trehalose in deionized water by A) slow freeze, no annealing, B) fast freeze, annealing, 
C) fast freeze, no annealing, and D) slow freeze, annealing. 
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Figure 2.9– Scanning electron micrographs (60X magnification) of milled lyophilized cakes 
of A) 10% trehalose, slow freeze, no annealing, B) 1% trehalose, fast freeze, no annealing, 
C) 1% trehalose, slow freeze, annealing, and D) 10% trehalose, fast freeze, annealing. 
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Figure 2.10– Scanning electron micrographs (150X magnification) of milled lyophilized 
cakes of A) 10% trehalose, slow freeze, no annealing, B) 1% trehalose, fast freeze, no 
annealing, C) 1% trehalose, slow freeze, annealing, and D) 10% trehalose, fast freeze, 
annealing. 
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Figure 2.11– Scanning electron micrographs (600X magnification) of milled lyophilized 
cakes of A) 10% trehalose, slow freeze, no annealing, B) 1% trehalose, fast freeze, no 
annealing, C) 1% trehalose, slow freeze, annealing, and D) 10% trehalose, fast freeze, 
annealing. 
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Figure 2.12– Scanning electron micrographs (60X magnification) of SFD particles of A) 
10% trehalose, 500 L/hr, 25 mL/min, B) 10% trehalose, 500 L/hr, 3 mL/min, C) 1% 
trehalose, 500 L/hr, 3 mL/min, and D) 1% trehalose, 250 L/hr, 25 mL/min. 
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Figure 2.13– Scanning electron micrographs (150X magnification) of SFD particles of A) 
10% trehalose, 500 L/hr, 25 mL/min, B) 10% trehalose, 500 L/hr, 3 mL/min, C) 1% 
trehalose, 500 L/hr, 3 mL/min, and D) 1% trehalose, 250 L/hr, 25 mL/min. 
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Figure 2.14– Particle size distributions of A) hydroxypropyl methylcellulose (HPMC LMW), 
B) HPMC HMW, C) carboxymethylcellulose (CMC LMW), D) CMC HMW, E) chitosan 
(Chit), and F) sodium alginate (SA). 
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Figure 2.15– The half normal % probability as a function of effect for the median diameter 
(D50) of particles produced by FD followed by milling and sieving. 
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Figure 2.16– Cuboidal plot indicating the effects of freezing rate (A-=Slow, A+=Fast), solute 
concentration (B-=1%, B+=10%), and annealing (C-=No, C+=Yes) on median diameter 
(D50) of particles produced by FD followed by milling and sieving. 
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Figure 2.17– The half normal % probability as a function of effect for the 90% diameter 
(D90) of particles produced by FD followed by milling and sieving. 
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Figure 2.18– Cuboidal plot indicating the effects of freezing rate (A-=Slow, A+=Fast), solute 
concentration (B-=1%, B+=10%), and annealing (C-=No, C+=Yes) on 90% diameter (D90) of 
particles produced by FD followed by milling and sieving. 
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Figure 2.19– The half normal % probability as a function of effect for the 10% diameter 
(D10) of particles produced by FD followed by milling and sieving. 
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Figure 2.20– Cuboidal plot indicating the effects of freezing rate (A-=Slow, A+=Fast), solute 
concentration (B-=1%, B+=10%), and annealing (C-=No, C+=Yes) on 10% diameter (D10) of 
particles produced by FD followed by milling and sieving. 
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Figure 2.21– The half normal % probability as a function of effect for the span of particles 
produced by FD followed by milling and sieving. 
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Figure 2.22– Cuboidal plot indicating the effects of freezing rate (A-=Slow, A+=Fast), solute 
concentration (B-=1%, B+=10%), and annealing (C-=No, C+=Yes) on span of particles 
produced by FD followed by milling and sieving.  
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Annealing
A- A+
B- 
B+ 
C-
C+
 2.15 
 1.77333
 2.01667 
 3.3
 3.32667
 3.78667
 3.12667
 2.28667
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Figure 2.23– Diagram showing factors that must be taken into consideration for freeze-
drying. 
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Figure 2.24– The half normal % probability as a function of effect for the median diameter 
(D50) of particles produced by SFD. 
A: Sol. Feed  
B: Airflow 
C: Sol. Conc. Half Normal % probability 
Effect
0.00 5.01 10.02 15.03 20.03 
0 
20 
40 
60 
70 
80 
85 
90 
95 
97 
99 
A 
B
 
 
 
 102
Figure 2.25– Cuboidal plot indicating the effects of solution feed rate rate (A-=3 mL/min, 
A+=25 mL/min), airflow rate (B-=250 L/hr, C+=500 L/hr), and solute concentration (C-
=1%, C+=10%) on median diameter (D50) of particles produced by SFD. 
Sol. Feed  
Airflow 
Sol. Conc.
A- A+
B- 
B+ 
C-
C+
 20.9833 
 28.3233
 18.41 
 22.38 
 48.7767
 42.85
 39.78
 38.8233
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Figure 2.26– The half normal % probability as a function of effect for the 90% diameter 
(D90) of particles produced by SFD. 
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Figure 2.27– Cuboidal plot indicating the effects of solution feed rate (A-=3 mL/min, A+=25 
mL/min), airflow rate (B-=250 L/hr, C+=500 L/hr), and solute concentration (C-=1%, 
C+=10%) on 90% diameter (D90) of particles produced by SFD. 
Sol. Feed  
Airflow 
Sol. Conc.
A- A+
B- 
B+ 
C-
C+
 44.6067 
 52.9633
 36.0867 
 39.17 
 151.873
 105.593
 90.0933
 82.8
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Figure 2.28– The half normal % probability as a function of effect for the 10% diameter 
(D10) of particles produced by SFD. 
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Figure 2.29– Cuboidal plot indicating the effects of solution feed rate (A-=3 mL/min, A+=25 
mL/min), airflow rate (B-=250 L/hr, C+=500 L/hr), and solute concentration (C-=1%, 
C+=10%) on 10% diameter (D10) of particles produced by SFD. 
Sol. Feed  
Airflow 
Sol. Conc.
A- A+
B- 
B+ 
C-
C+
 4.93333 
 8.04 
 4.77 
 7.75333 
 8.89
 9.43333
 10.7733
 13.54
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Figure 2.30– The half normal % probability as a function of effect for the span of particles 
produced by SFD. 
A: Sol. Feed  
B: Airflow 
C: Sol. Conc. 
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Figure 2.31– Cuboidal plot indicating the effects of solution feed rate (A-=3 mL/min, A+=25 
mL/min), airflow rate (B-=250 L/hr, C+=500 L/hr), and solute concentration (C-=1%, 
C+=10%) on span of particles produced by SFD. 
Sol. Feed  
Airflow 
Sol. Conc.
A- A+
B- 
B+ 
C-
C+
 1.89333 
 1.57667 
 1.72667 
 1.38333 
 2.91
 2.24333
 1.99333
 1.78333
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Figure 2.32– Plot of airflow versus solution feed rate to identify run conditions to produce 
formulation for human use (target D50= 40 µm). 
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Figure 2.33– Scanning electron micrographs of spray-freeze-dried (SFD) formulation for 
human use at A) 60X magnification, B) 150X magnification, and C) 600X magnification. 
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Figure 2.34– Particle size distribution of spray-freeze-dried (SFD) trehalose for human use. 
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Figure 2.35– Scanning electron micrographs of SFD formulation for use in rats at A) 60X 
magnification, B) 150X magnification, C) 600X magnification, and D) 1500X magnification. 
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Figure 2.36– Plot of airflow versus solution feed rate to identify run conditions to produce 
formulation for use in rats (target D50= 25 µm). 
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Figure 2.37– Particle size distribution of spray-freeze-dried (SFD) trehalose for use in rats. 
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Figure 2.38– Diagram showing factors that must be taken into consideration for spray-freeze-
drying. 
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3 PHYSICO-CHEMICAL CHARACTERIZATION 
3.1 Introduction 
Nasal powders are best characterized in terms of particle morphology, size, and 
distribution as described in the previous chapter.  There are, however, a number of other 
physico-chemical characteristics of a these particles that may be quantified. They include: 
flow properties to quantify particle-particle interactions; surface area of the particles a 
measure of porosity and factor in dissolution; solid-state characteristics of the particles; 
powder moisture content; temperature and humidity which influence the physical stability; 
and the dispersion properties of the vaccine formulation as it relates to efficient delivery. 
One method to assess potential for powder flow is to measure the bulk and tapped 
densities. The bulk density is the mass of a powder divided by the volume prior to packing. 
The tapped density is equal to the mass divided by the volume of the powder after it has been 
tapped until no further decreases in volume occur (Carr 1965). The Carr’s compressibility 
index (CCI) is parameter for quantifying the powder flow and is defined as (Carr 1965): 
100% x 
Density Tap
DensityBulk Density TapCCI ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −=   (3.01)   
As powder flow improves, the bulk density approaches the tap density and any further 
tapping will not cause a decrease in volume. Therefore, as the CCI decreases to 0%, powder 
flow improves as particle interactions decrease (Carstensen 1993).  
 When a powder is poured onto a surface from a fixed height, it forms a cone. The 
angle formed by the cone to the horizontal surface can be calculated and is known as the 
static angle of repose (Crowder 2003). This angle is another measure of the potential flow 
properties of a powder. As the static angle of repose increases, powder flow decreases. The 
static angle of repose has been stated to be an indirect measure of particle size, shape, 
porosity, cohesion, fluidity, surface area, and bulk (Carr 1965). 
 The surface area of a particle can be computed by direct calculation from the particle 
size distribution data or by measurement of the amount of a gas adsorbed onto a sample of 
powder to form a monolayer (Martin and Bustamante 1993). The latter technique is most 
accurate and relevant to further applications. When a mixture of nitrogen and helium 
(typically 30% nitrogen) are passed through a cell containing the powder, adsorption and 
desorption of nitrogen gas are measured with a thermal conductivity detector. At low 
pressures, the volume of nitrogen gas that adsorbs to a given mass of powder increases 
linearly until a monolayer of nitrogen is formed. The Brunauer-Emmett- Teller (BET) allows 
for the calculation of this volume and is described as: 
⎟⎟⎠
⎞
⎜⎜⎝
⎛−+=− 00
)1(1
)( P
P
CV
C
CVPPV
P
mm
    (3.02) 
where V is the volume of nitrogen adsorbed, P is the pressure, P0 is the saturation vapor 
pressure of liquid nitrogen, Vm is the volume of gas required to form a monolayer at normal 
temperature and pressure, and C is a constant related to the difference between the heat of 
vaporization of a monolayer and the heat of vaporization of liquid nitrogen (Crowder 2003). 
Vm and C can be determined graphically by the linear plot of P/(V(P0-P)) against P/P0. When 
C is large (i.e. the heat of adsorption is higher than the heat of vaporization), the slope of the 
plot is equal to 1/Vm. This allows for a single point measurement to determine surface area, 
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assuming that the gas forms a monolayer over the powder, which is not unreasonable for 
nitrogen (Brunauer, Emmett et al. 1938). The specific surface area is the surface area per 
gram of the sample (Martin and Bustamante 1993).  
Differential scanning calorimetry (DSC) is a method of monitoring phase transitions 
that occur when the temperature of a material is increased (Martin and Bustamante 1993). 
The glass transition temperature (Tg) of a material is the temperature at which a supercooled 
noncrystalline liquid existing below its crystallization temperature (amorphous state) 
converts to a glass. The amorphous state and its glass are metastable and kinetically-
dependent transitions. Tg is usually applicable to completely or partially amorphous 
powders, such as lyophilized powders. Above Tg, the material (eg. protein, polymer, 
phosholipid bilayer, sugars, inorganic molecules) becomes rubbery, lacking long-range order 
and capable of elastic or plastic deformation without fracture. To assure long-term stability of 
the virus in the dried solid formulation, the Tg of the lyophilized solid-state material must 
exceed the planned storage temperature, such that the solid-state material exists in the glassy 
state (having low molecular mobility) rather than in the amorphous state which has a higher 
molecular mobility, and hence, greater physical and chemical reactivity and instability 
(degradation) (Carpenter, Pikal et al. 1997). 
Moisture content measurement involves monitoring the weight change of a material 
after heating. It is useful in the measurement of moisture content, since any water present in 
the material can result in loss of activity of proteins (loss of H-bonds which maintain the 
active conformation) or can affect the structural stability of the powder (Chang, Reeder et al. 
1996). Water weight will be lost during heating allowing percent weight loss of the material 
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to be calculated. When used together, moisture content analysis and DSC allow for a 
determination of the stability of the materials in different temperature ranges (Brittain 1995).  
Forces of interaction must be considered when developing dry powder formulations. 
Interparticulate forces can be influenced by particle properties and properties of the 
surrounding medium (Baron and Willeke 2001). As the size of the particles decreases, 
surface area increases and there may be greater contact between individual particles (Hickey 
and Ganderton 2001). Therefore, surface area plays a crucial role in the degree of particle 
interactions. The forces of attraction that can exist between particles include van der Waals 
forces, electrostatic forces, and capillary forces (Mullins, Michaels et al. 1992). The force 
necessary to detach a particle from a surface can be measured by subjecting particles to a 
centrifugal force perpendicular to the surface and determining the speed of rotation required 
to detach the particle (Clarke, Peart et al. 2002). In the aerodynamic method, the velocity of 
air required to remove a certain percentage of monodisperse particles from a surface is 
measured. An impact energy apparatus was previously developed to enable characterization 
of the amount of energy required to remove particles from a hard surface (Concessio 1997; 
Concessio, Van Oort et al. 1998). The process utilizes microscopy, for particles > 10µm in 
median diameter, to size the particles remaining on the surface after successive strikes with a 
hammer applied by rotation of a pendulum.  
The use of cascade impactors for particle size characterization has been previously 
discussed (1.1.9). The flow rates of air through the impactor stages effectively characterize 
deposition of particles in the respiratory tract. Current methods to determine in vitro 
deposition of nasal sprays utilizing the cascade impactor involve using a “short stack” (stages 
0, 1, 2, and filter, (Suman, Laube et al. 2002; Newman, Pitcairn et al. 2004)) with a 2L 
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expansion chamber. However, there is currently no well established method in place to 
characterize deposition of particles greater than about 10 µm. At aerodynamic diameters of 
up to 20 µm, as much as 10% of the particles could potentially enter the respiratory tract, 
leading to potential toxicity problems (Bates, Fish et al. 1966). Significant pulmonary 
deposition can occur for nasal preparations that have a large quantity of particles with small 
aerodynamic diameters (<5 µm). The Food and Drug Administration (FDA) requires proof 
that when a nasal preparation is delivered, it does not penetrate to the lungs (FDA 2003). 
However, in vitro approaches to characterizing respirable particles were limited and did not 
account for the full range of sizes that might potentially deposit in the lungs. Radionuclide 
imaging is commonly performed to satisfy this requirement by showing deposition in the 
nasal cavity, but none in the lung (Newman, Steed et al. 1995). This process can be very 
costly. An in vitro system would be ideal for predicting the potential for deposition of a nasal 
formulation in the pulmonary region. A modified Andersen Mk II non-viable cascade 
impactor was calibrated (Appendix A.3) and was used to characterize potential deposition 
into the lower respiratory tract. 
In the following sections, powder physico-chemical properties of bulk/tapped density, 
angle of repose, thermal, surface area, moisture content analyses and dispersion 
characteristics with respect to bulk and spray-freeze-dried (SFD) trehalose and mucoadhesive 
compounds (MA) are described.  
3.2 Methods 
3.2.1  Bulk/tapped density  
The bulk and tapped densities were determined for sieved fractions of trehalose, bulk 
and sieved MA, and SFD powders (n=3). Approximately 10 mL of powder was employed to 
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conduct each measurement by pouring into a graduated cylinder (Martin and Bustamante 
1993).  
3.2.2  Static angle of repose 
Measurements of the static angle of repose were conducted for sieved fractions of 
trehalose, bulk and sieved MA, and SFD powders (n=3). Approximately 10 mL of powder 
was poured through a glass funnel (7cm diameter entry reducing, over a distance of 5 cm, to 
a 1.5 cm diameter vertical tube 3 cm in length) onto a flat collection surface where the angle 
to the horizontal was measured (Carstensen 1993). 
3.2.3  Surface Area 
Single-point surface area analysis was performed on sieved trehalose (1.5-1.75 g) and 
SFD (0.5-0.75 g) powders (Quantasorb Jr., Quantachrome Corp., Boynton Beach, FL). 
Accurately weighed samples were degassed under vacuum at 60°C for 5 hours with nitrogen 
followed by repetitive adsorption and desorption of the adsorbate, 30% nitrogen in helium 
gas. 
3.2.4 Moisture Content 
Moisture content determination was conducted (Mettler LJ16 Moisture Analyzer, 
Mettler-Toledo, Columbus, OH). Each sample was loaded onto an aluminum tray coating the 
bottom with a thin layer of powder. The initial powder weight was recorded. The powder was 
then heated to 150°C and the final weight of the powder was measured accurately and 
precisely, using a moisture balance (n=3). The difference between the final and initial 
powder weight was the water content in the sample and it was recorded as a percent of the 
total weight. 
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3.2.5 True Density 
 True density measurements were conducted with a helium pycnometer 
(Ultrapycnometer, Quantachrome Instruments, Boynton Beach, FL.) on bulk trehalose and 
SFD powders ((Martin and Bustamante 1993), n=3).  
3.2.6 Thermal Analysis 
 Differential scanning calorimetry (Perkin Elmer DSC 6, Wellesley, MA) was 
performed on powder samples. Known quantities of powder were sealed in an aluminum pan 
and differences in heat flow were measured against an empty pan. SFD powders were 
pretreated at 60°C for 5 hours. Analysis was performed between 50 and 250°C at a ramp rate 
of 10°C per minute for bulk and SFD trehalose and between 50 and 220°C at a ramp rate of 
5, 10, 20, and 40°C per minute for MA. 
3.2.7 Physical Stability 
WIIV of the H1N1 strain, A/PR/8/34 (Charles River SPAFAS, North Franklin, CT), 
was propagated in the allantoic cavity of SPF eggs, purified from sucrose gradient, 
inactivated by formaldehyde, and resuspended in Hepes-saline at a concentration of 2 mg H 
/mL. The hemagglutination assay (HA) titer for the WIIV, as provided by the manufacturer, 
was 1:131,072 for 0.05 mL. Liquid preparation of whole inactivated influenza virus from the 
vendor was diluted to 2 μg H/25 μL with sterile saline and sealed in 1.7 mL centrifuge tubes. 
About 5 mg total 25 µm SFD powder for rat use containing 5 µg H/5 mg trehalose was 
packed into each capsule and sealed in a vial. Vials containing liquid or powder samples 
were stored in the following conditions: 37°C and 80% RH, 23°C and 40% RH, 4°C and 
50% RH. Samples were taken at different time points for determination of HA titers for up to 
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12 weeks. Two samples were taken from each storage condition at defined time points. 
Powder was reconstituted with saline to 1 mg influenza virus/mL, based on H content. The 
HA titers of each formulation at different time points were compared to the week 0 sample 
(without storage) of the same formulation and the percentage change in HA titer was taken as 
an indicator of sample stability. All samples were analyzed in duplicate. Fifty μL of double 
serial diluted inactivated influenza virus samples were added to wells containing 50 μL of 
0.5% chicken red blood cells (Charles River SPAFAS) and incubated at RT for 1 hr for the 
HA assay. The endpoint HA titer was defined as the reciprocal of the highest influenza 
vaccine dilution showing complete hemagglutination of chicken red blood cells.  
3.2.8 Impact Energy Separation 
An impact force particle dispersion device was developed previously (Concessio 
1997). The instrument was constructed of stainless steel, and consisted of a pendulum 
arranged with a hammer head at one end capable of impinging on a vertically mounted 
sapphire disc, 20mm in diameter and 2mm thick (Tech. Spec. sapphire windows, Edmund 
Scientific, Industrial Optics Div., Barrington, NJ). Three different hammer head weights of 
35, 45, and 55g were utilized to increase the hammer load. The sieved trehalose or SFD 
powder to be evaluated was thinly coated on the sapphire disc which was tilted to pour off 
the excess powder. This resulted in a uniform coating of the sapphire disc. The coating was 
achieved by virtue of the adhesive forces exhibited by the particles. The disc was carefully 
placed into the slot and subjected to an impact by the pendulum hammer head. Photographs 
were taken after each impact by a digital camera (Nikon CoolPix 5000, Nikon, Corp., Japan) 
mounted onto a light microscope (Leica Corp., Ernst-Leitz-Strasse, Germany). Image 
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analysis software (ImageJ, U. S. National Institutes of Health, Bethesda, Maryland) was used 
to determine the median diameter of particles remaining on the surface.   
3.2.9 Modified Cascade Impactor 
Powder dispersion was performed by fluorescent labeling SFD human trehalose by 
preparing a 0.05% blend with micronized disodium fluorescein. A monodose insufflator 
(MDS, Miat Corp., Milan, Italy) and a specialized powder delivery device developed by 
BDT (Becton Dickinson Technologies, Research Triangle Park, NC), described in (Huang, 
Garmise et al. 2004), but with a modified nozzle for human delivery were characterized using 
a calibrated, modified Andersen MKII non-viable cascade impactor (Graseby Andersen, 
Smyrna, GA), described in Appendix 3, with a one-liter inlet port (Figure 3.1). Dispersion 
properties were studied at a flow rate of 15 L/min (n=5). The collection plates were coated 
with 1% silicon oil (Fisher Scientific, Fair Lawn, NJ) in hexane (Sigma-Aldrich, St Louis, 
MO). Glass fiber filters with a pore size of 0.22 μm (Graseby Andersen, Smyrna, GA) were 
used below the last stage of the impactor. Gelatin capsules (size 3, Capsugel Inc., Peapack, 
NJ) were filled with 5 mg of the blend. A vacuum pump was used to draw air through the 
impactor at 15 L/min. Following piercing of each capsule, sampling was continued for 10 
seconds. The device and collection plates were washed with known quantities of phosphate 
buffer (pH 7.4). Samples were analyzed using a spectrofluorometer (Chameleon Plate 
Reader, Hidex Oy, Turku, Finland) operated at an excitation wavelength of 500 nm and 
emission wavelength of 550. A standard curve was prepared with disodium fluorescein 
concentrations ranging from 0-100 ng/mL in phosphate buffer.  
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3.3 Results and Discussion 
3.3.1 Bulk/tapped density 
Flow properties are a manifestation of the action of cohesive (and adhesive in 
mixtures) forces acting on a powder. In these experiments, manufacturing conditions were 
optimized for producing particles of the desired size (~40 µm for use in humans and ~25 µm 
for use in rats), not for flow properties. However, the flow properties do affect the 
performance of the final product. The bulk (0.1-0.2 g/mL) and tapped (0.1-0.3 g/mL) 
densities of the SFD powders were significantly lower than bulk trehalose (Table 3.1, 0.5 and 
0.6 g/mL, respectively). The bulk and tap densities of the MA were similar to sieved 
trehalose (Table 3.2). The bulk and tap densities (0.7-0.9 g/mL and 0.9-1.0 g/mL, 
respectively) of SA were much larger than any of the other MA. 
Large cohesive forces acting on a powder, result in poor flow properties and render it 
easily compressible (i.e. the higher the CCI). A free-flowing powder has a CCI less than 
~20% to 21% (Carr 1965). The 40 µm SFD use and sieved trehalose (~20-23%) had lower 
CCIs than the SFD rat trehalose (~36%). Based on CCI, the 40 µm SFD powder was the only 
one considered free-flowing. Bulk and sieved fractions of SA and chitosan (~9, 16, 21, and 
21, respectively) were the only MA to be considered free-flowing. 
3.3.2 Static angle of repose 
A large static angle of repose is indicative of large cohesive forces within the powder. 
As a guide, powders with static angles of repose less than 40° are considered to be free-
flowing powders; with angles greater than 50°, the powders flow poorly or not at all (Carr 
1965). Tables 3.1 and 3.2 show the angles of repose for each of the powders studied. The 
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static angle of repose of 25 µm SFD (~36°) was larger than the 40 µm SFD and sieved 
trehalose (~20-23°), but all three powders are regarded as free-flowing. All of the MA were 
considered free-flowing with the exception of sieved CMC HMW (~43°), bulk chitosan 
(~41°), and sieved chitosan (~40°). 
The ability of a powder to flow is one of the factors that affect the mixing of different 
materials to form a powder blend and is influenced by particle size, size distribution, shape, 
surface texture, surface energy, chemical composition, moisture content, and other factors 
(Staniforth 2002). This may be important for the blending of the virus and excipient with the 
mucoadhesive compound. Also, because nasal delivery requires a fluidization of the powder 
bed, it is conceivable that flow properties of powders could affect the emitted dose from the 
device and delivery of the vaccine to the nasal cavity. 
The CCI and static angles of repose of the powders did not always agree with regards 
to which powders had a better ability to flow. The CCI identified both the bulk and sieved 
fractions of chitosan as free-flowing, while the static angle of repose results differed. This 
has been seen in the literature (Li, Rudolph et al. 2004). One potential reason for this 
occurrence is the adhesive forces of the chitosan to the graduated cylinder are greater that the 
energy put into the system by tapping, making it seem as if there is little difference between 
the bulk and the tapped densities. A majority of the powders did not flow well based on CCI, 
but did flow well based on static angle of repose. This was seen in all of the powders with 
fibrous shapes seen in SEM. The shape of these particles could have played a role in the 
differences between the bulk and tapped densities. Bulk and sieved fractions of SA exhibited 
good flow in both methods. Particle shape may also play a role due to their proximity to 
being spherical. CMC HMW did not flow well in either method. 
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3.3.3 Surface Area 
 The specific surface area of the powders was measured using nitrogen adsorption 
(Table 3.1). The specific surface area of the SFD powders (~1.2-1.7 m2/g) was significantly 
greater than the bulk, sieved trehalose (~0.5 m2/g). This is consistent with the literature (Maa, 
Nguyen et al. 1999; Costantino, Firouzabadian et al. 2000; Yu, Johnston et al. 
2006).Surprisingly, the specific surface area of the 40 µm SFD formulation was greater than 
the specific surface area of the 25 µm SFD formulation. One potential explanation for this is 
that the 25 µm SFD formulation had a large proportion of its particles spherical, while the 40 
µm SFD, though a majority of the particles were spherical, a substantial number were opened 
spheres and irregularly shaped particles. 
3.2.4 Moisture Content 
The moisture contents of the trehalose powders are shown in Table 3.1. Moisture 
content was low in SFD powders because of the lyophilization process. Lyophilized powders 
generally have 3-5% moisture present. The sieved trehalose, as a dihydrate, has greater 
moisture content (~10%) than the SFD powders (2.5-5.5%). The moisture contents of HPMC 
LMW and HPMC HMW (3-5%) were significantly lower than the other MA (>10%, Table 
3.2). 
3.3.5 True Density 
 The true density of the powders was measured using helium pycnometry. The true 
density of 25 µm SFD, 40 µm SFD, bulk trehalose, SFD were 1.5237 ± 0.0560 , 1.5750 ± 
0.2168, and 1.5381 ± 0.0151 g/mL, respectively. The SFD process did not alter the true 
density of the starting material. 
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3.3.6 Thermal Analysis 
Thermal scans of SFD powders and bulk trehalose are shown in Figure 3.2. In order 
to establish the characteristic Tg associated with the SFD amorphous solids, the powder had 
to be treated to remove the moisture. Consequently, powders were held at 60°C for 5 hours. 
The peaks of interest of the SFD powder are the Tg at 117°C, a crystallization peak at 174°C, 
and a sharp melting peak at 214°C. The results obtained, and shown in Figure 3.2, are 
consistent with that in the literature (Surana, Pyne et al. 2004). Bulk trehalose dehydrate 
exhibited a sharp peak at 100°C, indicating the removal of surface moisture. At ~120°C, the 
bound water of crystallization was removed from the trehalose dihydrate. The melting peak 
can be seen at 214°C. These curves indicate the production of an amorphous powder by SFD. 
The relatively high Tg indicate that the trehalose should be stable under normal handling 
conditions. 
 Thermal scans of the HPMC LMW (Figure 3.3) and HPMC HMW (Figure 3.4) were 
completed and exhibited a glass transition at 170°C (very subtle in HMW). The HPMC 
LMW degrades at 275°C, while the HPMC HMW degrades at 330°C, which is expected due 
to the increase in the molecular weight. CMC LMW (Figure 3.5) and CMC HMW (Figure 
3.6) were examined. They both underwent an exothermic reaction at 290°C and 315°C. This 
is believed to be a thermal gelling phenomenon followed by disintegration. SA (Figure 3.7) 
demonstrated removal of water at 100°C and degradation at 200°C. Chitosan (Figure 3.8) 
exhibited water loss at 100°C and degraded at 310°C. All MA appeared stable under the 
normal handling conditions of a dry powder nasal product. 
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3.3.7 Physical Stability 
A functional stability test of the vaccine was conducted. Vials containing liquid or 
powder samples were stored under the following conditions: 4°C and 50% RH, 23°C and 
40% RH, 37°C and 80% RH, which were as close to standard conditions of refrigeration, 
room and accelerated storage (5 ± 3°C, 25 ± 2°C and 60 ± 5% RH, 40 ± 2°C and 75 ± 5% 
RH, (FDA 2003)) as was possible with existing equipment. Samples were taken at different 
time points for determination of HA titers for up to 12 weeks. Experiments were run in 
duplicate to allow for more time points due to a limited amount of the high-cost WIIV. The 
HA titers of each formulation at different time points were compared to week 0 sample 
(without storage) of the same formulation and percentage change in HA titer was taken as an 
indicator of sample stability (Figure 3.9). At 4°C and 50% RH, powder vaccine retained 
100% of HA activity for the duration of the 12 weeks. However, the HA activity of the liquid 
formulation under these conditions dropped to 75% after week 2. Similarly, at 23°C and 40% 
RH, the powder vaccine retained 100% of HA activity, whereas the HA activity of the liquid 
dropped to 50% at week 2 and was further reduced to 25% of pre-storage levels at week 8. 
The powder formulation showed a drop in stability over time under the accelerated storage 
conditions (37°C and 80% RH). Under these conditions HA activity was reduced to 75% of 
pre-storage levels by week 2 and 50% by week 4, decreasing to only 6.25% of activity 
remaining by week 12. Nonetheless, the powder formulation was still more stable than the 
corresponding liquid, which lost 100% of activity by week 8. These results demonstrate that 
the vaccine storage stability exhibited by the powder formulation is improved with respect to 
liquid.  
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The high Tg and low moisture content (< 3%) of the trehalose are two important 
factors in the increased stability of the powder formulation. To assure the long-term stability 
of a biological macromolecules, particularly proteins and peptides, as a dried solid, the Tg of 
the amorphous phase must exceed the planned storage temperature (Pikal 1994; Carpenter, 
Pikal et al. 1997). Since water is a plasticizer of the amorphous phase, low residual moisture 
is needed to ensure stability (Carpenter and Chang 1996). The Tg of ~117°C far exceeds the 
maximum storage temperature that a powder product would experience. The loss of activity 
seen under accelerated conditions may be explained by the large surface area of the SFD 
trehalose particles. Greater stability might be achieved by optimization, with control of 
surface area as an objective in a designed experiment.   
3.3.8 Impact Energy Separation 
Microscopy was utilized to characterize the size and distribution of particles detached 
from the impaction surface as a function of impact energy (Table 3.3). The size of which 
84% of particles are less than (D84) remaining on the sapphire disc following impact 
decreased with the logarithm of increasing impact energy, as shown in Figure 3.10. Smaller 
particles were detached by the heavier hammer weights, resulting in a smaller D84 for all of 
the powders up to impact energies of 20 mJ. At energies greater than that, the D84 increased, 
indicating the formation of aggregates and particles from areas above the field of view 
detaching but reattaching at a lower point. Similar trends were observed for all powders 
evaluated by microscopy. The sample to sample variability was much greater for the bulk 
sieved trehalose than either of the SFD powders after impacts greater than 20 mJ. This may 
be due to the needle-like shape of the bulk sieved trehalose compared to the spherical shape 
of the SFD powders. Particle geometry has been shown to have an effect on adhesion when 
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comparing cylindrical and spherical particles (Mullins, Michaels et al. 1992). The increased 
contact area could result in a greater probability of the particles reattaching to the sapphire 
disc after detachment.  
Figure 3.11 shows the D84 of sieved trehalose, 25 µm SFD, and 40 µm SFD particles 
remaining on a sapphire disc as a function of impact energy applied by a pendulum for the 
first four strikes of the pendulum. At impact energies of 5.0 and 11.1 mJ, the D84 of particles 
remaining for 25 µm SFD was significantly greater than the sieved trehalose and 40 µm SFD 
particles (P<0.05). The slope of the best fit line of the sieved and 40 µm SFD trehalose 
particles were similar, while the slope of the 25 µm SFD was much steeper. This is in 
agreement with the other flow properties of these powders. The 25 µm SFD had a greater 
CCI and static angle of repose than the sieved and 40 µm SFD trehalose powders. 
3.3.9 Modified Cascade Impactor 
There is interest in needle-free approaches using small, convenient, unit-dose delivery 
systems to facilitate mass vaccination (Giudice and Campbel 2006). The development of 
devices for dry powder nasal vaccine formulations has recently been discussed in detail 
(Sullivan, Mikszta et al. 2006). Particle delivery systems require characterization by relevant 
sizing methods. An inertial impaction method, designed to sample and size particles 
dispersed in air, would be a valuable tool in determining potential for particles to deposit in 
the nasal cavity and the fraction of the powder, in various size ranges, that would pass 
through this region and enter the lungs. The latter component is undesirable as the lungs are 
not the intended route of administration and may be the site of potential toxicity. Inertial 
impactors, operated under conventional conditions, do not sample particles above 10 µm but 
it is known that substantial quantities of particles in the 10-20 µm size range can deposit in 
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the lungs when inhaled through the nose. Since the impactor arrangement (stages employed 
and operating flow rate) requires particles >10 µm but < 20 µm (Bates, Fish et al. 1966)) to 
be sampled the instrument required calibration under the new conditions. Extensive 
experiments, involving the delivery of monodisperse aerosols, (Vibrating Orifice Aerosol 
Generator, Model 3450, TSI, Inc., Shoreview, MN) were conducted to map the collection 
efficiency curve (≥9 particle sizes, n=3) for each of the three stages of the impactor under 
defined sampling airflow conditions (15 L/min). These experiments are described in 
Appendix 2. 
The mass of particles entering the impactor should be equivalent to the total mass of 
particles from each collection surface. However, this is rarely the case because not all 
particles impact on the collection surfaces. Mass balance may not be achieved, as some 
particles will not be recovered. These particles are commonly referred to as wall or inter-
stage losses (Vaughn 1989). If these losses exceed 5%, the USP recommends that they be 
included with the associated collection surfaces (USP 2006). Initial experiments completed 
using the modified cascade impactor yielded a recovery of ~70% of the entering mass. It was 
determined that the solid center portion of the Stage -2 orifice plate was collecting a 
significant number of particles. Experiments were repeated, but the center of that orifice plate 
was coated, using the same method as that for the collection plates and washed separately 
with a known volume of phosphate buffer (pH 7.4). Recovery then increased to 99.9 ± 7.2%. 
The dispersion properties of the 40 µm SFD formulation from both the MDS and 
BDT devices are shown (Figure 3.12). There were no significant differences between the 
mass fractions of powder collected on any portion of the modified cascade impactor. 
Approximately 50% of powder was collected in the inlet device, while no other stage 
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collected greater than 20%. A significant amount of powder (~15%) was recovered from the 
orifice plate for Stage -2. Less than 10% of the powder was collected on Stage -2, Stage -0, 
or the filter.  
The recovered mass was adjusted for the amount of powder that left the device 
(Figure 3.13). There were no significant differences between the emitted dose (ED) fractions 
of powder collected on any portion of the modified cascade impactor. Over 60% of powder 
was collected in the inlet device, while no other stage collected greater than 20%. A 
significant amount of powder (~20%) was recovered from the orifice plate for Stage -2. 
Approximately 10% of the powder was collected on each of Stage -2, and the filter, while < 
10% was collected on Stage -0.  
The ED and lung dose fraction (LDF) are shown in Table 3.4. The LDF is the mass 
fraction of powder collected below the Stage -2. It represents the mass that could potentially 
enter the lower respiratory tract. There were no significant differences between the ED and 
LDF when comparing the two devices. This indicates that the dispersion properties of these 
devices are similar. 
The use of a blended fluorescent label assumes that the shear on the particles upon 
dispersion is insufficient to separate the micronized fluorescein from the SFD trehalose. 
Inspection of the data (Figure 2.48, Chapter 2) shows that the fraction of the 40 µm SFD 
trehalose in the micron size range (0.22-12µm, those particles collected on the filter), as 
determined by laser diffraction was ~11%. This is approximately the same percentage of 
particles collected by the MCI with the fluorescein particles. Dissociation of micronized 
fluorescein from the trehalose particle would result in larger filter deposition than would be 
predicted by laser diffraction. 
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3.4 Summary 
Powders manufactured by SFD, bulk trehalose, and MA were characterized. Bulk and 
tap densities, and the static angle of repose were measured to quantify the powders’ potential 
ability to flow, which may be important for blending the virus and excipient with the 
mucoadhesive compound and subsequent powder dispersion. The surface area of the SFD 
powders was measured to assess the available surface and the extent of porosity. True density 
measurements were performed on bulk and SFD trehalose to determine if any changes to 
material density occurred during the SFD process. The moisture content and thermal analysis 
was performed to indicate the temperature at which physical transformations occur. Liquid 
and SFD powder vaccine formulations were stored for 12 weeks under a variety of 
temperatures and relative humidities to assess the stability of the formulations. Two devices 
were utilized with a calibrated, modified cascade impactor to characterize the dispersion 
properties of the 40 µm SFD trehalose. 
Sieved trehalose and 40 µm SFD had lower CCIs than the 40 µm SFD trehalose. 
Based on CCI, 40 µm SFD was the only powder to be considered free-flowing. Bulk and 
sieved fractions of SA and chitosan were the only MA to be considered free-flowing. The 
static angle of repose of SFD rat was larger than 25 µm SFD and bulk, sieved trehalose, but 
all three powders are regarded as free-flowing. All of the MA were considered free-flowing 
with the exception of sieved CMC HMW, bulk chitosan, and sieved chitosan. 
The surface areas of the SFD formulations were significantly greater than bulk 
trehalose, while the true densities of the SFD formulations and bulk trehalose were the same, 
indicating that the SFD process produced porous particles. The moisture content of the SFD 
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powders was significantly less than the bulk trehalose and the MA. Additionally, the thermal 
analysis indicated that the SFD powders were amorphous. 
At 4°C and 50% RH and 23°C and 40% RH, powder vaccine retained 100% of HA 
activity for the duration of the 12 weeks, while the liquid formulation decreased in activity. 
Even at the most aggressive storage conditions (37°C and 80% RH), the powder performed 
better than the liquid formulation. These results demonstrate the improved vaccine storage 
stability provided by the powder formulation.  
Impact energy separation can be a useful tool in characterizing the adhesive and 
cohesive forces of powders. With each successive strike of a pendulum, the D84 of particles 
remaining on the sapphire disc decreased at energies up to 20 mJ. Trends seen after 
increasing impact energies were in agreement with the flow properties of the powders. 
Current cascade impactor protocols do not completely rule out nasal preparations 
entering the lower respiratory tract. The modified cascade impactor will give a more 
complete picture of the deposition of particles in the 10 to 20 µm size range. This method is 
significant in evaluating the powder that could potentially enter the lungs, which is 
undesirable as it may be associated with adverse effects. There were no significant 
differences between the mass fractions of powder collected on any portion of the modified 
cascade impactor, regardless of device. For the 25 µm SFD trehalose, there were no 
significant differences between the ED and LDF when comparing the two devices. This 
indicates that the dispersion properties of these devices are similar. These powders were 
further characterized with respect to: (specific aim 1) the physico-chemical properties of MA 
and their influence on residence time in the nasal cavity of the rat (Chapter 4) and; (specific 
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aim 2) immunogenicity of a dry powder whole inactivated influenza virus (WIIV) vaccine 
following nasal delivery to rats (Chapter 5).  
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Table 3.1– The flow properties, specific surface area, and moisture content of 25 µm spray-
freeze-dried (SFD) trehalose, 40 µm SFD trehalose- human formulation, and sieved trehalose 
(Mean (SD), n=3). 
 
Powder 
Bulk 
Density 
(g/mL) 
Tap 
Density 
(g/mL) 
Carr's 
Compress. 
Index (CCI) 
Static 
Angle of 
Repose (°) 
Specific 
Surface 
Area 
(m2/g) 
Moisture 
Content 
(%) 
25 µm SFD 0.2 (0.01) 0.3 (0.01) 34.8 (0.9) 36.1 (2.1) 1.25 5.39 (0.52) 
40 µm SFD 0.1 (0.00) 0.1 (0.00) 19.3 (1.0) 25.4 (0.4) 1.65 2.42 (0.52) 
Sieved* 0.5 (0.01) 0.6 (0.01) 23.0 (1.3) 21.6 (1.5) 0.49 9.64 (0.06) 
* Published in (Garmise, Mar et al. 2006). 
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Table 3.2– Flow properties and moisture content analysis of bulk or 45-75 µm sieved 
fractions of a) hyrdroxypropyl methylcellulose (HPMC LMW), b) HPMC HMW, c) 
carboxymethylcellulose sodium (CMC LMW), d) CMC HMW, e) chitosan (Chit) and f) 45-
125 µm sieved fraction of sodium alginate (SA, Mean (SD), n=3). 
 
Powder 
Bulk 
Density 
(g/mL) 
Tap 
Density 
(g/mL) 
Carr's 
Compress. 
Index (CCI) 
Static Angle 
of Repose (°) 
Moisture 
Content (%) 
Bulk 0.5 (0.01) 0.6 (0.00) 22.20 (1.92) 32.15 (0.35) HPMC 
LMW Sieved 0.5 (0.01) 0.6 (0.01) 23.45 (1.99) 31.42 (0.31) 3.53 (0.14) 
Bulk 0.3 (0.01) 0.5 (0.01) 25.37 (1.22) 37.71 (0.61) HPMC 
HMW Sieved 0.4 (0.06) 0.6 (0.09) 24.03 (3.35) 34.10 (0.36) 5.47 (0.15) 
Bulk 0.5 (0.01) 0.7 (0.01) 23.82 (1.44) 32.62 (1.60) CMC 
LMW Sieved 0.5 (0.01) 0.7 (0.01) 29.14 (1.90) 36.59 (1.02) 13.40 (0.01) 
Bulk 0.5 (0.01) 0.7 (0.01) 29.96 (2.17) 36.53 (2.78) CMC 
HMW Sieved 0.5 (0.00) 0.6 (0.01) 28.73 (0.83) 43.20 (0.84) 13.33 (1.09) 
Bulk 0.9 (0.02) 0.9 (0.03) 8.94 (1.54) 20.29 (4.35) SA Sieved 0.7 (0.003) 0.9 (0.01) 16.05 (1.07) 29.29 (1.56) 11.21 (0.01) 
Bulk 0.2 (0.01) 0.3 (0.00) 21.02 (1.12) 41.41 (1.45) Chitosan Sieved 0.2 (0.00) 0.3 (0.00) 20.71 (1.09) 40.04 (3.03) 10.85 (0.16) 
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Table 3.3– The diameter which 84% of particles remaining (D84) on the surface of a sapphire 
disc after repeated striking with increased energy by an impact energy separation device 
(Mean (SD), n=3). 
 
Energy (mJ) 25 um SFD 40 um SFD Trehalose (45-75 um) 
0.98 52.5 (5.1) 30.6 (2.6) 31.1 (3.8) 
4.99 44.4 (5.5) 29.0 (4.7) 22.4 (4.8) 
11.10 37.0 (9.8) 28.6 (6.9) 21.5 (7.0) 
19.38 18.0 (3.7) 18.5 (3.2) 18.0 (11.1) 
41.42 29.0 (8.9) 27.1 (0.5) 12.8 (3.5) 
64.43 32.0 (9.9) 23.8 (3.4) 25.0 (16.6) 
83.67 17.3 (8.5) 8.9 (0.3) 21.9 (15.8) 
101.25 16.6 (7.2) 8.5 (0.7) 19.5 (13.7) 
 
 140
Table 3.4– The emitted dose (ED) and lung dose fraction (LDF) of 0.05% fluorescein in 40 
µm SFD trehalose from a monodose insufflator and a Becton Dickinson Technologies (BDT) 
device (Mean ± SD, n=5).  
 
Device ED (%) LDF (%) 
Monodisperse insufflator 85.3 ± 5.4 10.3 ± 1.9 
BDT device 81.6 ± 6.7 11.8 ± 3.4 
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Figure 3.1– The modified three-stage Andersen cascade impactor, with FDA guidance 
document induction port, for nasal product characterization. 
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Figure 3.2– Differential scanning calorimetry (DSC) heating scans of: A) spray-freeze-dried 
(SFD) human and B) bulk trehalose. Following drying at 60°C for 5 hours, the 40 µm SFD 
trehalose samples were heated to 250°C at 10°C/min. The 40 µm SFD trehalose was also 
scanned at 40°C/min to better resolve the Tg at ~110°C. Bulk trehalose was not pre-treated 
and was heated from room temperature to 250°C at 10°C/min. 
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Figure 3.3– Differential scanning calorimetry (DSC) heating scans of hydroxypropyl 
methylcellulose (HPMC LMW) powder heated from 10°C to 250°C at different heating rates.  
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Figure 3.4– Differential scanning calorimetry (DSC) heating scans of hydroxypropyl 
methylcellulose (HPMC HMW) powder heated from 10°C to 450°C at different heating 
rates.  
 
0 50 100 150 200 250 300 350 400 450 500
Temperature (C)
H
ea
t F
lo
w
- E
xo
 U
p
10°C/min
20°C/min
40°C/min
5°C/min
H
ea
t F
lo
w
- E
xo
 U
p
 
 
 145
Figure 3.5– Differential scanning calorimetry (DSC) heating scans of 
carboxymethylcellulose sodium (CMC LMW) powder heated from 10°C to 450°C at 
different heating rates.  
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Figure 3.6– Differential scanning calorimetry (DSC) heating scans of 
carboxymethylcellulose sodium (CMC HMW) powder heated from 10°C to 400°C at 
different heating rates.  
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Figure 3.7– Differential scanning calorimetry (DSC) heating scans of sodium alginate (SA) 
powder heated from 10°C to 325°C at different heating rates.  
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Figure 3.8– Differential scanning calorimetry (DSC) heating scans of chitosan powder heated 
from 10°C to 375°C at different heating rates. 
 
0 50 100 150 200 250 300 350 400
Temperature (C)
H
ea
t F
lo
w
- E
xo
 U
p
10°C/min
20°C/min
40°C/min
5°C/min
H
ea
t F
lo
w
- E
xo
 U
p
 
 
 
 149
Figure 3.9– Vaccine stability study performed on liquid (open square) or powder (closed 
diamond) vaccine stored under the following conditions: A) 4°C, 50% RH, B) 25°C, 40% 
RH, and C) 37°C, 80% RH. The HA titers of each formulation at different time points were 
measured and compared to the week 0 sample (without storage) of the same formulation. 
Each data point represents the mean of duplicate samples. 
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Figure 3.10– The diameter at which 84% of particles are less than (D84) of sieved trehalose, 
25 µm spray-freeze-dried (SFD), and 40 µm SFD particles remaining on a sapphire disc as a 
function of the logarithm of impact energy applied by a pendulum (mean).  
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Figure 3.11– The diameter at which 84% of particles are of smaller diameter (D84) for sieved 
trehalose, 25 µm spray-freeze-dried (SFD), and 40 µm SFD particles remaining on a sapphire 
disc as a function of impact energy applied by a pendulum (mean, SE).  
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Figure 3.12– The mass fraction of 0.05% fluorescein in SFD human trehalose dispersed from 
the monodose insufflator (MDS) and the Becton Dickinson Technologies (BDT) device in 
the modified cascade impactor (mean ± SD, n=5). 
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Figure 3.13– The mass fraction of the emitted dose of 0.05% fluorescein in SFD human 
trehalose dispersed from a monodose insufflator (MDS) and the Becton Dickinson 
Technologies (BDT) device in the modified cascade impactor (mean ± SD, n=5). 
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4 EFFECTS OF MUCOADHESIVE COMPOUNDS 
4.1 Introduction 
Residence time on the nasal mucosa is a determinant of effectiveness of vaccine 
delivery and response (Bacon, Makin et al. 2000). To afford protection vaccines must present 
antigen to the target nasal-associated lymphoid tissue (NALT). Mucoadhesive compounds 
(MA) have been studied to prolong the residence time on a mucosal surface (Aspden, Mason 
et al. 1997; Soane, Frier et al. 1999; Bacon, Makin et al. 2000; Ugwoke, Agu et al. 2000; 
Ugwoke, Agu et al. 2000; Illum, Fisher et al. 2001; Soane, Hinchcliffe et al. 2001; Cheng, 
Dyer et al. 2005). However, most of these systems utilize liquid formulations containing MA 
in solution. Powder systems require dissolution/hydration to occur for the system to be 
effective in impeding mucociliary clearance. Release of the active component from a powder 
to the nasal cavity must take into account wettability, dissolution rate, and the interaction 
between adjacent MA particles and mucus. 
Dissolution rate is an important characteristic of a dry powder for nasal delivery, 
Particle size and morphology influence wetting and the rate of dissolution (Behl, Pimplaskar 
et al. 1998). In order for the immersion of a solid in a liquid to occur, the liquid must displace 
air and spread over the surface of the solid (Gennaro and Remington 1995). The contact 
angle a liquid droplet makes at the surface of a solid reflects powder wetting. While 
lyophilized formulations tend to dissolve easily in aqueous solutions, solid MA can induce 
varying contact angles that may result in delayed or prolonged effect compared to the same 
compounds in a liquid formulation. 
Particle swelling, or hydration, influences mucoadhesion. There are conflicting 
reports regarding any direct correlation between swelling and mucoadhesion (Ch'ng, Park et 
al. 1985; Bottenberg, Cleymaet et al. 1991). The rate and extent of swelling may be 
important for the action of MA (Banker and Rhodes 1989). Polymer swelling is conducted by 
exposing polymer to a relevant solvent and measuring its uptake as an increase in mass 
(Gennaro and Remington 1995). 
Mucus is a viscoelastic fluid. Its behavior can be described mathematically in terms 
of viscosity (Newtonian or non-Newtonian) and elasticity (Young’s modulus) components. 
In order to consider the influence of a mucoadhesive powder on mucus displacement, its 
effects on rheological properties must be considered. MAs are thought to influence the 
viscous component of mucus behavior. Viscosity, η, is the resistance of a fluid to flow 
(Martin and Bustamante 1993).  Increasing viscosity of a solution increases its resistance to 
flow. The force per unit area required to induce flow is called the shear stress. The difference 
in velocity between two planes of liquid is known as the shear rate. Viscosity can be 
determined from the ratio of shear stress to shear rate.  
For systems in which the shear stress is directly proportional to the shear rate, the 
system is classified as Newtonian. However most pharmaceutical formulations do not exhibit 
this proportionality and are referred to as non-Newtonian (Martin and Bustamante 1993). 
There are three types of non-Newtonian systems: plastic, pseudoplastic, and dilatant 
(Gennaro and Remington 1995). Plastic flow usually occurs in colloidal solutions and 
emulsions and is characterized by the curve of shear stress versus shear rate intersecting the 
shear stress axis above the origin. This indicates that a shear stress of a certain value must be 
exceeded for flow to occur. The stress that needs to be overcome is the value at the point off 
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intersection with the axis and is known as the yield stress. Below the yield stress, the 
substance acts as an elastic material. Pseudoplastic flow, which can be seen in liquid 
dispersions of tragacanth, sodium alginate, methylcellulose, and carboxymethylcellulose 
sodium, is characterized by a decrease in viscosity with an increasing shear rate (Martin and 
Bustamante 1993). This is the case because these long-chain macromolecules align, as the 
shear stress is increased. Therefore, internal resistance decreases (shear-thinning). Dilatant 
flow, which usually describes suspensions with a high percentage of dispersed solids, is 
indicated by a volume increase as it is sheared (shear-thickening). The MA used in these 
experiments have characteristic structures they might be anticipated to exhibit pseudoplastic 
flow in solution. 
There are numerous instruments available for the determination of viscosity of a 
solution (Gennaro and Remington 1995). They include, but are not limited to the capillary, 
cone and plate, cup and bob, and falling sphere. However, choice of instrument is dependent 
on whether the system is Newtonian or non-Newtonian. For an instrument such as the 
capillary viscometer, a constant shear stress is applied, by gravity, and this allows 
measurement of the viscosity at a single point. On the other hand, an instrument such as the 
cone and plate viscometer can vary the shear stress applied and can be used to characterize 
both Newtonian and non-Newtonian systems. In the present studies two instruments were 
employed: an Ostwald viscometer to estimate the Newtonian viscosity of dilute solutions and 
a cone and plate viscometer to estimate non-Newtonian viscosity of more concentrated 
solutions.  
The ultimate measure of the effectiveness of a MA in retarding mucociliary clearance 
is in vivo evaluation by direct imaging or indirect mass balance methods. Both techniques 
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require marker compounds and sensitive detection systems. The radioisotope, technetium, 
99mTc, may be employed as a marker in scintigraphy studies and is frequently used for this 
purpose in both animals and man (Newman, Pitcairn et al. 2004). The half life of 99mTc is 6 
hours, which is convenient for use in these types of studies (Gennaro and Remington 1995). 
The gamma ray energy of 99mTc is 140 KeV, which may be detected with a gamma camera. 
The risk of radiation to exposed patients/workers is low because 99mTc emits few beta-rays. 
Also, 99mTc is readily available in hospitals because it is widely used for diagnostic imaging 
(DiPiro 1997). This marker is usually associated with colloid in order to conduct mucociliary 
clearance studies to eliminate the potential for another clearance mechanism, absorption, to 
interfere with measurements (Lay, Berry et al. 1995). 
This chapter describes the evaluation of polymer powders for their potential as 
mucoadhesives. The wettability of these powders was determined by measuring the contact 
angle. The swelling index of polymer powders was measured. Powder dissolution in 
phosphate buffer was conducted. Deposition and clearance of a liquid formulation was 
imaged using a radiolabeled solution in a rat. Finally, the residence time of the formulation in 
the nasal cavity of rats was measured by conducting nasal lavage mass balance studies using 
a radolabeled powder and scintillation counting. 
4.2 Methods 
In Vitro Characterization 
4.2.1 Wettability 
Compacts of MA alone were manufactured using a single station tablet press (Carver 
Press, Model C, Wabash, IN) and flat-faced circular punches (Elizabeth Carbide Co, 
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Elizabeth Township, PA). The contact angle of a 10 μL drop of phosphate buffer (pH 6.0) on 
their surface was observed by light microscopy (n=3). Images of the droplet were captured 
by a digital camera (Nikon Coolpix 5000, Sony Corporation, Japan) and the contact angle 
was measured with image analysis software (Image J, Chapter 2). 
4.2.2 Rheology 
4.2.2.1 Capillary Viscometry 
Fifteen milliliters of phosphate buffer solution (pH 7.4) were equilibrated in a water 
bath (American Scientific Products, Model BT-23, McGraw Park, IL.) at 37.0 ± 0.5°C. 
Excipient powder (1.5 g) was poured onto the surface of the buffered solutions. Stirring was 
achieved by means of a magnetic stir bar placed in the buffer (Flexa Mixer, Fisher Scientific, 
Pittsburgh, PA). Measurements were taken at 0, 15, 30, 45, and 60 minutes for unstirred 
systems and at 0, 5, 10, and 15 minutes for stirred systems with each time point performed as 
an independent sample (n=3). The latter sample periods were adopted in response to the rapid 
dissolution rates under stirred conditions. After each measurement, solution was removed 
from the vial, filtered with a 5 µm filter, and stored at 37°C. Solution density was measured 
by weighing a known volume of sample. Solution viscosity was determined using a capillary 
viscometer (Ubbelohde Type 1 or 1b, Schott Gerate, Hofheimi a. Ts, Germany) and a Schott 
Gerate AVS 400 measuring unit coupled with a thermostat (CT 1450). The temperature was 
maintained at 37 ± 0.2°C (Manufacturers specification for thermostat). The kinetic energy 
correction term of the viscometer is presumed to be within experimental error attributable to 
the instrument and was, therefore, neglected, according manufacturer’s instructions.  
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4.2.2.2 Cone and Plate Viscometry 
 One and a half milliliters of 1% MA in phosphate buffer solution (pH 7.4) were 
applied evenly on the plate of a cone and plate viscometer (Bohlin Gemini, Malvern 
Instruments Ltd., Worcestershire, UK) at 37.0 ± 0.1°C. Each solution was analyzed in 
triplicate. 
4.2.3 Polymer Swelling 
Compacts (300 ± 15 mg) containing MA alone were manufactured by the single 
station tablet press and circular, convex punches. Each compact was placed in a USP type I 
dissolution basket, weighed, submerged in forty milliliters of phosphate buffer solution (pH 
6.0) and equilibrated in a water bath (American Scientific Products) at 37.0 ± 0.5°C. The 
experiments were conducted under unstirred conditions, relevant to the nasal cavity, 
requiring that the dissolution baskets were not rotated. After a fixed time interval, excess 
fluid was removed and the sample was weighed. Weights were taken at 0, 5, 10, 15, 30, and 
60 minutes (n=3), with each time point representing an independent sample. Additional 
experiments were carried out to establish maximum swelling. The swelling index (SI) was 
calculated by dividing the difference between the final and initial weights of the compact by 
its initial weight.  
In Vivo Characterization 
Animal Care 
Female Brown Norway rats (125–175 g, Charles River, Raleigh, NC) were kept under 
standard conditions in AAALAC approved facilities under IACUC approved protocol (06-
265.0-A). The animals were kept in a controlled temperature room (22 ± 1°C with 12 hour 
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light and dark cycles and had free access to food and water. Rats were anesthetized by 
intraperitoneal injection of 40 mg/kg ketamine, 2 mg/kg xylazine and 0.75 mg/kg 
acepromazine before immunization. 
4.2.4 Gamma Scintigraphy 
The radiolabeled tracer, 99mtechnetium-sulfur colloid (99mTc-SC), was used to gauge 
deposition of delivered activity and the subsequent course of clearance from the nasal cavity 
by mucociliary transport with a γ-camera (Picker Dyna Camera 4, Picker, Northford, CT). 
The camera was set with an 18% window around the peak energy of 99mTc (140 KeV) and 
was shielded with a pinhole collimator. Pinhole collimation provided the adequate spatial 
resolution necessary for distinguishing location and retention of radioactivity within the nasal 
cavity. The labeled colloid solution was freshly prepared according to the manufacturer's 
(Cis, Bedford, MA) instructions, and is nonpyrogenic, isotonic, and at a neutral pH. 
Preparation of 99mTc-SC from commercial kits with the thiosulfate method is reported to 
produce polydisperse sub-micrometer particles (Lay, Berry et al. 1995). The particle size of 
the readiolabeled colloid was measured by dynamic light scattering of the sample suspension 
(Nicomp Model 370 Particle Sizing Systems, Santa Barbara, CA). An anesthetized, female 
Brown Norway rat (200g) was imaged in supine position following pipette aspiration 
delivery to the nostrils of 25 uL saline containing approximately 10 μCi of 99mTc-SC for 30 
minutes, with 120 second frames. The camera was set with an 18% window around the peak 
energy of 99mTc and was shielded with a pinhole collimator. Activity levels were adjusted for 
radioactive decay using the equation: 
)(
0
kteXX −=       (4.01) 
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where X0 is the activity at time zero, X is the activity at a given time, t, Co is the initial 
activity, and k is the decay constant. 
4.2.5 Residence Time Study 
Liquid formulations of saline or 1% MA in saline containing insoluble 99mTc-SC were 
delivered by placing 25 μL of solution into the right nostril of an anesthetized rat using a 10-
100 μL pipette. Several methods were evaluated for radiolabeling powders. To label powder 
formulations, saline containing insoluble 99mTc-sulfur colloid were centrifuged at 12000 rpms 
for 10 minutes. Supernatant was removed and the pellet was washed three times with ethanol. 
The pellet was allowed to dry before being blended with the rat spray-freeze-dried trehalose 
with a mortar and pestle. Five milligram quantities were weighed out and placed in gelatin 
capsules (size 3, Capsugel, Greenwood, SC). An alternative method was thoroughly 
evaluated and appeared unsuitable for the purposes of the present study (Appendix 3).  
Powder formulations were delivered using compressed air at 20 psig through a timed 
solenoid switch and a 100 μL pipette containing the contents of one dosage capsule in the 
right nostril of the anesthetized rat. The time points analyzed were 5, 15, and 120 minutes 
(n=3) and 30, 60, and 180 minutes (n=1). Rats were euthanized following cardiac puncture 
by CO2 inhalation and nasal washes were collected by cannulating the trachea and rapidly 
instilling four aliquots of 1.5 mL of sterile saline. Fluid passed from the trachea through the 
nostrils was collected and analyzed in a radioisotope calibrator (Model CRC-4, Capintech, 
Inc. Pittsburgh, PA). All samples quantities were adjusted for radioactive decay. 
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4.3 Results and Discussions 
In Vitro Characterization 
4.3.1 Wettability  
Contact angles are presented in Table 4.1. The contact angle is a measure of the 
forces of attraction/repulsion between the liquid and solid phase. On extremely hydrophilic 
surfaces, a water droplet will completely spread resulting in a contact angle of zero. This 
occurs for surfaces that have a large affinity for water, including materials that absorb water. 
On many hydrophilic surfaces, water droplets will exhibit contact angles of 10° to 30°. On 
highly hydrophobic surfaces, a large contact angle (70° to 90°) is seen. If no wetting occurs, 
then the contact angle is 180°. The contact angle directly provides information on the 
interaction energy between the surface and the liquid. The contact angle of the HPMC LMW 
(~41°) and HPMC HMW (~55°) were significantly greater than the other polymers (P<0.05, 
Figure 4.1). This is expected due to the hydrophobic nature of the HPMC functional groups. 
CMC, however, has more hydrophilic functional groups, which will interact with the aqueous 
solution, resulting in a lower contact angle (~29°). Chitosan had the smallest contact angle 
(~23°) and the portion exposed to the buffer swelled up, taking up the liquid into the 
compact. The results of these studies show the relative wetting to be HPMC HMW>HPMC 
LMW>CMC (HMW and LMW)>Chitosan which is consistent with the reverse relative 
propensity for influencing dissolution rate. 
4.3.2 Rheology 
The viscosity of the solvent was used as the quantitative measure for the 
concentration of MA in solution as a function of time in stirred and unstirred systems (Table 
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4.1). This is based on the assumption that solutions will be dilute and, therefore, will display 
a linear relationship between relative viscosity and concentration of polymer, according to 
Einstein equation (Hiemenz 1984). The viscosities of the CMC polymers and SA were 
significantly greater than the HPMC polymers (P<0.05) for both the unstirred and stirred 
systems. This coincides with the significantly greater contact angle seen in the HPMC 
polymers. For both the unstirred and stirred systems, the viscosities of the chitosan and 1% 
trehalose (0.74 ± 0.00 cps) were not significantly different than buffer alone (P<0.05). The 
viscosities of completely dissolved MA solutions were too great to be measured by the 
capillary viscometer, so the cone and plate viscometer was used. When completely dissolved, 
the viscosities of HPMC HMW and CMC HMW were orders of magnitude greater than the 
viscosities of the other solutions. 
Beyond the effects of MA on viscosity as estimated in aqueous solutions, the 
influence of these materials on other mucus rheological properties is also important. The 
analysis of semisolids, such as mucus, requires a different approach than liquids. A semisolid 
demonstrates both the viscous properties of a liquid and the elastic properties of a solid. 
While the viscosity of a solution, as described above is determined by the ratio of shearing 
force to shearing rate, the elasticity of a solid is determined by the ratio of the stress to the 
strain. Once the cilia have penetrated the mucus, deforming it, the elasticity of the mucus will 
act to restore the mucus to its original shape. If the mucus does not have enough elasticity, it 
will not move like a sheet. On the other hand, if it is too elastic, it will not flow (Silberberg 
1983). A viscosity around 15 cps is the optimal for mucociliary clearance (Chen and Dulfano 
1978). Mucus samples from rats have been employed to demonstrate that the ratio between 
viscosity and elasticity is an important determinant of the mucociliary clearance rate. 
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However, significant variability in mucus transport occurs in response to other factors 
(Lorenzi, Bohm et al. 1992). These factors include, but are not limited to, disease (infection, 
cystic fibrosis), lifestyle factors (smoking), and drugs (ipatropium bromide, methacholine, 
norfloxacin). 
4.3.3 Polymer Swelling 
Swelling indices are presented in Table 4.2. The SI of the HPMC polymers is 
significantly lower than the other compounds at all time points (P<0.05, Figure 4.2). The SI 
of the CMC HMW and SA is significantly higher than the CMC LMW and chitosan at 60 
min (P<0.05). The average time for particles to clear through the nasal cavity is 10-20 
minutes in normal health human adults (Liote, Zahm et al. 1989). It has been suggested 
previously that an increase in the residence time in the nasal cavity can increase the immune 
response elicited by a dry powder nasal vaccine, but residence time data was not shown 
(Huang, Garmise et al. 2004). An ideal MA would be able to swell to absorb the excess 
liquid and increase the viscosity of the mucus, thus decreasing mucociliary clearance. In 
these experiments, CMC HMW and SA had a large SI consistent with the large effect on 
viscosity, noted above, at both the 15 and 60 minute time points.  
In Vivo Characterization 
4.3.4 Gamma Scintigraphy 
The particle size characteristics of the 99mTc-SC were an average size of 650 nm, 
with a standard deviation of 60 nm. These were suitable for labeling the powders for nasal 
delivery as nanoparticles have been shown to coat the surfaces of large particles (Singh and 
Gao 1999). 
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The images illustrating the dynamic clearance of saline containing insoluble 99mTc-
sulfur colloid are shown (Figure 4.2). At 0 (image 1), 2 (image 2), 16 (image 8), and 30 
(image 16) minutes, the activities were (after decay correction) 3230, 3072, 2413, and 2078 
cts/120sec, respectively. The saline was cleared at a rate of ~1%/min of the initial aspirated 
dose. One major disadvantage of using radiolabeled preparations was that the formulation is 
labeled, not the drug entity/biological. Images of the nasal cavity reflected the presence of the 
formulation, not necessarily the active component. This initial study demonstrated that there 
were limitations to conducting extended clearance studies from rodents following nasal 
delivery. Reproducible marker placement, liquid volume, efficiency of powder delivery, 
sensitivity of the camera, orientation of the head (body prone or supine), potential retrograde 
clearance, imaging with a parallel hole vs. pin hole were perceived variables that would 
require assessment (Newman, Pitcairn et al. 2001). The facility costs and camera time to 
conduct a thorough assessment of these variables were considered prohibitive by the 
collaborator on these studies. 
4.3.5 Residence Time Study 
Gamma scintigraphy imaging has proved a useful tool for imaging aerosol deposition 
but in light of the scope of a validation study an alternative approach was needed to assess 
the residence time of the formulation in the nasal cavity. A nasal lavage technique was 
utilized to recover the radioactivity remaining in the nasal cavity as a function of time. Each 
time point represents one animal. Replicates were completed for only half of the time points 
in order to conserve animals. The three time points chosen were indicative of the whole 
curve. 
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Initial experiments were completed with a novel labeling machine (Appendix A.4). 
However, this system was unable to remove all of the water content from the nebulized 
suspension. The remaining moisture caused the SFD- rat powder to collapse and aggregate. 
When the system was run for short periods of time to prevent the moisture uptake, 
radioactivity levels were just above than the detectable limit of calibrator, which was not 
suitable for three hour studies. An alternative admixture technique was adopted. A blend 
uniformity study was completed by weighing 5 mg of powder, placing the powder in a 
gelatin capsule, and scintillation counting was conducted. Each capsule was within a relative 
standard deviation of the target radioactivity. 
Comparing the percentage of radioactivity as a function of time, the saline resided 
longer in the nasal cavity of the Brown Norway rats than the trehalose (Figure 4.3). Liquid 
and SFD powder formulations containing the MA and saline alone were compared. The 
curve for liquid HPMC HMW was similar to saline alone at the majority of the time points, 
but the powder HPMC HMW did not reside as long in the nasal cavity as the liquid 
formulations (Figure 4.4). The curve for powder CMC HMW was similar to saline alone at 
almost all of the time points, but the liquid CMC HMW seemed to remain in the nasal cavity 
longer than the saline and powder formulations (Figure 4.5). The liquid SA was similar to 
saline alone at almost all of the time points, but the powder SA seemed to initially be cleared 
faster than the liquid formulations and remain at the same level in the nasal cavity for the rest 
of the study (Figure 4.6). The powder chitosan was similar to saline alone at almost all of the 
time points, but lower quantities of radioactivity were detected for the powder chitosan at the 
180 minute time point (Figure 4.7). 
 167
Regression analysis was performed by mathematically fitting the data to assess 
residence time differences (see Appendix 3). A two-compartment model was chosen because 
in most of the curves, there was an initial steep removal of radioactivity from the nasal cavity 
due to rapid unhindered clearance followed by a more gradual elimination attributable to 
material that is sequestered in some manner, perhaps adhered to mucus or epithelium. While 
mechanistically different, from a modeling perspective these phases may be considered 
equivalent to the distribution phase and the elimination phase after an IV bolus. The particle 
size of the 99mTc-SC is too large to be absorbed through the nasal epithelium; the only means 
of elimination is mucociliary clearance from the nasal cavity and being swallowed. The 
equation for a two-compartment model with elimination only from the central compartment 
after an IV bolus is: 
)()( dtbt ceaey −− +=      (4.02) 
where y is the radioactivity remaining and t is the time in minutes. The model was fit to the 
average value of replicates and each individual point. The correlation coefficient and 
parameters (a, b, c, and d) determined by the regression analysis are shown (Table 4.3). All 
of the curves exhibited good fit (R2 > 0.94).  
Parameters a and b are representative of initial clearance of the radioactivity from the 
nasal cavity. They compose the term of a two-compartment IV bolus equation that represents 
the distribution phase. With the exception of the liquid SA, the distribution constant (b) was 
larger for the powder formulations than the liquids. This is surprising because run-off and 
swallowing of the liquid formulations, unhindered clearance, was expected to account for a 
large, immediate decrease in the radioactivity remaining. However, the viscosity of 1% 
HPMC HMW and CMC HMW is much greater than 1% SA, which may explain the increase 
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in residence time. The powders with the least effect on viscosity (trehalose alone and 
Chitosan with trehalose) were initially cleared much more rapidly than the other 
formulations.  
Parameters c and d are indicative of mucociliary clearance rate. They compose the 
term of a two-compartment IV bolus equation that represents the elimination phase. The 
elimination constant (d) was very similar for all of the liquid formulations and powder No 
MA, CMC HMW, and Chit, while the powder HPMC HMW and SA were significantly 
lower. These results are expected because HPMC HMW and SA exhibited the greatest 
viscosity, when fully dissolved, and swelling index, respectively. Based on the in vitro 
results, the powder CMC would be expected to have a lower elimination constant. 
The area under the curve (AUC) can be used to determine the total amount of 
radioactivity in the nasal cavity for the duration of the experiments (Figure 4.8). The AUC of 
the liquid formulations were greater than all of the powder formulations, with the exception 
of SA. However, all of the AUCs except trehalose alone and HPMC trehalose were similar 
(roughly 8000-10000). The rank of the AUC of the liquid formulations (CMC HMW>HPMC 
HMW, SA>No MA) was consistent with the viscosities of the 1% solutions (HPMC 
HMW>CMC HMW>SA>No MA). However, it should be noted that larger viscosity does 
not directly correlate to great increased in residence time (No MA vs HPMC HMW). The 
rank of the powder formulations (SA>CMC HMW, Chit>HPMC HMW, No MA) was 
consistent with the contact angle (Chit<CMC HMW<SA<HPMC HMW), viscosity 
(unstirred at 60 minutes, SA>CMC HMW>HPMC HMW>Chit, No MA), and SI at 60 
minutes (CMC HMW, SA>Chit>HPMC HMW>No MA). 
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4.4 Summary 
In vitro experiments were performed to obtain data as potential predictors of the 
effect that mucoadhesive compounds (MA) may have on the residence time of liquid and 
powder preparations in the nasal cavity. Wettability of the powders was determined by 
placing a drop of buffer on a compact of the MA and measuring the angle formed by the 
droplet on the surface. The dissolution rate of the powders was determined by placing the 
powder on the buffer and measuring the viscosity of the buffer over time with a capillary or 
cone and plate viscometer in unstirred and stirred systems. Swelling indices were completed 
to determine the rate and amount of water uptake of the powders by placing compacts of the 
powders in buffer and measuring the weight gained by water uptake as a function of time. 
Gamma scintigraphy and residence time studies were completed to determine the effect of 
formulation on the residence time in the nasal cavity of Brown Norway rats.  
The contact angle of the HPMC HMW and HPMC LMW were significantly greater 
than the other polymers, indicating a prolonged dissolution time. For both the unstirred and 
stirred systems, the viscosities of the CMC polymers and SA were significantly greater than 
the HPMC polymers. The swelling indices of CMC HMW and SA were significantly greater 
than the other MA. Gamma scintigraphy allowed for the visual imaging of clearance of saline 
from the nasal cavity of a Brown Norway rat. The residence time studies indicated that 
increasing the viscosity did not significantly increase the residence time. The serious 
implications of this observation for the subsequent immunogenicity studies, and for the 
clinical application of this approach, are taken up in more depth in the Chapter 6.  Powder 
formulations required MA to achieve comparable residence times to liquid formulations with 
or without mucoadhesive in Brown Norway rats. The rank order of residence time for 
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powders is SA>CMC HMW, Chit>HPMC HMW, No MA. The in vitro and in vivo 
experiments indicate that SA and CMC HMW in powder formulations have the greatest 
effect on increasing residence time in the nasal cavity of Brown Norway rats. These MA 
were subsequently prepared in a dry powder influenza vaccine for nasal delivery to rats to 
determine if residence time in the nasal cavity correlates to the immune response elicited by 
the vaccine (Chapter 5). 
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Table 4.1– Contact angle and dissolution as measured by viscosity (unstirred and stirred 
systems) of hydroxypropyl methylcellulose (HPMC), carboxymethylcellulose sodium 
(CMC), sodium alginate (SA), and chitosan (Mean (SD), n=3). 
 
Dissolution- 
Unstirred 
(Viscosity, η (cps)) 
Dissolution- Stirred 
(Viscosity, η (cps)) Viscosity, η (cps)) Compound Contact Angle (°) 
15 min 60 min 5 min 15 min 1% w/v Solution 
HPMC LMW 41.5 (0.9) 0.9 (0.0) 1.1 (0.0) 0.9 (0.0) 1.1 (0.1) 1.6 (0.8) 
HPMC HMW 55.2 (2.0) 0.9 (0.1) 0.9 (0.1) 1.1 (0.1) 1.1 (0.1) 13183.1 (2166.5) 
CMC LMW 28.6 (0.6) 1.5 (0.1) 3.3 (0.1) 1.4 (0.0) 2.3 (0.1) 3.9 (0.3) 
CMC HMW 29.8 (1.5) 1.5 (0.2) 2.5 (0.8) 1.8 (0.4) 2.0 (0.1) 2334.2 (310.2) 
SA 34.8 (1.1) 2.0 (0.7) 4.3 (0.6) 2.0 (0.7) 4.4 (2.6) 11.4 (0.6) 
Chitosan 22.7 (2.9) 0.8 (0.0) 0.8 (0.0) 0.8 (0.0) 0.8 (0.0) 0.8 (0.0) 
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Table 4.2– Swelling indices of compacts of hydroxypropyl methylcellulose (HPMC), 
carboxymethylcellulose sodium (CMC), sodium alginate (SA), and chitosan (Mean (SD), 
n=3). 
 
Swelling Index (SI) Compound 15 min 60 min Maximum Swelling 
HPMC LMW 0.46 (0.12) 1.14 (0.02) 1.85 (0.29) 
HPMC HMW 0.70 (0.02) 1.44 (0.00) 10.26 (0.43) 
CMC LMW 1.51 (0.14) 2.37 (0.09) 2.84 (0.03) 
CMC HMW 2.05 (0.09) 5.09 (0.24) 29.81 (0.65) 
SA 2.02 (0.16) 4.70 (0.26) 8.18 (0.70) 
Chitosan 1.90 (0.22) 2.11 (0.16) 2.13 (0.19) 
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Table 4.3– Correlation coefficient and parameters determined by regression analysis of two-
compartment model curves determined by the % radioactivity remaining as a function of 
time in Brown Norway rats of liquid and powder formulations containing saline (liquid, No 
MA) and 1% hydroxypropyl methylcellulose (HPMC), carboxymethylcellulose sodium 
(CMC), or sodium alginate (SA) or trehalose alone (powder, No MA) and 3% HPMC, CMC, 
SA, and chitosan (Chit). 
 
Liquid Formulations Powder Formulations 
 No MA HPMC HMW 
CMC 
HMW SA No MA 
HPMC 
HMW 
CMC 
HMW SA Chit 
r2 0.99 0.96 0.97 0.97 0.94 0.99 0.94 0.99 0.95 
a 43.06 28.41 34.26 16.82 51.88 72.86 43.80 51.19 34.32 
b 0.0631 0.2099 0.094 46.35 4762871.86 0.2272 0.5548 0.2455 12956 
c 55.33 72.03 63.95 83.18 48.12 27.34 56.20 48.67 65.68 
d 0.0028 0.0043 0.0021 0.0058 0.0057 .0000893 0.0034 0.0002 0.0050 
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Figure 4.1– Contact angle (θ) of phosphate buffer (pH 6.0) on compacts of hydroxypropyl 
methylcellulose (HPMC), carboxymethylcellulose sodium (CMC), sodium alginate (SA), and 
chitosan (Chit). 
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Figure 4.2– The dynamic clearance of 25 uL saline containing insoluble Tc-sulfur colloid 
delivered to an anesthetized, female Brown Norway rat (200g) in the supine position 
following pipette aspiration delivery to the nostrils for 30 minutes, with 120 second frames. 
 
1 2 3 4
5 6 7 8
9 10 11 12
13 14 15 16  
 176
Figure 4.3– The percentage of radioactivity remaining in the nasal cavity of Brown Norway 
rats as a function of time when radiolabeled saline (Liq- No MA) or trehalose (Pow- No MA) 
is delivered (error bars represent standard deviations of n=3 at 15, 30, and 120 minute time 
points). 
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Figure 4.4– The percentage of radioactivity remaining in the nasal cavity of Brown Norway 
rats as a function of time when radiolabeled saline (Liq- No MA), 1% hydroxypropyl 
methylcellulose in radiolabeled saline (Liq- HPMC HMW) or 3% hydroxypropyl 
methylcellulose in radiolabeled trehalose (Pow- HPMC HMW) is delivered (error bars 
represent standard deviations of n=3 at 15, 30, and 120 minute time points). 
 
0
20
40
60
80
100
120
0 20 40 60 80 100 120 140 160 180 200
Time (mins)
R
ad
io
ac
tiv
ity
 R
em
ai
ni
ng
 (%
)
Liq- No MA
Liq- HPMC HMW
Pow- HPMC HMW
 
 178
Figure 4.5– The percentage of radioactivity remaining in the nasal cavity of Brown Norway 
rats as a function of time when radiolabeled saline (Liq- No MA), 1% 
carboxymethylcellulose sodium in radiolabeled saline (Liq- CMC HMW) or 3% 
carboxymethylcellulose sodium in radiolabeled trehalose (Pow- CMC HMW) is delivered 
(error bars represent standard deviations of n=3 at 15, 30, and 120 minute time points). 
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Figure 4.6– The percentage of radioactivity remaining in the nasal cavity of Brown Norway 
rats as a function of time when radiolabeled saline (Liq- No MA), 1% sodium alginate in 
radiolabeled saline (Liq- SA) or 3% sodium alginate in radiolabeled trehalose (Pow- SA) is 
delivered (error bars represent standard deviations of n=3 at 15, 30, and 120 minute time 
points). 
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Figure 4.7– The percentage of radioactivity remaining in the nasal cavity of Brown Norway 
rats as a function of time when radiolabeled saline (Liq- No MA) or 3% Chitosan in 
radiolabeled trehalose (Pow- Chit) is delivered (mean where error bars represent standard 
deviations of n=3 at 15, 30, and 120 minute time points). 
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Figure 4.8– The area under the curve of the percentage of radioactivity as a function of time 
curves for liquid and powder formulations containing no mucoadhesive (No MA), 
hydroxypropyl methylcellulose (HPMC HMW), sodium alginate (SA), 
carboxymethylcellulose sodium (CMC HMW), and chitosan (Chit). 
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 5 IMMUNOGENICITY OF DRY POWDER INTRANASAL INFLUENZA 
VACCINE WITH A MUCOADHESIVE COMPOUND 
5.1 Introduction 
Influenza infection results from deposition of influenza virus into the upper 
respiratory tract (Chapter 1, Section 1.1.6). Therefore, particles intended for the prevention of 
influenza must be targeted to the nasal-associated lymphoid tissue (NALT). The immune 
response elicited by the antigen in a host was summarized previously (Chapter 1, Section 
1.1.1.5). The humoral immune response generates binding antibodies specific to an antigen. 
The initiation of the humoral immune response requires: 1) exposure to an antigen (in this 
case, whole inactivated influenza virus (WIIV)), 2) penetration of the mucosal surface for the 
antigen to be endocytosed by an M cell or phagocytosed by a dendritic cell, and 3) an 
interaction between B lymphocytes and the antigen presenting cells (Pier, Lyczak et al. 
2004).  
Mucosal surfaces are very susceptible to virus entry because of their extensive surface 
area and their functions require the epithelium to be exposed to the environment. This makes 
it difficult for the antibodies produced by systemic immune response to sufficiently protect it. 
The presence of local lymphocytes and the nearby location of local lymphoid tissue (NALT) 
make mucosal immunization ideal due to its ability to protect locally and systemically. 
Mucosal immunization promotes formation of both immunoglobulin G (IgG) and 
immunoglobulin A (IgA). Immunoglobulin M (IgM) has a molecular weight of 900 kD and 
constitutes 6% of total Ig. IgM is the first antibody of the immune response (Roitt and Delves 
2001). Upon first exposure to an antigen, there is an early burst of antigen specific IgM 
within the first 7 days, while antigen specific IgG synthesis takes longer to reach a maximal 
rate, usually 2-3 weeks (Figure 7.1). On secondary exposure to the same antigen, again there 
is an early burst of IgM. The IgG levels, however, rapidly increase within two weeks to a 
level much higher than first exposure and have a significantly higher binding affinity to the 
antigen than on first exposure (Gosling and Basso 1994). IgA synthesis resembles the pattern 
of IgG synthesis. IgG has a molecular weight of 150 kD and accounts for 80% of total Ig 
(Roitt and Delves 2001). It is the major Ig of general circulation. The site of entry into the 
host will influence the isotype of antibody produced. There are four isotypes of IgG (IgG1, 
IgG2, IgG3, IgG4) (Leffell, Donnenberg et al. 1997). IgG1 is the dominant subclass, 
accounting for 65% of total IgG. IgA is the predominant isotype of antibody in seromucous 
secretions, specifically in the upper respiratory tract (Roitt and Delves 2001). IgA has a 
molecular weight of 395 kD and accounts for 13% of total Ig. There are two isotypes of IgA 
(IgA1, IgA2). IgA constitutes 10% of the total proteins in the upper respiratory tract 
secretions. IgA1 subclass accounts for two-thirds of the total secretory IgA (sIgA). IgG is 
present only in trace amounts in the upper respiratory tract secretions.  
 Viruses are unique in that they can be neutralized by antibodies alone, unlike bacteria 
that require secondary effectors (Dimmock, Easton et al. 2001). It is possible to determine if 
antibodies are present for a specific antigen because their interaction is so specific. For this 
reason, serological tests such as an enzyme-linked immunosorbent assay (ELISA) can be 
used to quantify antibodies in serum. ELISAs employ a plate coated with the antigen against 
which antibodies are to be developed for quantification. Serum samples are added to allow 
the antibody to bind to the antigen. A secondary, conjugated antibody is added that is 
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covalently linked to an enzyme. Substrate is added and a quantifiable colorimetric assay can 
be used to determine the amount of antibody present. A classical serological test may also be 
employed to quantify antibodies by hemagglutination-inhibition assay (HAI). Virus is added 
to serial dilutions of serum. The presence of antibodies will neutralize the viruses’ ability to 
bind to red blood cells, preventing agglutination which can be detected visually. 
Brown Norway rats are considered the strain of choice for conducting humoral 
response immunogenicity studies (Lebrec and Burleson 1994; Lebrec, Sarlo et al. 1996). The 
mouse is the most commonly used model for influenza vaccination, but small nostril size 
prevents reproducible dosing of powders to the nasal cavity. There are limited options for 
whole organism assessment of influenza vaccines for nasal delivery.   
In the following studies here, intranasal vaccination with WIIV was assessed in 
Brown Norway rats. A dose-response curve of IM injection and IN liquid was established to 
determine the appropriate dose for a formulation study. Nasal powders with and without MA 
were compared to IM and IN suspensions. Both serum and mucosal antibodies were 
quantified.  
5.2 Methods 
Animal Care 
Female Brown Norway rats (125–175 g, Charles River, Raleigh, NC) were kept under 
standard conditions in AAALAC approved facilities under IACUC approved protocol (06-
265.0-A). The animals were kept in a controlled temperature room (22 ± 1°C with 12 hour 
light and dark cycles and had free access to food and water. Rats were anesthetized by 
intraperitoneal injection of 40 mg/kg ketamine, 2 mg/kg xylazine and 0.75 mg/kg 
acepromazine before immunization. 
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5.2.1 Dose-Response Experiments 
WIIV was used as a liquid preparation without addition of adjuvants, as provided by 
the vendor. Rats were immunized two times IM or IN with the liquid suspension on days 0 
and 21. The doses for IM immunization were 0.5, 1, 1.5, 2, 2.5, 5, 10, 20, or 40 μg of HA in 
100 μL of sterile normal saline and administered in the muscle of the left hind leg of the 
animal with a 25-gauge needle (n=3). The same doses of HA for IN immunization were 
administered in 25 μL of sterile normal saline with a 10-100 μL pipette (n=3). 
5.2.1.1 Sample Collection 
Blood was obtained, under anesthesia; from the tail artery three weeks post 
vaccination. Blood was centrifuged at 13201 X g for 10 minutes; serum supernatant was 
removed and stored at −80°C. Two weeks following the boost immunization, rats were 
euthanized following cardiac puncture by CO2 inhalation and nasal washes were collected by 
cannulating the trachea and rapidly instilling 1ml of sterile saline. Fluid passed from the 
trachea through the nostrils was collected and stored at −80°C. 
5.2.1.2 ELISA 
Whole virus-specific antibody titers were determined by ELISA. Plates (96-well, 
Nalgen Nunc Maxisorb, Rochester, NY) were coated with 100 μL of 1 μg/mL (based on total 
protein content as above) whole inactivated influenza virus at 4°C overnight, then blocked at 
37°C for 1 hour with PBS Tween 20 (PBST; Sigma) containing 5% non-fat dry milk. After 
washing, serial dilutions of sera or nasal wash (100 μL/well) were added and incubated at 
37°C for 1 hour. Plates were washed again, then incubated at 37°C for 45 minutes with 
horseradish peroxidase (HRP) conjugated secondary antibodies: goat anti-rat Ig (H+L) 
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(Southern Biotechnology Associates, Inc, Birmingham, AL) or goat anti-rat IgA (Bethyl 
Laboratories, Montgomery, TX). Plates were developed by incubating for 30 minutes at 
room temperature with 3,3’,5,5’-tetramethyl Benzidine (TMB) substrate (Sigma). After 
stopping the reaction using 0.5M H2SO4, plates were read at 450 nm. The endpoint titers 
were defined as the highest reciprocal dilution of sera or nasal wash yielding an OD450 value 
at least 3X background obtained using samples obtained prior to immunization. All 
standards, samples, and controls were analyzed in duplicate. 
5.2.3 Formulation evaluation 
Rats were immunized IM with the liquid formulation or IN with either the liquid or 
the powder formulation on days 0 and 21. Each dose contained 2 μg H/100 μL volume for 
IM injection, 2 μg H/25 μL for IN liquid or 5 μg H/5 mg total powder. IM and IN liquid 
formulations were administered as described above. Powder formulations were delivered 
using compressed air at 20 psig through a timed solenoid switch and a 100 μL pipette in the 
right nostril of the anesthetized rat. The efficiency of dosing resulted in an actual dose 
delivered to the animal nasal cavity of 2 μg. There were five powder formulation groups. 
SFD WIIV/trehalose and CMC HMW, SA, chitosan, or HPMC HMW was added at 3% w/w. 
Each treatment group consisted of six animals. 
5.2.3.1 IgG Isotyping 
Virus-specific IgG1, IgG2a and IgG2b were measured by ELISA as above, 
substituting reagents provided in IgG isotyping kits (Bethyl Laboratories). IgG1, IgG2a and 
IgG2b concentrations were determined using standard curves, as per the manufacturer’s 
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instructions. The sensitivity of isotyping ELISA is in the range of 3–1000 ng/mL. Samples 
were diluted to fall within the standard curve range. 
5.2.3.2 HAI Assay 
Test sera were inactivated at 56°C for 10 minutes to destroy complement and HAI 
inhibitors. Twenty-five milliliter of double serial diluted test sera were then added to wells 
containing 25 μL of four hemagglutinating units of influenza virus followed by adding 50 μL 
of 0.5% chicken red blood cells to each well. Plates were then incubated at room temperature 
for 1 hour. The endpoint HAI titer was defined as the reciprocal of the highest serum dilution 
that completely inhibited hemagglutination of the chicken red blood cells. 
5.2.3.3 Endotoxin Quantification 
 A commercially available kit (QCL-1000 Chromogenic Limulus Amebocyte Lysate 
(LAL) Endpoint Assay, Cambrex Corp., East Rutherford, NJ) was purchased for 
quantification of endotoxin present in MA. Briefly, MA were dissolved in pyrogen-free water 
and diluted to fall within range of the standard curve. 
5.2.3.4 Statistical Analysis 
 Analysis of variance was performed on the logarithmic transformation of titer values 
at α=0.05 to determine any differences between the dosing groups. A two-tailed t-test 
assuming unequal variances was used to compare the immune response elicited by IM 
injection and IN liquid at the same dose for the dose response study. For comparisons of two 
means, Scheffé’s method was used at α=0.05. 
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5.3 Results and Discussion 
5.3.1 Dose-Response Experiments 
To determine an appropriate dose for use in the formulation experiments, various 
doses were prepared and inoculated into rats either IM or IN with liquid formulations. The 
immune responses following inoculation were assessed after an initial vaccination and after a 
boost dose. IN delivery of liquid vaccine provided equivalent serum antibody titers as those 
obtained by IM injection at doses ≥2.5 μg after the initial vaccination (Figure 5.2). At doses 
≤2 μg, the serum antibody titers elicited by IM injection were significantly greater than that 
of IN liquid after the first dose (P<0.05). After the boost dose, the immune response elicited 
at doses of 0.5, 1, 2.5, 5, and 10 μg is equivalent for both the IM injection and the IN liquid 
(Figure 5.3). The serum antibody titers are significantly greater for the IM injection than the 
IN liquid at 1.5 and 2 μg, while they are greater for the IN liquid than the IM injection at 20 
and 40 μg doses.  
Nasal lavage fluids were assessed for influenza-specific IgA responses in order to 
evaluate nasal mucosal immune response following IN delivery vaccine. Positive nasal IgA 
responses were seen after administration of IN liquid, regardless of dose (Figure 5.4). The 
local immune response increases with dose until reaching a plateau at ≥5 μg. No detectable 
IgA responses were observed following IM injection.  
The range of doses utilized provided insight into an appropriate dose for use in 
subsequent experiments. When comparing different formulations, it is important to choose a 
dose on the steepest slope of the concentration curve to maximize the potential differences in 
immunogenicity.  If too low or too high of a dose is administered, differences in the immune 
response elicited may not be evident. However, on the upward slope, even subtle differences 
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in immunogenicity can be detected. A 2 μg dose was chosen as it elicited a significantly 
greater immune response than doses ≤1.5 μg and significantly less than doses ≥ 5 μg when 
administered as an IN liquid. There were also significant differences between the IN liquid 
and IM injection upon administration of the 2 μg dose after the initial vaccination and the 
boost. 
5.3.2 Formulation evaluation  
To evaluate the immune responses elicited by a powder influenza vaccine, various 
formulations were prepared and rats were inoculated IN. The immune responses following 
inoculation with the powder formulation, with or without MA, and the responses to the liquid 
formulation administered IN or IM were assessed. IM delivery of liquid vaccine provided 
equivalent serum antibody titers to those obtained by IN powder without MA, CMC HMW, 
SA, and HPMC HMW, and significantly greater serum antibody titers than IN liquid and IN 
powder with chitosan after the initial vaccination (Figure 5.5, P<0.05). IM delivery of liquid 
vaccine provided equivalent serum antibody titers to those obtained by IN liquid and IN 
powder with No MA, CMC HMW, SA, and HPMC HMW, and significantly greater serum 
antibody titers than IN powder with chitosan after boosting (P<0.05). IN liquid vaccine 
provided equivalent serum antibody titers to those obtained by IN powder without MA, CMC 
HMW, SA, chitosan, and HPMC HMW after the initial vaccination. IN liquid provided 
significantly greater serum antibody titers than IN powder with chitosan after boosting, and 
was equivalent to all other formulations (P<0.05).  
Initial studies of the formulation and dosing of a dry powder influenza vaccine for 
nasal delivery have been described (Huang, Garmise et al. 2004; Garmise, Mar et al. 2006) 
WIIV and trehalose were freeze-dried, milled, and sieved to produce particles in the 45-125 
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µm size range. Antibody responses were elicited in rats using a 100 μg powder vaccine and 
chitosan blend that generated strong nasal mucosal and systemic immune responses. The 
chitosan mucoadhesive powder formulation generated significantly greater antibody titers 
compared to IM injection, IN liquid, or IN powder without mucoadhesive formulations at 
this dosing level after initial vaccination. Similar serum antibody titers were seen in chitosan 
mucoadhesive powder, IM injection, and IN liquid. Comparable nasal IgA titers were 
generated in the IN groups containing antigen, while no nasal IgA response was seen in 
animals dosed IM or with excipients alone intranasally.  
In the present experiments, similar serum antibody levels to the previous study were 
achieved after dosing IN liquid 2 μg H after the initial vaccination and boosting and the IM 
after boosting to the previous experiment. However, a 10-fold higher response was generated 
by IM injection after initial vaccination than the previous experiment. The IN powder 
containing chitosan elicited a 10-fold higher response after the initial vaccination, but a 
comparable response after boosting. One possible explanation for this could be due to a 
potential adjuvant effect caused by impurities in the chitosan. In the present studies, highly 
purified (< 2% impurities) chitosan was blended with the WIIV-SFD particles. This chitosan 
did not require cryo-milling to produce particles in the desired size range. MA utilized in the 
present study were assayed to quantify for the presence of endotoxin. There was no more 
than 0.11 ng of endotoxin present in the MA in any dose of vaccine, an order of magnitude 
lower than normally administered as an adjuvant (Nelson, Prior et al. 2004). In both the 
previous and current studies, after initial vaccination and a boost, comparable serum antibody 
levels were seen when dosed IM, IN liquid, or IN powder with MA. 
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5.3.3.1 IgG Isotyping 
Serum IgG1, IgG2a and IgG2b isotypes were measured as an indirect assessment of 
T-helper (Th) cell activity (Figure 5.6). In rats, IgG1 and IgG2a antibodies are associated 
with Th2 activity, while IgG2b antibody is suggestive of a Th1 response (Bazin 1990). All 
groups generated a mixed and balanced response consisting of IgG1, IgG2a and IgG2b. 
There was no major shift of the Th1/Th2 response across the different formulations. The data 
show that all of the formulations and routes of administration elicited a mixed IgG subclass 
response, which may be important for protection against influenza and other pathogens. 
5.3.3.2 HA Inhibition (HAI) Assay 
HAI titers also displayed a similar pattern of response as ELISA and IgG isotyping 
(Figure 5.7). 
5.3.3.3 Nasal IgA Titers 
Substantial IgA titers were seen in all rats after intranasal immunization (Figure 5.8). 
All of the nasal IgA titers elicited from nasal formulations were significantly greater than IM 
injection except for IN powder with chitosan (P<0.05). There were no statistically significant 
differences seen between any of the IN formulations. The production of a mucosal immune 
response in the form of IgA production demonstrates that intranasal delivery of the WIIV 
will produce both a local and systemic immune response. 
 
In Chapter 4 one powder, containing SA, was shown to have an increased residence 
time in the nasal cavity. No statistically significant differences were noted between 
formulations in eliciting both IgA and IgG responses. However, the trend was that SA 
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elicited the highest IgA response of all treatments including solution. Even as it elicited one 
of the higher IgG responses, arguably the trehalose alone and liquid treatments elicited 
greater responses. While trends in the immune responses may be interpreted to support the 
original hypothesis, powder preparations containing WIIV were not statistically different in 
their effect. 
 5.4 Summary 
 A dose-response experiment ranging from 0.5 to 40 μg equivalent H was performed 
using IM and IN liquids to determine an appropriate dose to quantify potential differences in 
antibody response elicited as a function of formulation in Brown Norway rats. Animals were 
given an initial dose, followed by a boost dose three weeks later. Serum samples taken three 
weeks after the initial dose and two weeks after the boost were analyzed by ELISA for the 
presence of antibodies. Two weeks after the boost dose, the animals were sacrificed and nasal 
washes were taken to quantify the production of mucosal antibodies. Once a dose was 
determined, IM injection, IN liquid, and IN powders containing trehalose alone, or 3% SA, 
CMC HMW, HPMC HMW, and chitosan were dosed as described above. IgG, IgG isotypes, 
and HAI were quantified using serum, while the IgA was quantified using nasal washings. 
IN delivery of liquid vaccine provided equivalent serum antibody titers as those 
obtained by IM injection at doses ≥2.5 μg after the initial vaccination, but at doses ≤2 μg, the 
serum antibody titers elicited by IM injection were significantly greater than that of IN liquid 
after the first dose. After the boost dose, the immune response elicited at doses of 0.5, 1, 2.5, 
5, and 10 μg is equivalent for both the IM injection and the IN liquid Positive nasal IgA 
responses were seen after administration of IN liquid, regardless of dose. No detectable IgA 
responses were observed following IM injection. A 2 μg dose was chosen to use in the 
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formulation experiments. In the formulation experiments, IM delivery of liquid vaccine 
provided equivalent serum antibody titers as those obtained by IN powder with No MA, 
CMC HMW, SA, and HPMC HMW after the initial dose and equivalent serum antibody 
titers as those obtained by IN liquid and IN powder with No MA, CMC HMW, SA, and 
HPMC HMW after the boost. IN liquid vaccine provided equivalent serum antibody titers as 
those obtained by IN powder with No MA, CMC HMW, SA, chitosan, and HPMC HMW 
after the initial vaccination. IN liquid provided significantly greater serum antibody titers 
than IN powder with chitosan after boosting, and was equivalent to all other formulations. 
IgG isotyping and HAI displayed similar patterns of response as serum antibody levels. 
 While no significant differences between powder and liquid formulations were 
observed, trends were consistent with the observations from the residence time studies with 
respect to the eliciting an immune response.  The following chapter will discuss in greater 
detail the conclusions that may be drawn from these findings with respect to the hypothesis 
and specific aims and the implications for the potential future studies.   
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Figure 5.1– The primary and secondary immune response elicited by a vaccine and boost 
dose as a function of time (Adapted from (Gosling and Basso 1994)). 
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Figure 5.2– Serum antibody titers elicited after primary vaccination in a dose-response study, 
3 weeks after dosing of whole inactivated influenza virus in the rat model either 
intramuscularly (IM) or intranasally (IN) in saline (n=3, error bars represent positive standard 
deviation).  
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Figure 5.3– Serum antibody titers elicited after boost vaccination in a dose-response study, 2 
weeks after dosing of whole inactivated influenza virus in the rat model either 
intramuscularly (IM) or intranasally (IN) in saline (n=3, error bars represent positive standard 
deviation).  
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Figure 5.4– Mucosal antibody titers elicited after primary and boost vaccination in a dose-
response study, 2 weeks after boost dosing of whole inactivated influenza virus in the rat 
model intranasally (IN) in saline (n=3, error bars represent positive standard deviation). 
There was no mucosal immune response elicited in any of the rats dosed intramuscularly 
(IM). 
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Figure 5.5– Serum antibody titers elicited after primary vaccination in a formulation study, 3 
weeks after initial dosing (Bleed 1) and 2 weeks after boost dosing (Bleed 2) of whole 
inactivated influenza virus in the rat model either intramuscularly (IM) or intranasally (IN) in 
saline or IN powder with a mucoadhesive compound (n=6, error bars represent positive 
standard deviation).  
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Figure 5.6– Concentration of IgG isotypes elicited after primary and boost vaccination in a 
formulation study, 2 weeks after boost dosing of whole inactivated influenza virus in the rat 
model either intramuscularly (IM) or intranasally (IN) in saline or IN powder with a 
mucoadhesive compound (n=6, error bars represent standard deviation). Naïve, unimmunized 
rats were used as controls. 
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Figure 5.7– Hemagglutin inhibition titers elicited after primary and boost vaccination in a 
formulation study, 2 weeks after boost dosing of whole inactivated influenza virus in the rat 
model either intramuscularly (IM) or intranasally (IN) in saline or IN powder with a 
mucoadhesive compound (n=6, error bars represent standard deviation). 
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Figure 5.8– Formulation nasal lavage. 
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6 CONCLUSIONS AND FUTURE WORK 
6.1  Conclusions 
Needle-free vaccine delivery is a major current objective with respect to the treatment 
of global infectious disease (Giudice and Campbel 2006). There would be significant 
advantages to the development and delivery of dry powder intranasal vaccines designed to 
overcome a number of the short comings associated with currently marketed intramuscular 
(IM) and intranasal (IN) liquid influenza vaccines. The limitations, pertaining to IM 
injection, are based on the requirement for: 1) invasive injections, 2) delivery by trained 
health care professionals, 3) refrigeration, 4) sterility, and 5) disposal of biological waste. 
The live, attenuated IN vaccine must be stored frozen and thawed immediately before use 
and has not been approved for use in select populations such as children, the elderly and the 
immunocompromised, which are most commonly affected by the virus. The present work 
involved the manufacture and development of a dry powder, inactivated, heat-stable 
influenza vaccine for nasal delivery which was intended to overcome these shortcomings. 
Mucoadhesive compounds (MA), such as chitosan, have been widely used to increase the 
residence time in the nasal cavity and therefore, increase the immune response elicited by a 
nasal vaccine. The literature primarily focuses on the use of liquid formulations and there has 
been no study published comparing in vitro characterization of nasal powder formulations to 
in vivo experiments for use in nasal vaccines. It was proposed that maximal mucosal and 
systemic antibody production would be elicited by a dry powder nasal vaccine formulation 
containing whole inactivated influenza virus by increasing the local residence time. This 
hypothesis was addressed by the following series of specific aims. 
1. To prepare particles containing whole inactivated influenza virions and to evaluate 
the powder properties for nasal delivery.  
2. To demonstrate the effectiveness of the powder vaccine delivered intranasally in 
eliciting a local IgA and systemic IgG immune response in vivo. 
 
To prepare particles containing whole inactivated influenza virions and to evaluate the 
powder properties for nasal delivery.  
Two manufacturing methods were employed to produce particles suitable for nasal 
delivery: freeze-drying (FD) followed by milling and sieving, and spray-freeze-drying (SFD). 
Designed experiments examining three factors (freezing rate, solute concentration, and 
annealing for freeze-drying and solution feed rate, atomization airflow rate, and solute 
concentration for spray-freeze-drying) in a full 23 factorial design were used to produce 
particles suitable for nasal delivery. The primary characteristics (measured by laser 
diffraction) were: median diameter (D50), 90% diameter (D90), 10% diameter (D10), and span 
(D90-D10/D50).  
Freeze-drying followed by milling and sieving produced particles well below the 
targeted particle size for human delivery (D50=40 µm). Also, a significant percentage of the 
powder was in a size range that could potentially deposit in the lower respiratory tract (the 
lungs). Additionally, heterogeneous shape of the milled particles is unsuitable for blending 
with MA. Freeze-drying followed by milling and sieving produced particles suitable for nasal 
delivery to rats (D50=25 µm) under the following conditions: 10% trehalose solution, frozen 
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at the slow freezing rate, without annealing, lyophilized, milled at 200 rpms for 30 minutes, 
and sieved in tap mode for 2 hours. 
An optimized spray-freeze-drying run of 10% trehalose, a 20 mL/min solution feed 
rate and an atomization airflow rate of 300 L/hr was employed to successfully produce 
spherical particles for potential human delivery with a D50=38.5 µm. Also, an optimized 
spray-freeze-drying run of 10% trehalose, a 10 mL/min solution feed rate and an atomization 
airflow rate of 500 L/hr successfully produce particles for rat delivery with a D50=26.9 µm. 
Ultimately, the morphological and size characteristics of the SFD particles were considered 
superior to the FD particles with respect to the potential for blending reproducibly with MA 
and minimizing the presence of small particles with potential for deposition in the lower 
respiratory tract. The SFD particles were selected for use in subsequent vaccine formulations. 
SFD and MA powders were characterized for their physico-chemical properties. 
Based on Carr’s Compressibility Index (CCI), 25 µm SFD was the only powder to be 
considered free-flowing. Bulk and sieved fractions of SA and chitosan were the only MA to 
be considered free-flowing. The static angle of repose of SFD rat was larger than 25 µm SFD 
and bulk, sieved trehalose, but all three powders are regarded as free-flowing. All of the MA 
were considered free-flowing with the exception of sieved CMC HMW, bulk chitosan, and 
sieved chitosan. Impact energy separation can be a useful tool in characterizing the adhesive 
and cohesive forces of powders. Trends seen after increasing impact energies were in 
agreement with the flow properties of the powders. 
The surface areas of the SFD formulations were significantly greater than bulk 
trehalose, while the true densities of the SFD formulations and bulk trehalose were the same, 
indicating that the SFD process produced porous particles. The moisture content of the SFD 
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powders was significantly less than the bulk trehalose and the MA. Additionally, the thermal 
analysis indicated that the SFD powders were amorphous. Results from stability studies 
performed at different temperatures and relative humidities (4°C and 50% RH, 23°C and 
40% RH, and 37°C and 80% RH) demonstrate the improved vaccine storage stability 
provided by the powder formulation compared to liquid formulation.  
A modified cascade impactor (MCI) was developed to characterize the particle size 
fraction capable of deposition in the lower respiratory tract. This is an important measure of 
the potential for delivery to a site which is not the route of administration, and which could 
lead to potential toxicity. Monodisperse aerosols were utilized to calibrate the Stage -2 and 
Stage -0 of an Andersen Mk II non-viable cascade impactor at 15 liters per minute flow rate. 
This novel setup extended the ceiling of the range of particle sizes that the cascade impactor 
can characterize from 8.7 to 16.5 µm. The MCI was used to characterize the dispersion of the 
SFD human powder from two devices: monodose insufflator and a device developed by 
Becton Dickinson Technologies (BDT). No significant differences were seen in any of the 
mass fractions, between devices and both delivered a potential lung dose fraction (LDF) of 
10-12%.  
In vitro experiments were performed to predict the effect that mucoadhesive 
compounds (MA) had on the residence time of formulations in the nasal cavity. Wettability, 
dissolution rate, and swelling indices were completed on MA to characterize hydroxypropyl 
methylcellulose (HPMC), carboxymethylcellulose sodium (CMC), sodium alginate (SA), and 
chitosan. The contact angle of the HPMC HMW and HPMC LMW were significantly greater 
than the other polymers, indicating a prolonged dissolution time. This correlated with the 
dissolution studies that indicated that CMC HMW and SA dissolved at a faster rate than the 
 206
HPMC compounds. The swelling indices of CMC HMW and SA were significantly greater 
than the other MA. Based on in vitro experiments, CMC HMW and SA were identified as 
two compounds that can increase residence time in the nasal cavity by dissolving in the nasal 
mucosa, allowing for chain entanglement with mucin, and taking up a substantial amount of 
fluid, increasing the viscosity of the nasal mucus. 
Gamma scintigraphy and residence time studies were completed to determine the 
effect of formulation on the residence time in the nasal cavity of Brown Norway rats. Gamma 
scintigraphy allowed for the visual clearance of saline from the nasal cavity of a Brown 
Norway rat. The residence time studied indicated that increasing the viscosity did not have a 
great effect on the residence time and powder formulations required MA to have comparable 
residence times to liquid formulations with or without mucoadhesive in Brown Norway rats. 
The rank order of residence time for powders is SA>CMC HMW, Chit>HPMC HMW, No 
MA. The in vitro and in vivo experiments indicate that SA and CMC HMW in powder 
formulations have the greatest effect on increasing residence time in the nasal cavity of 
Brown Norway rats. 
 
To demonstrate the effectiveness of the powder vaccine delivered intranasally in eliciting a 
local IgA and systemic IgG immune response in vivo. 
A dose-response experiment ranging from 0.5 to 40 μg equivalent HA was performed 
using IM and IN liquids to determine an appropriate dose to quantify potential differences in 
antibody response elicited as a function of formulation in Brown Norway rats. IN delivery of 
liquid vaccine provided equivalent serum antibody titers as those obtained by IM injection at 
doses ≥2.5 μg after the initial vaccination, but at doses ≤2 μg, the serum antibody titers 
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elicited by IM injection were significantly greater than that of IN liquid after the first dose. 
After the boost dose, the immune response elicited at doses of 0.5, 1, 2.5, 5, and 10 μg is 
equivalent for both the IM injection and the IN liquid. Positive nasal IgA responses were 
seen after administration of IN liquid, regardless of dose. No detectable IgA responses were 
observed following IM injection. A 2 μg dose was chosen to use in the formulation 
experiments. 
Once a dose was determined, IM injection, IN liquid, and IN powders containing 
trehalose alone, or 3% SA, CMC HMW, HPMC HMW, and chitosan were dosed. IM 
delivery of liquid vaccine provided equivalent serum antibody titers as those obtained by IN 
powder with no MA, CMC HMW, SA, and HPMC HMW after the initial dose and 
equivalent serum antibody titers as those obtained by IN liquid and IN powder with no MA, 
CMC HMW, SA, and HPMC HMW after the boost. IN liquid vaccine provided equivalent 
serum antibody titers as those obtained by IN powder with no MA, CMC HMW, SA, 
chitosan, and HPMC HMW after the initial vaccination. IgG isotyping and HAI displayed a 
similar pattern of response as the IgG. While no significant differences between powder and 
liquid formulations were observed. Trends are consistent with the observations from the 
residence time studies with respect to the eliciting an immune response.  
Preliminary experiments evaluating residence time of various preparations in the 
nasal cavity of Sprague Dawley rats (350-400 g) were conducted using the same procedure 
used in Brown Norway rats (Appendix A.5). These studies were completed prior to those in 
Brown Norway rats; however, it was important to conduct replicate experiments in the strain 
of rats that would be employed in the immunogenicity studies. In Sprague Dawley rats, all of 
the liquid formulations with MA and powder formulations had larger areas under the 
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radiolabeled preparation retention curve (AUC) than the saline (Liq- No MA). Figure 6.1 
shows the AUC data for both Brown Norway (Figure 4.8, Chapter 4, Section 4.3.5) and 
Sprague Dawley (Figure A.5.5, Appendix 5) rats. There is a clear pattern of increased 
residence time for powder formulations compared with liquid formulations in Sprague 
Dawley rats which is echoed in the Brown Norway rats, with the exception of the high AUCs 
for liquids in the latter strain. All of the powders, with the exception of Pow- SA (trehalose 
and SA) had longer residence times than the liquid formulations with the same MA, in 
Sprague Dawley rats. The AUC of the Liq- SA and Pow- SA were the same. The rank order 
of powders was Pow- CMC>Pow- HPMC HMW, Pow- No MA>Pow- SA>Pow- Chit. 
Compared to the AUC of the Brown Norway rats, the residence time of the liquids in 
Sprague Dawley rats was significantly lower, while the residence time of the Pow- No MA 
and Pow- HPMC HMW were significantly greater. This data indicates residence time 
differences between strains of rats. This may be due to variability from strain to strain or to 
differences in the size of the animals. The Brown Norway rats are used as an immunological 
model, but it would be plausible to think that the differences in residence time seen in the 
Sprague Dawley rats could potentially lead to differences in the immune response elicited if 
this was a susceptible strain. Moreover, if size of nasal cavity with respect to delivered dose 
is of significance then other species, such as the rabbit may be a logical selection for further 
studies (Little, Ivins et al. 2006).  
 
While no significant differences between powder and liquid formulations were 
observed in Brown Norway rats, there is reason to believe that this will not necessarily be the 
case in the other species. As previously mentioned, the location of the nasal-associated 
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lymphoid tissue (NALT) in the rat is in the anterior portion of the nasal cavity. All of the 
nasal formulations come in contact with this tissue. Differences in residence time may 
become important if the target tissue is located in the posterior portion of the nasal cavity, as 
is currently thought to be the case in humans.  
The dose response, while apparently sufficient to conduct the study of the antigen, 
ultimately did not facilitate clear discrimination of effects. At extremely low IM doses the 
immune response elicited was not significantly different than that at high doses. However, 
the immune response elicited by IN liquid at a dose of 0.5 μg was significantly lower than 
that of IM, but was still substantial. Other antigens may be more discriminating based on 
their dose response profiles. 
Mucosal and systemic responses to WIIV were elicited following dry powder nasal 
vaccine delivery at a level equivalent to IN and IM delivery of solutions. However, it is 
unclear whether local residence time played a role in the animal model of immunogenicity 
employed in these studies. Consequently, the hypothesis is not fully supported by the 
evidence presented. Further work, in a more anatomically relevant animal model, may 
demonstrate conclusively the influence of mucoadhesive compounds on vaccine residence 
time at the nasal mucosa with implications for elicited immune response. 
These experiments described did address the potential to overcome cold chain 
requirements (needed for vaccine stability) and to provide single-use, non-refillable delivery 
technologies that require minimal training. An inactivated, heat-stable, unit-dose vaccine was 
developed that can elicit both a local and systemic immune response in Brown Norway rats 
comparable to IM injection, which would be beneficial when used for influenza prevention, 
since the virus enters the host by this route. Further development of this approach may 
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ultimately provide a safe and an effective alternative to the currently available influenza 
vaccines.  
 
6.2 Future Work 
 A dry powder nasal influenza vaccine was manufactured utilizing HPMC, CMC, SA, 
or chitosan as MA in Brown Norway rats. These are a small subset of polymers that may be 
utilized to vary residence time in the nasal cavity. Other compounds include, but should not 
be limited to: polyacrylic acids, polyvinyl pyrrolidone, polyethylene glycols, and poly(lactic-
co-glycolic acid). These compounds have been shown, in separate studies, to increase the 
residence time in the nasal cavity (Ugwoke, Agu et al. 2005). With the characterization 
approach described here, a large number of compounds can be systematically screened and 
ranked based on the contact angles, dissolution rates, and swelling indices. 
A direct imaging approach to quantify residence time in the nasal cavity is desirable. 
The sequential lavage method, described here, is time consuming and costly because each 
data point represents one or more animals. An imaging technique would allow fewer animals 
to be dosed sequentially in a relatively non-invasive manner and monitored over a period of 
time. Inter-animal variability would be avoided as each animal would be its own control. 
Once this method was established it would be an ethically superior approach to the sequential 
lavage studies, as animals could potentially be rested and used in subsequent experiments.  
The immune response experiments should be completed in other susceptible rat 
strains or species. Comparisons should be made between strains and species to allow 
extrapolation to man. Unlike rats, rabbits and pigs are relatively small animals with NALT 
configurations similar to that in humans. Difference in NALT location may help in 
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determining if the length of residence time in the nasal cavity can affect the immune response 
elicited. Ultimately, it would be desirable to conduct studies of residence times in humans. 
However, evidence of safety of the entire formulation and its components would be required 
prior to the performance of such studies. 
The ultimate test of the effectiveness of a vaccine is a challenge study, which 
involves vaccination of animals and exposure to virulent micro-organism to demonstrate 
protection from infection. A rat-adapted influenza virus (RAIV) has been previously 
described (Lebrec and Burleson 1994). Briefly, a human A/Port Chalmers/1/73 (H3N2) 
influenza virus has been adapted to be infectious in rats as a model of mild pulmonary 
influenza virus infection. The timeline of events in the rats after infection is known and 
physical symptoms of the virus, usually seen in the first 48 hours following inoculation 
include: epithelial lesions of the nose and septum, epithelial erosion, an influx of neutrophils 
into the respiratory tract. Ninety-six hours after infection, the presence of virus in the tissue is 
minimal. After vaccination, rats exposed to the RAIV will not show any signs of infection if 
the vaccination is successful. Use of this method is limited because the RAIV is proprietary. 
There are few alternative models in mice and ferrets (McLaren, Potter et al. 1974; Alymova, 
Kodihalli et al. 1998), but better models are required since anatomical and physiological 
relevance are as important as immunological relevance. Rabbits, non-human primates and 
pigs are considered anatomically and physiologically relevant (Ivins, Pitt et al. 1998; 
Macklin, McCabe et al. 1998; Little, Ivins et al. 2006), but their use in influenza challenge 
studies is as yet unproven.  
The scope of the work performed does not have to be limited to the influenza virus. 
The immune response experiments can be completed utilizing a variety of different antigens. 
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Differences in the immunogenicity of the antigen could potentially lead to different outcomes 
of these experiments. It is possible that an increase in residence time in the nasal cavity can 
increase the immune response elicited by a low potency antigen. This could enable a wide 
variety of vaccines to be produced without the presence of an adjuvant, while still achieving 
the same immune response. Current interest in biodefense has increased research with respect 
to both human (e.g. anthrax, (Jiang, Joshi et al. 2006)) and animal (e.g. Newcastle disease in 
chickens, (Corbanie, Remon et al. 2006)) 
This project focused on the use of dry powder nasal vaccines. These principles can be 
applied to drugs. An extended residence time in the nasal cavity will allow larger quantities 
of drug to pass through the nasal epithelium into systemic circulation or allow longer activity 
for locally acting compounds. However, this is a well documented application of both 
mucoadhesives and nasal delivery. The significance of the present work may be for 
macromolecules where in addition to enhanced residence time and local delivery to nasal 
cavity, stable preparations are required. Currently, the only macromolecule delivered nasally 
is calcitonin for the treatment of osteoporosis (Body 2002). The present observations may be 
useful for developing stable preparations of other peptides or proteins.  
In conclusion, potential future studies may be grouped into several categories: (a) 
studies of formulation effects on residence time in other anatomically and physiologically 
relevant species; (b) performance of challenge studies in the rat or mouse or development of 
models in other species; (c) application to other antigens for vaccination of humans or 
animals and (d) application to drugs, notably macromolecules, where some features of 
preparations described in these studies would offer advantages with respect to existing 
approaches.         
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Figure 6.1– The area under the curve of the percentage of radioactivity as a function of time 
curves for liquid and powder formulations containing no mucoadhesive (No MA), 
hydroxypropyl methylcellulose (HPMC HMW), sodium alginate (SA), 
carboxymethylcellulose sodium (CMC HMW), and chitosan (Chit) in Brown Norway and 
Sprague Dawley rats.  
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 APPENDICES 
 
Appendix A.1- ANALYSIS OF VARIANCE (ANOVA), RESIDUAL PLOTS, AND 
INTERACTION GRAPHS FOR DESIGNED EXPERIMENTS 
 
FREEZE-DRYING 
  
 Design Summary 
 
 Study Type Factorial  Experiments           24 
 Initial Design 2 Level Factorial Blocks  No Blocks 
 Center Points 0 
 Design Model 3FI 
 
  
Response Name Units Obs Minimum Maximum Trans Model 
Y1 D50 um 24 10.67 28.65 None 3FI 
Y2 D90 um 24 22.97 89.94 None R2FI 
Y3 D10 um 24 0.97 6.95 None 3FI 
Y4 Span  24 1.77 3.94 None 3FI 
 
 
 
Factor Name Units Type Low Actual 
High 
Actual 
Low 
Coded 
High 
Coded 
A Freeze Rate  Categorical Slow Fast -1.000 1.000 
B Concentration g/100 mL Numeric 1.00 10.00 -1.000 1.000 
C Annealing  Categorical No Yes -1.000 1.000 
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MEDIAN DIAMETER (D50) 
  
Response: D50
  
Factor Name Units Type -1 Level +1 Level 
 A Freeze Rate  Categorical Slow Fast 
 B Conc. g/100 mL Numeric 1.00 10.00 
 C Annealing  Categorical No Yes 
 
 ANOVA for Selected Factorial Model 
   
Source Sum of Squares DF 
Mean 
Square F Value Prob > F 
Model 924.34 7 132.05 416.40 < 0.0001 
Residual 5.07 16 0.32   
Pure Error 5.07 16 0.32   
Cor Total 929.41 23    
 
 Root MSE 0.56  R-Squared  0.9945 
 Dep Mean 18.43  Adj R-Squared 0.9922 
 C.V. 3.06  Pred R-Squared 0.9877 
 PRESS 11.42  Adeq Precision 54.071  Desire > 4 
 
Factor Coefficient Estimate DF 
Standard 
Error 
t for 
H0Coeff=0 
Prob > |t| VIF 
Intercept 18.43 1 0.11    
A-Freeze Rate 0.95 1 0.11 8.26 < 0.0001 1.00 
B-Conc. 0.25 1 0.11 2.14 0.0482 1.00 
C-Annealing -4.40 1 0.11 -38.24 < 0.0001 1.00 
AB 2.28 1 0.11 19.87 < 0.0001 1.00 
AC 2.20 1 0.11 19.15 < 0.0001 1.00 
BC 2.79 1 0.11 24.31 < 0.0001 1.00 
ABC 0.60 1 0.11 5.23 < 0.0001 1.00 
 
  Final Equation in Terms of Coded Factors: 
 
D50 = 18.43 + 0.95*A + 0.25*B - 4.40*C + 2.28*AB + 2.20*AC + 2.79*BC + 0.60*ABC 
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Diagnostics Case Statistics 
  
Std 
Order 
Actual 
Value 
Predicted 
Value Residual Distance 
Student 
Residual 
Cook's 
Leverage Outlier t 
1 27.78 28.31 -0.53 0.333 -1.145 0.082 -1.158 
2 28.49 28.31 0.18 0.333 0.399 0.010 0.388 
3 28.65 28.31 0.34 0.333 0.747 0.035 0.736 
4 22.29 22.44 -0.15 0.333 -0.319 0.006 -0.310 
5 21.67 22.44 -0.77 0.333 -1.667 0.174 -1.776 
6 23.35 22.44 0.91 0.333 1.986 0.247 2.216 
7 19.92 19.84 0.077 0.333 0.167 0.002 0.162 
8 19.69 19.84 -0.15 0.333 -0.333 0.007 -0.324 
9 19.92 19.84 0.077 0.333 0.167 0.002 0.162 
10 19.84 20.71 -0.87 0.333 -1.885 0.222 -2.069 
11 20.49 20.71 -0.22 0.333 -0.471 0.014 -0.459 
12 21.79 20.71 1.08 0.333 2.356 0.347 2.823 
13 10.81 10.73 0.083 0.333 0.181 0.002 0.176 
14 10.70 10.73 -0.027 0.333 -0.058 0.000 -0.056 
15 10.67 10.73 -0.057 0.333 -0.123 0.001 -0.119 
16 12.06 11.26 0.80 0.333 1.747 0.191 1.881 
17 10.97 11.26 -0.29 0.333 -0.623 0.024 -0.611 
18 10.74 11.26 -0.52 0.333 -1.124 0.079 -1.134 
19 11.06 11.04 0.023 0.333 0.051 0.000 0.049 
20 11.01 11.04 -0.027 0.333 -0.058 0.000 -0.056 
21 11.04 11.04 0.003 0.333 0.007 0.000 0.007 
22 22.91 23.11 -0.20 0.333 -0.428 0.011 -0.417 
23 22.95 23.11 -0.16 0.333 -0.341 0.007 -0.331 
24 23.46 23.11 0.35 0.333 0.768 0.037 0.758 
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Figure A.1.1– Residuals plotted versus predicted values for the model describing the effect of 
various factors on median diameter (D50) of powders manufactured by FD followed by 
milling and sieving. 
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Figure A.1.2– Interaction graphs indicating the effects of a) solute concentration (B-=1%, 
B+=10%) and freezing rate (A-=Slow, A+=Fast), and b) annealing (C-=No, C+=Yes) and 
freezing rate (A-=Slow, A+=Fast) on median diameter (D50) of particles produced by FD 
followed by milling and sieving. 
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Figure A.1.3– Interaction graphs indicating the effects of annealing (C-=No, C+=Yes) and 
solute concentration (B-=1%, B+=10%) on median diameter (D50) of particles produced by 
FD followed by milling and sieving. 
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90% DIAMETER (D90) 
 
Response:  D90 
  
Factor Name  Units   Type -1 Level +1 Level 
 A Freeze Rate      Categorical       Slow Fast 
 B Concentration g/100 mL   Numeric    1.00 10.00 
 C Annealing      Categorical     No Yes 
 
 ANOVA for Selected Factorial Model 
 
Source Sum of Squares DF 
Mean 
Square F Value Prob > F 
Model 7380.68 4 1845.17 43.27 < 0.0001 
Residual 810.20 19 42.64   
Lack of Fit 124.32 3 41.44 0.97 0.4326 
Pure Error 685.88 16 42.87   
Cor Total 8190.88 23    
 
 Root MSE 6.53  R-Squared  0.9011 
 Dep Mean 53.99  Adj R-Squared 0.8803 
 C.V.  12.09  Pred R-Squared 0.8422 
 PRESS  1292.73 Adeq Precision 20.036   Desire > 4 
 
  
Factor Coefficient Estimate DF 
Standard 
Error 
t for 
H0Coeff=0 
Prob > |t| VIF 
Intercept 53.99 1 1.33    
A-Freeze Rate 10.01 1 1.33 7.51 < 0.0001 1.00 
B-Concentration -0.087 1 1.33 -0.065 0.9486 1.00 
C-Annealing -12.19 1 1.33 -9.15 < 0.0001 1.00 
BC 7.65 1 1.33 5.74 < 0.0001 1.00 
 
    Final Equation in Terms of Coded Factors: 
    
   D90 = 53.99 + 10.01*A - 0.087*B - 12.19*C + 7.65*BC 
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Diagnostics Case Statistics 
  
Std 
Order 
Actual 
Value 
Predicted 
Value Residual Distance 
Student 
Residual 
Cook's 
Leverage Outlier t 
1 66.74 63.91 2.83 0.208 0.487 0.012 0.477 
2 65.57 63.91 1.66 0.208 0.285 0.004 0.278 
3 70.28 63.91 6.37 0.208 1.096 0.063 1.102 
4 75.13 83.94 -8.81 0.208 -1.516 0.121 -1.574 
5 78.41 83.94 -5.53 0.208 -0.951 0.048 -0.949 
6 87.42 83.94 3.48 0.208 0.599 0.019 0.589 
7 45.89 48.43 -2.54 0.208 -0.438 0.010 -0.428 
8 44.89 48.43 -3.54 0.208 -0.610 0.020 -0.600 
9 47.00 48.43 -1.43 0.208 -0.247 0.003 -0.241 
10 59.73 68.46 -8.73 0.208 -1.502 0.119 -1.558 
11 63.23 68.46 -5.23 0.208 -0.900 0.043 -0.895 
12 89.94 68.46 21.48 0.208 3.697 0.719 6.793 * 
13 23.24 24.22 -0.98 0.208 -0.168 0.001 -0.164 
14 22.97 24.22 -1.25 0.208 -0.215 0.002 -0.209 
15 22.97 24.22 -1.25 0.208 -0.215 0.002 -0.209 
16 48.91 44.24 4.67 0.208 0.803 0.034 0.795 
17 42.18 44.24 -2.06 0.208 -0.355 0.007 -0.347 
18 45.12 44.24 0.88 0.208 0.151 0.001 0.147 
19 40.36 39.35 1.01 0.208 0.174 0.002 0.170 
20 38.68 39.35 -0.67 0.208 -0.115 0.001 -0.112 
21 39.15 39.35 -0.20 0.208 -0.034 0.000 -0.033 
22 62.59 59.37 3.22 0.208 0.553 0.016 0.543 
23 59.15 59.37 -0.22 0.208 -0.039 0.000 -0.038 
24 56.24 59.37 -3.13 0.208 -0.539 0.015 -0.529 
 
* Case(s) with |Outlier t| > 3.50 
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Figure A.1.4– Residuals plotted versus predicted values for the model describing the effect of 
various factors on 90% diameter (D90) of powders manufactured by FD followed by milling 
and sieving. 
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Figure A.1.5– Interaction graphs indicating the effects of annealing (C-=No, C+=Yes) and 
solute concentration (B-=1%, B+=10%) on 90% diameter (D90) of particles produced by FD 
followed by milling and sieving. 
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10% DIAMETER (D10) 
  
Response: D10
 
 Factor Name         Units Type -1 Level +1 Level 
 A Freeze Rate  Categorical Slow Fast 
 B          Concentration     g/100 mL  Numeric 1.00 10.00 
 C Annealing   Categorical No Yes 
 
ANOVA for Selected Factorial Model 
 
Source Sum of Squares DF 
Mean  
Square F Value Prob > F 
Model 60.35 7 8.62 49.11 < 0.0001 
Residual 2.81 16 0.18   
Pure Error 2.81 16 0.18   
Cor Total 63.16 23    
 
 Root MSE 0.42  R-Squared  0.9555 
 Dep Mean 4.94  Adj R-Squared 0.9361 
 C.V.  8.48  Pred R-Squared 0.8999 
 PRESS  6.32  Adeq Precision 18.107   Desire > 4 
  
Factor Coefficient Estimate DF 
Standard 
Error 
t for H0 
Coeff=0 Prob > |t| VIF 
Intercept 4.94 1 0.086    
A-Freeze Rate 0.22 1 0.086 2.55 0.0213 1.00 
B-Concentration -0.19 1 0.086 2.19 0.0435 1.00 
C-Annealing -1.06 1 0.086      -12.34 < 0.0001 1.00 
AB 0.81 1 0.086 9.44 < 0.0001 1.00 
AC 0.52 1 0.086 6.02 < 0.0001 1.00 
BC 0.30 1 0.086 3.56 0.0026 1.00 
ABC 0.56 1 0.086 6.50 < 0.0001 1.00 
 
    Final Equation in Terms of Coded Factors: 
  
D10= 4.94 + 0.22*A + 0.19*B - 1.06*C + 0.81*AB + 0.52*AC + 0.30*BC + 0.56*ABC 
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   Diagnostics Case Statistics 
  
Std 
Order 
Actual 
Value 
Predicted 
Value Residual Distance 
Student 
Residual 
Cook's 
Leverage Outlier t 
1 6.66 6.66 -0.003 0.333 -0.010 0.000 -0.009 
2 6.95 6.66 0.29 0.333 0.838 0.044 0.830 
3 6.38 6.66 -0.28 0.333 -0.828 0.043 -0.820 
4 5.54 5.57 -0.027 0.333 -0.078 0.000 -0.075 
5 5.49 5.57 -0.077 0.333 -0.224 0.003 -0.217 
6 5.67 5.57 0.10 0.333 0.302 0.006 0.293 
7 5.92 5.93 -0.0067 0.333 -0.019 0.000 -0.019 
8 5.86 5.93 -0.067 0.333 -0.195 0.002 -0.189 
9 6.00 5.93 0.073 0.333 0.214 0.003 0.208 
10 5.78 5.84 -0.057 0.333 -0.166 0.002 -0.161 
11 5.90 5.84 0.063 0.333 0.185 0.002 0.179 
12 5.83 5.84 -0.0067 0.333 -0.019 0.000 -0.019 
13 4.05 4.03 0.023 0.333 0.068 0.000 0.066 
14 4.06 4.03 0.033 0.333 0.097 0.001 0.094 
15 3.97 4.03 -0.057 0.333 -0.166 0.002 -0.161 
16 2.81 2.77 0.043 0.333 0.127 0.001 0.123 
17 2.73 2.77 -0.037 0.333 -0.107 0.001 -0.104 
18 2.76 2.77 -0.0067 0.333 -0.019 0.000 -0.019 
19 2.94 2.28 0.66 0.333 1.920 0.230 2.118 
20 0.97 2.28 -1.31 0.333 -3.839 0.921 -13.238 * 
21 2.94 2.28 0.66 0.333 1.920 0.230 2.118 
22 6.56 6.48 0.083 0.333 0.244 0.004 0.236 
23 6.49 6.48 0.013 0.333 0.039 0.000 0.038 
24 6.38 6.48 -0.097 0.333 -0.283 0.005 -0.274 
  
* Case(s) with |Outlier t| > 3.50 
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Figure A.1.6– Residuals plotted versus predicted values for the model describing the effect of 
various factors on 10% diameter (D10) of powders manufactured by FD followed by milling 
and sieving. 
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Figure A.1.7– Interaction graphs indicating the effects of a) solute concentration (B-=1%, 
B+=10%) and freezing rate (A-=Slow, A+=Fast), and b) annealing (C-=No, C+=Yes) and 
freezing rate (A-=Slow, A+=Fast) on 10% diameter (D10) of particles produced by FD 
followed by milling and sieving. 
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Figure A.1.8– Interaction graphs indicating the effects of annealing (C-=No, C+=Yes) and 
solute concentration (B-=1%, B+=10%) on 10% diameter (D10) of particles produced by FD 
followed by milling and sieving. 
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SPAN 
  
Response: Span 
 
Factor Name         Units Type -1 Level +1 Level 
 A        Freeze Rate       Categorical       Slow Fast 
 B        Concentration       g/100mL  Numeric     1.00 10.00 
 C        Annealing    Categorical         No Yes 
 
         ANOVA for Selected Factorial Model 
 
Source Sum of Squares DF 
Mean 
Square F Value Prob > F 
Model 11.73 7 1.68 27.75 < 0.0001 
Residual 0.97 16 0.060   
Pure Error 0.97 16 0.060   
Cor Total 12.70 23    
 
 Root MSE 0.25  R-Squared          0.9239 
 Dep Mean 2.72  Adj R-Squared         0.8906 
 C.V.  9.03  Pred R-Squared        0.8288 
 PRESS  2.17  Adeq Precision        14.188  Desire > 4 
  
Factor Coefficient Estimate DF 
Standard 
Error 
t for H0 
Coeff=0 Prob > |t| VIF 
Intercept 2.72 1 0.050    
A-FreezeRate 0.41 1 0.050 8.19 < 0.0001 1.00 
B-Concen -0.038 1 0.050 -0.76 0.4560 1.00 
C-Annealing 0.066 1 0.050 1.31 0.2080 1.00 
AB -0.39 1 0.050 -7.71 < 0.0001 1.00 
AC -0.16 1 0.050 -3.21 0.0055 1.00 
BC 0.045 1 0.050 0.90 0.3831 1.00 
ABC -0.37 1 0.050 -7.37 < 0.0001 1.00 
 
    Final Equation in Terms of Coded Factors: 
   
 Span= 2.72 + 0.41*A - 0.038*B + 0.066*C - 0.39*AB - 0.16*AC + 0.045*BC - 0.37*ABC 
 
 
 230
Diagnostics Case Statistics 
  
Std 
Order 
Actual 
Value 
Predicted 
Value Residual Distance 
Student 
Residual 
Cook's 
Leverage Outlier t 
1 2.16 2.15 0.01 0.333 0.050 0.000 0.048 
2 2.06 2.15 -0.090 0.333 -0.448 0.013 -0.437 
3 2.23 2.15 0.080 0.333 0.399 0.010 0.388 
4 3.27 3.33 -0.057 0.333 -0.282 0.005 -0.274 
5 3.21 3.33 -0.12 0.333 -0.581 0.021 -0.569 
6 3.50 3.33 0.17 0.333 0.864 0.047 0.856 
7 2.01 2.02 -0.067 0.333 -0.033 0.000 -0.032 
8 1.98 2.02 -0.037 0.333 -0.183 0.002 -0.177 
9 2.06 2.02 0.043 0.333 0.216 0.003 0.209 
10 2.72 3.13 -0.41 0.333 -2.026 0.257 -2.276 
11 3.86 3.13 0.73 0.333 3.654 0.835 8.698 * 
12 2.80 3.13 -0.33 0.333 -1.628 0.166 -1.725 
13 1.77 1.77 -0.033 0.333 -0.017 0.000 -0.016 
14 1.77 1.77 -0.0033 0.333 -0.017 0.000 -0.016 
15 1.78 1.77 0.0067 0.333 0.033 0.000 0.032 
16 3.82 3.79 0.033 0.333 0.166 0.002 0.161 
17 3.60 3.79 -0.19 0.333 -0.930 0.054 -0.926 
18 3.94 3.79 0.15 0.333 0.764 0.036 0.754 
19 3.28 3.30 -0.020 0.333 -0.100 0.001 -0.097 
20 3.24 3.30 -0.060 0.333 -0.299 0.006 -0.290 
21 3.38 3.30 0.080 0.333 0.399 0.010 0.388 
22 2.18 2.29 -0.11 0.333 -0.532 0.018 -0.519 
23 2.29 2.29 0.0033 0.333 0.017 0.000 0.016 
24 2.39 2.29 0.10 0.333 0.515 0.017 0.503 
 
* Case(s) with |Outlier t| > 3.50 
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Figure A.1.9– Residuals plotted versus predicted values for the model describing the effect of 
various factors on span of powders manufactured by FD followed by milling and sieving. 
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Figure A.1.10– Interaction graphs indicating the effects of a) solute concentration (B-=1%, 
B+=10%) and freezing rate (A-=Slow, A+=Fast), and b) annealing (C-=No, C+=Yes) and 
freezing rate (A-=Slow, A+=Fast) on span of particles produced by FD followed by milling 
and sieving. 
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Figure A.1.11– Interaction graphs indicating the effects of annealing (C-=No, C+=Yes) and 
solute concentration (B-=1%, B+=10%) on span of particles produced by FD followed by 
milling and sieving. 
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SPRAY-FREEZE DRYING 
 
 
Design Summary 
 
Study Type  Factorial  Experiments 24 
Initial Design  2 Level Factorial Blocks  No Blocks 
Center Points 0 
Design Model 3FI 
 
 
Response Name Units Obs Minimum Maximum Trans Model 
Y1 D50 um 24 15.76 50.92 None Main effects 
Y2 D90 um 24 24.42 181.67 None Main effects 
Y3 D10 um 24 4.13 13.63 None Main effects 
Y4 Span  24 1.28 3.39 None Main effects 
 
 
 
Factor Name Units Type Low Actual 
High 
Actual 
Low 
Coded 
High 
Coded 
A Sol. Feed mL/min Numeric 3.00 25.00 -1.000 1.000 
B Air Flow L/hr Numeric 250.00 500.00 -1.000 1.000 
C Sol. Conc. g/100 mL Numeric 1.00 10.00 -1.000 1.000 
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MEDIAN DIAMETER (D50) 
 
Response: D50
 
 Factor Name Units Type           -1 Level  +1 Level 
 A Sol. Feed  mL/min Numeric 3.00    25.00 
 B Air Flow L/hr Numeric 250.00  500.00 
 C Sol. Conc. g/100 mL Numeric 1.00    10.00 
 
         ANOVA for Selected Factorial Model 
 
 
Source Sum of Squares DF Mean Square F Value Prob > F 
Model 2582.00 2 1291.00 59.43 < 0.0001 
Residual 456.20 21 21.72   
Lack of Fit 166.13 5 33.23 1.83 0.1632 
Pure Error 290.07 16 18.13   
Cor Total 3038.20 23    
 
 Root MSE 4.66 R-Squared 0.8498 
 Dep Mean 32.54 Adj R-Squared 0.8355 
 C.V. 14.32 Pred R-Squared 0.8039 
 PRESS 595.85 Adeq Precision 15.425  Desire > 4 
 
Factor Coefficient Estimate DF 
Standard 
Error 
t for H0 
Coeff=0 Prob > |t| VIF 
Intercept 32.54 1 0.95    
A-Sol. Feed 10.02 1 0.95 10.53 < 0.0001 1.00 
B-Air Flow -2.69 1 0.95 -2.83        0.0100       1.00 
 
   Final Equation in Terms of Coded Factors: 
    
  D50= 32.54 + 10.02*A - 2.69*B 
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Diagnostics Case Statistics 
 
Std 
Order 
Actual 
Value 
Predicted 
Value Residual Distance 
Student 
Residual 
Cook's 
Leverage Outlier t 
1 20.63 25.22 -4.59 0.125 -1.052 0.053 -1.055 
2 21.60 25.22 -3.62 0.125 -0.830 0.033 -0.823 
3 20.72 25.22 -4.50 0.125 -1.031 0.051 -1.033 
4 44.97 45.25 -0.28 0.125 -0.064 0.000 -0.063 
5 50.92 45.25 5.67 0.125 1.301 0.081 1.324 
6 50.44 45.25 5.19 0.125 1.190 0.067 1.203 
7 15.82 19.83 -4.01 0.125 -0.920 0.040 -0.917 
8 22.46 19.83 2.63 0.125 0.603 0.017 0.593 
9 16.95 19.83 -2.88 0.125 -0.661 0.021 -0.652 
10 39.72 39.87 -0.15 0.125 -0.033 0.000 -0.032 
11 40.19 39.87 0.32 0.125 0.075 0.000 0.073 
12 39.43 39.87 -0.44 0.125 -0.100 0.000 -0.097 
13 37.78 25.22 12.56 0.125 2.882 0.395 3.617 * 
14 20.80 25.22 -4.42 0.125 -1.013 0.049 -1.014 
15 26.39 25.22 1.17 0.125 0.269 0.003 0.263 
16 42.79 45.25 -2.46 0.125 -0.564 0.015 -0.555 
17 42.22 45.25 -3.03 0.125 -0.695 0.023 -0.686 
18 43.54 45.25 -1.71 0.125 -0.392 0.007 -0.384 
19 15.76 19.83 -4.07 0.125 -0.934 0.042 -0.931 
20 22.12 19.83 2.29 0.125 0.525 0.013 0.516 
21 29.26 19.83 9.43 0.125 2.163 0.223 2.394 
22 38.63 39.87 -1.23 0.125 -0.283 0.004 -0.277 
23 38.62 39.87 -1.25 0.125 -0.286 0.004 -0.279 
24 39.22 39.87 -0.65 0.125 -0.148 0.001 -0.144 
    
* Case(s) with |Outlier t| > 3.50 
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Figure A.1.12– Residuals plotted versus predicted values for the model describing the effect 
of various factors on median diameter (D50) of powders manufactured by SFD. 
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90% DIAMETER (D90) 
  
Response: D90
 
 Factor Name Units Type -1 Level +1 Level 
 A Sol. Feed  mL/min Numeric             3.00               25.00 
 B Air Flow L/hr Numeric           250.00            500.00 
 C Sol. Conc. g/100 mL Numeric             1.00               10.00 
 
         ANOVA for Selected Factorial Model 
 
Source Sum of Squares DF Mean Square F Value Prob > F 
Model 29155.57 2 14577.78 36.66 < 0.0001 
Residual 8350.40 21 397.64   
Lack of Fit 4865.17 5 973.03 4.47 0.0097 
Pure Error 3485.23 16 217.83   
Cor Total 37505.97 23    
 
 Root MSE 19.94  R-Squared     0.7774 
 Dep Mean 75.40  Adj R-Squared     0.7562 
 C.V. 26.45  Pred R-Squared     0.7092 
 PRESS 10906.64  Adeq Precision     12.922  Desire > 4 
 
Factor Coefficient Estimate DF 
Standard 
Error 
t for H0 
Coeff=0 Prob > |t| VIF 
Intercept 75.40 1 4.07    
A-Sol. Feed 32.19 1 4.07 7.91 < 0.0001 1.00 
B-Air Flow -13.36 1 4.07 -3.28 0.0036 1.00 
 
   Final Equation in Terms of Coded Factors: 
  
  D90= 75.40 + 32.19*A - 13.36*B 
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Diagnostics Case Statistics 
 
Std 
Order 
Actual 
Value 
Predicted 
Value Residual Distance 
Student 
Residual 
Cook's 
Leverage Outlier t 
1 44.01 56.57 -12.56 0.125 -0.673 0.022 -0.664 
2 46.37 56.57 -10.20 0.125 -0.547 0.014 -0.5373 
3 43.44 56.57 -13.13 0.125 -0.704 0.024 -0.695 
4 115.37 120.95 -5.58 0.125 -0.299 0.004 -0.293 
5 181.67 120.95 60.72 0.125 3.255 0.505 4.513 * 
6 158.58 120.95 37.63 0.125 2.017 0.194 2.193 
7 33.55 29.85 3.70 0.125 0.199 0.002 0.194 
8 40.25 29.85 10.40 0.125 0.558 0.015 0.548 
9 34.46 29.85 4.61 0.125 0.247 0.003 0.242 
10 90.08 94.23 -4.15 0.125 -0.222 0.002 -0.217 
11 89.36 94.23 -4.87 0.125 -0.261 0.003 -0.255 
12 90.84 94.23 -3.39 0.125 -0.182 0.002 -0.177 
13 72.04 56.57 15.47 0.125 0.829 0.033 0.823 
14 37.91 56.57 -18.66 0.125 -1.000 0.048 -1.000 
15 48.94 56.57 -7.63 0.125 -0.409 0.008 -0.401 
16 102.73 120.95 -18.22 0.125 -0.977 0.045 -0.976 
17 98.50 120.95 -22.45 0.125 -1.204 0.069 -1.217 
18 115.55 120.95 -5.40 0.125 -0.290 0.004 -0.283 
19 24.42 29.85 -5.43 0.125 -0.291 0.004 -0.284 
20 39.99 29.85 10.14 0.125 0.544 0.014 0.535 
21 53.10 29.85 23.25 0.125 1.247 0.074 1.264 
22 85.29 94.23 -8.94 0.125 -0.479 0.011 -0.470 
23 80.65 94.23 -13.58 0.125 -0.728 0.025 -0.720 
24 82.46 94.23 -11.77 0.125 -0.631 0.019 -0.622 
    
* Case(s) with |Outlier t| > 3.50 
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Figure A.1.13– Residuals plotted versus predicted values for the model describing the effect 
of various factors on 90% diameter (D90) of powders manufactured by SFD. 
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10% DIAMETER (D10) 
  
Response: D10
  
Factor Name Units Type -1 Level +1 Level 
 A Sol. Feed  mL/min Numeric 3.00 25.00 
 B Air Flow L/hr Numeric 250.00 500.00 
 C Sol. Conc. g/100 mL Numeric 1.00 10.00 
 
 ANOVA for Selected Factorial Model 
  
Source Sum of Squares DF Mean Square F Value Prob > F 
Model 170.36 4 42.59 20.26 < 0.0001 
Residual 39.94 19 2.10   
Lack of Fit 6.62 3 2.21 1.06 0.3940 
Pure Error 33.33 16 2.08   
Cor Total 210.31 23    
  
 Root MSE 1.45  R-Squared      0.8101 
 Dep Mean 8.52  Adj R-Squared      0.7701 
 C.V. 17.02  Pred R-Squared       0.6970 
 PRESS 63.73  Adeq Precision      12.458  Desire > 4 
  
Factor Coefficient Estimate DF 
Standard 
Error 
t for H0 
Coeff=0 Prob > |t| VIF 
Intercept 8.52 1 0.30    
A-Sol. Feed 2.14 1 0.30 7.24 < 0.0001 1.00 
B-Air Flow 0.69 1 0.30 2.34 0.0304 1.00 
C-Sol. Conc. 1.17 1 0.30 3.97 0.0008 1.00 
AB 0.81 1 0.30 2.72 0.0136 1.00 
 
         Final Equation in Terms of Coded Factors: 
   
  D10= 8.52 + 2.14*A + 0.69*B + 1.17*C + 0.81*AB 
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Diagnostics Case Statistics 
  
Std 
Order 
Actual 
Value 
Predicted 
Value Residual Distance 
Student 
Residual 
Cook's 
Leverage Outlier t 
1 4.85 5.31 -0.46 0.208 -0.358 0.007 -0.349 
2 4.96 5.31 -0.35 0.208 -0.273 0.004 -0.266 
3 4.99 5.31 -0.32 0.208 -0.249 0.003 -0.243 
4 8.34 7.99 0.35 0.208 0.274 0.004 0.267 
5 9.10 7.99 1.11 0.208 0.863 0.039 0.857 
6 9.23 7.99 1.24 0.208 0.964 0.049 0.962 
7 4.13 5.09 -0.96 0.208 -0.742 0.029 -0.732 
8 5.71 5.09 0.62 0.208 0.483 0.012 0.473 
9 4.47 5.09 -0.62 0.208 -0.478 0.012 -0.468 
10 10.80 10.98 -0.18 0.208 -0.141 0.001 -0.137 
11 10.81 10.98 -0.17 0.208 -0.133 0.001 -0.130 
12 10.71 10.98 -0.27 0.208 -0.211 0.002 -0.205 
13 9.83 7.66 2.17 0.208 1.681 0.149 1.773 
14 5.21 7.66 -2.45 0.208 -1.900 0.190 -2.055 
15 9.08 7.66 1.42 0.208 1.099 0.064 1.106 
16 9.51 10.34 -0.83 0.208 -0.641 0.022 -0.631 
17 9.05 10.34 -1.29 0.208 -0.997 0.052 -0.997 
18 9.74 10.34 -0.60 0.208 -0.462 0.011 -0.453 
19 4.26 7.44 -3.18 0.208 -2.462 0.319 -2.905 
20 8.95 7.44 1.51 0.208 1.173 0.072 1.185 
21 10.05 7.44 2.61 0.208 2.026 0.216 2.227 
22 13.63 13.33 0.30 0.208 0.231 0.003 0.225 
23 13.47 13.33 0.14 0.208 0.107 0.001 0.104 
24 13.52 13.33 0.19 0.208 0.146 0.001 0.142 
  
 
 
 
 243
Figure A.1.14– Residuals plotted versus predicted values for the model describing the effect 
of various factors on 10% diameter (D10) of powders manufactured by SFD. 
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Figure A.1.15– Interaction graphs indicating the effects of airflow rate (B-=1%, B+=10%) 
and solution feed rate (A-=Slow, A+=Fast) on 10% diameter (D10) of particles produced by 
SFD. 
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SPAN 
  
Response: Span 
  
Factor Name Units Type          -1 Level  +1 Level 
 A Sol. Feed  mL/min Numeric 3.00 25.00 
 B Air Flow L/hr Numeric 250.00 500.00 
 C Sol. Conc. g/100 mL Numeric 1.00 10.00 
 
 ANOVA for Selected Factorial Model 
 
Source Sum of Squares DF 
Mean 
Square F Value Prob > F 
Model 4.48 4 1.12 25.55 < 0.0001 
Residual 0.83 19 0.044   
Lack of Fit 0.17 3 0.058 1.42 0.2748 
Pure Error 0.66 16 0.041   
Cor Total 5.31 23    
  
    Root MSE   0.21  R-Squared 0.8432 
 Dep Mean   1.94  Adj R-Squared 0.8102 
 C.V.  10.79  Pred R-Squared 0.7499 
 PRESS 1.33 Adeq Precision 14.719  Desire > 4 
  
Factor Coefficient Estimate DF 
Standard 
Error 
t for H0 
Coeff=0 Prob > |t| VIF 
Intercept 1.94 1 0.043    
A-Sol. Feed 0.29 1 0.043 6.88 < 0.0001 1.00 
B-Air Flow -0.22 1 0.043 -5.08 < 0.0001 1.00 
C-Sol. Conc. -0.19 1 0.043 -4.50 0.0002 1.00 
AB -0.13 1 0.043 -2.98 0.0078 1.00 
 
   Final Equation in Terms of Coded Factors: 
  
   Span= 1.94 + 0.29*A - 0.22*B - 0.19*C - 0.13*AB 
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Diagnostics Case Statistics 
 
Std Order Actual Value 
Predicted 
Value Residual Distance 
Student 
Residual 
Cook's 
Leverage Outlier t 
1 1.90 1.93 -0.027 0.208 -0.145 0.001 -0.142 
2 1.92 1.93 -0.007 0.208 -0.038 0.000 -0.037 
3 1.86 1.93 -0.067 0.208 -0.360 0.007 -0.352 
4 2.38 2.77 -0.39 0.208 -2.088 0.229 -2.315 
5 3.39 2.77 0.62 0.208 3.337 0.586 5.047* 
6 2.96 2.77 0.19 0.208 1.027 0.056 1.029 
7 1.85 1.75 0.10 0.208 0.553 0.016 0.542 
8 1.55 1.75 -0.20 0.208 -1.058 0.059 -1.062 
9 1.78 1.75 0.033 0.208 0.177 0.002 0.172 
10 2.00 2.08 -0.080 0.208 -0.432 0.010 -0.422 
11 1.95 2.08 -0.13 0.208 -0.700 0.026 -0.691 
12 2.03 2.08 -0.050 0.208 -0.271 0.004 -0.264 
13 1.65 1.54 0.11 0.208 0.575 0.017 0.565 
14 1.57 1.54 0.027 0.208 0.145 0.001 0.142 
15 1.51 1.54 -0.033 0.208 -0.177 0.002 -0.172 
16 2.18 2.38 -0.20 0.208 -1.099 0.064 -1.105 
17 2.12 2.38 -0.26 0.208 -1.421 0.106 -1.463 
18 2.43 2.38 0.045 0.208 0.244 0.003 0.238 
19 1.28 1.36 -0.083 0.208 -0.445 0.010 -0.436 
20 1.40 1.36 0.037 0.208 0.199 0.002 0.194 
21 1.47 1.36 0.11 0.208 0.575 0.017 0.565 
22 1.85 1.70 0.15 0.208 0.826 0.036 0.819 
23 1.74 1.70 0.044 0.208 0.235 0.003 0.229 
24 1.76 1.70 0.064 0.208 0.342 0.006 0.334 
 
* Case(s) with |Outlier t| > 3.50 
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Figure A.1.16– Residuals plotted versus predicted values for the model describing the effect 
of various factors on span of powders manufactured by SFD. 
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Figure A.1.17– Interaction graphs indicating the effects of solute concentration (B-=1%, 
B+=10%) and freezing rate (A-=Slow, A+=Fast) on span of particles produced by SFD. 
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Appendix A.2- CALIBRATION OF THE ANDERSEN CASCADE IMPACTOR FOR 
THE CHARACTERIZATION OF NASAL PRODUCTS 
Theoretical Considerations 
The theoretical cut-off diameter of each stage of the impactor can be calculated by the 
formula: 
2/1
50
3
50 4
)(9
⎥⎥⎦
⎤
⎢⎢⎣
⎡=
Q
StkD
Cd
p
j
c ρ
ηπ
    (A.2.01) 
where d50 is the cut-off diameter, Cc is the Cunningham correction factor, η is the viscosity, 
Dj is the diameter of the jet, ρp is the density of the particle, and Q is the flow rate of the air 
(Hinds 1999). To modify the cut-off diameters of the stages of the cascade impactor, the 
most direct way is to change the flow rate of the air through the system, without changing 
any of the other factors. However, in order for the cascade impactor stage cut-off diameter to 
be relevant, the air flow must be turbulent. The Reynolds number (Re) is a dimensionless 
number that characterizes fluid flow through a pipe or around and obstacle. It is 
mathematically determined by the equation: 
η
ρVd=Re      (A.2.02) 
where V is the relative velocity and d is the particle diameter. For a cascade impactor, the Re 
must be between 500 and 3000.  
 The original Andersen MKII non-viable impactor consisted of eight stages (0-7) 
operated at a flow rate of 28.3 L/min, with particle size cut-off’s, in the respirable range, 
between 9 and 0.22 µm. If the flow rate is increased (to 60 or 90 L/min) the cut-off diameters 
for the collection efficiency curves on each stage become smaller and consequently, the 
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impactor becomes less useful in sizing aerosols in respirable size ranges. Consequently, 
additional stages (-2, -1 and -0) were designed for insertion at the higher flow rates to enable 
the respirable size range to be covered. It is fortuitous that if the impactor is operated at a low 
flow rate (e.g. 15 L/min) these additional stages will have particle size cut-off efficiencies 
that are higher than those of the conventional impactor. This is a desirable situation for 
evaluation of nasal products where a fraction of the particles that might deposit in the nose 
can potentially enter the lungs (in the range 10-20μm). However, the Andersen has not been 
calibrated at low flow rates with the supplementary stages inserted. 
In calibration experiments, the stages, -2, -1, and -0, originally designed for 90 L/min 
operation of an Andersen MKII non-viable impactor with known cut-off diameters at this 
flow rate were employed. According to the manufacturer, at 90 L/min, the cut-off diameters 
for these stages are 8.0, 6.5, and 5.2 µm, respectively. The predicted cut-off diameters at 15 
L/min can be calculated from the equation: 
d15 L/min= d90 L/min (90/15)1/2    (A.2.03) 
where dx is the cut-off diameter of a stage at x L/min (Van Oort, Downey et al. 1996). Using 
this formula, at 15 L/min, the theoretical cut-off diameters of stages -2, -1, and -0 are 19.6, 
17.2, and 12.4 µm, respectively. 
Materials and Methods 
 The Vibrating Orifice Aerosol Generator (VOAG, model 3450, TSI, Inc. Shoreview, 
MN) was used to produce monodisperse aerosol particles in the 9-22 µm particle size range. 
Solutions of oleic acid and fluorescein dissolved in methanol flowed through a 35 µm orifice 
in an inverted apparatus (Figure A.2.1). The aerosol passed a Polonium-210 radioactive 
source (Nuclespot Static Eliminator, NRD LLC., Grand Island, NY) to reduce the surface 
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charge on the formed droplets. Due to fluctuations in the fluid pressure seen in the syringe 
pump provided with the VOAG, a high pressure liquid chromatography (HPLC) pump 
(Model 510, Waters, Corp. Milford, MA) was used. Droplet sizes were based on the 
calculations of the operating variables of the VOAG and the volatile and nonvolatile 
components (Berglund and Liu 1973). The aerodynamic diameter (dae) was calculated from 
the equation: 
ppae dd ρ=      (A.2.04) 
where dp is the diameter of the droplet and ρp is the density of the droplet. Prior to and after 
each measurement of the impactor, the monodispersity of the aerosol was verified using a 
time-of-flight particle sizing instrument (Aerosizer LD, TSI, In., Shoreview MN) with the 
geometric standard deviation of the single droplets was <1.2 (Fuchs and Sutugin 1966). 
 After each measurement, the orifice plate, collection plate, and filter were washed 
separately with known quantities of 0.001M aqueous solution of sodium hydroxide. The 
recovered fluorescein content was quantified using fluorometry and the collection efficiency 
(E) was calculated by dividing the mass of fluorescein on the collection plate by the sum of 
the mass of fluorescein on the filter and collection plate. All measurements were completed 
in triplicate. 
Results and Discussion 
 The measured efficiency of each stage as a function of dae is shown (Table A.2.1). 
Stage -2 had a collection efficiency ranging from 13 to 83% for dae 10 to 20 µm. Stage -1 had 
a collection efficiency ranging from 14 to 84% for dae 10 to 20 µm. Stage -0 had a collection 
efficiency ranging from 10 to 75% for dae 8 to 16 µm.  
 252
The efficiency curves of all of the stages of the modified cascade impactor are shown 
(Figure A.2.2). The efficiency curves for Stages -1 and -2 fall are almost superimposable. 
Additionally, the efficiency curves for Stages -1 and -2 overlap with the efficiency curve for 
Stage -0. These deposition characteristics indicate that for the characterization of nasal 
preparations, only one of the stages, -1 and -2, of the cascade impactor is required; Stage -2 
was selected for inclusion.  
To determine the cut-off diameter for each stage, two methods were used. The first 
method used linear regression analysis of a best-fit line through only the linear portion of the 
data; 9.3808 to 15.0093 µm for Stage -0, 13.1332 to 18.7617 µm for Stage -1, and 13.1332 to 
20.6378 µm for Stage -2). The 50% efficiency was then calculated using the equation for the 
best-fit line. The second method utilized linear regression analysis of a 3-parameter sigmoid 
fit. This was applied to the entire data set from each impactor stage. The 50% efficiency was 
then calculated using the equation for the best-fit sigmoidal curve. Results are shown in 
Table A.2.2. There was no difference in cut-off diameters regardless of the method used to 
calculate it. However, the geometric standard deviations (GSD) of the curves, determined by 
dividing the d84 by d50, were different for Stages -1 and -0. This is important because the 
GSD is an indicator of the sharpness of the efficiency curve. Both had higher GSD 
determined by sigmoidal regression analysis, indicating a flatter curve compared to that 
determined by linear regression analysis. This indicates that the tails of these curves have a 
significant effect on the steepness of the efficiency curve. All of the models exhibited good 
fit on the data. 
 Based on the calibration of the Andersen Mk II cascade impactor at 15 LPM, the 
range of particles has been doubled, by extension to larger sizes, to include those that have a 
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lower but finite probability of penetration to the lungs but are known to exist in nasal 
products. The modified cascade impactor allows for the collection of particles below 16.5 
µm, compared to a calibrated collection efficiency cut-off 8.7 µm using the traditional setup 
at 28.3 LPM (Dunbar, Hickey et al. 1998). It is a tool that can be utilized as an alternative to 
imaging in predicting potential deposition in the lower respiratory tract. 
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Table A.2.1– The efficiency of each stage as a function of aerodynamic diameter (dae) at 15 
liters per minute (Mean (SD), n=3). 
 
dae (µm) 
Stage -2 
E (%) 
Stage -1 
E (%) 
Stage -0 
E (%) 
8.4427 10.55 (0.31)   
9.3808 24.67 (2.28)   
10.3189 30.96 (0.63) 13.86 (0.41) 13.03 (0.60) 
11.2570 40.79 (2.42) 16.17 (0.78) 16.22 (0.93) 
12.1951 50.14 (2.89) 21.35 (1.56) 19.64 (0.78) 
13.1332 56.41 (1.06) 25.81 (2.19) 22.07 (1.61) 
14.0712 68.70 (1.65) 33.71 (1.00) 26.77 (3.35) 
15.0093 73.95 (0.97) 43.60 (0.70) 37.59 (2.58) 
15.9474 75.20 (0.62) 49.71 (0.07) 42.18 (2.74) 
16.8855  59.59 (1.48) 53.24 (3.15) 
17.8236  67.18 (1.72) 65.71 (1.71) 
18.7617  75.62 (1.05) 73.58 (2.15) 
19.6997  77.73 (1.27) 78.75 (1.14) 
20.6378  84.01 (2.91) 83.58 (1.67) 
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Table A.2.2– The cut-off diameter, geometric standard deviation (GSD), and correlation 
coefficient (R2) determined by linear and sigmoidal regression analysis. 
 
Linear regression analysis Sigmoidal regression analysis 
Stage Cut-off diameter 
(µm) 
GSD R2
Cut-off 
diameter 
(µm) 
GSD R2
Stage -2 16.5 1.23 0.9873 16.5 1.24 0.9879 
Stage -1 15.9 1.24 0.9985 15.9 1.30 0.9977 
Stage -0 12.3 1.30 0.9943 12.2 1.55 0.9925 
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Figure A.2.1– Experimental setup for the calibration of the cascade impactor (CI) at 15 liters 
per minute.  
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Figure A.2.2– Calibration of the cascade impactor at 15 liters per minute.  
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Figure A.2.3– The efficiency curves of Stages -2 and -0 for the modified cascade impactor at 
15 liters per minute. 
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Nonlinear Regression 
Equation: Sigmoidal, Sigmoid, 3 Parameter  
y= a/(1+exp(-(x-x0)/b)) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9962 0.9925 0.9908  2.4728  
 
             Coefficient Std. Error t P VIF  
a 113.1907 9.9821 11.3394 <0.0001 39.4446<  
b 3.0342 0.2533 11.9793 <0.0001 5.8004<  
x0 17.1853 0.6246 27.5125 <0.0001 41.9096<  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression3 30912.9410 10304.3137  
Residual 9 55.0332 6.1148  
Total 12 30967.9742 2580.6645  
 
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression2 7295.6769 3647.8384 596.5589 <0.0001  
Residual 9 55.0332 6.1148  
Total 11 7350.7101 668.2464  
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Statistical Tests: 
PRESS  110.5894 
Durbin-Watson Statistic  1.2334 Failed  
Normality Test  Passed (P = 0.8554) 
K-S Statistic = 0.1678 Significance Level = 0.8554 
Constant Variance Test  Passed (P = 0.8001) 
Power of performed test with alpha = 0.0500: 1.0000 
Regression Diagnostics: 
Row       Std. Res.    Stud. Res.    Stud. Del. Res.  
3 0.9558 1.0429 1.0487  
4 0.8770 0.9620 0.9575  
5 0.5346 0.5845 0.5619  
6 -0.6076 -0.6593 -0.6371  
7 -1.2494 -1.3523 -1.4283  
8 0.1865 0.2042 0.1930  
9 -1.2244 -1.3739 -1.4571  
10 -0.2270 -0.2595 -0.2455  
11 1.2877 1.4623 1.5789  
12 1.0537 1.1809 1.2112  
13 -0.0159 -0.0188 -0.0177  
14 -0.8644 -1.4296 -1.5331  
 
Influence Diagnostics:  
Row    Cook's Dist   Leverage           DFFITS  
3 0.0691 0.1601 0.4579  
4 0.0626 0.1687 0.4314  
5 0.0223 0.1635 0.2484  
6 0.0257 0.1507 -0.2684  
7 0.1046 0.1464 -0.5916  
8 0.0028 0.1660 0.0861  
9 0.1630 0.2057 -0.7416  
10 0.0069 0.2348 -0.1360  
11 0.2063 0.2245 0.8495  
12 0.1190 0.2038 0.6128  
13 4.7554E-0050.2875 -0.0113  
14 1.1823 0.6344 -2.0197  
 
95% Confidence: 
Row     Predicted   95% Conf-L   95% Conf-U     95% Pred-L    95% Pred-U  
3 10.6666 8.4281 12.9050 4.6414 16.6917  
4 14.0512 11.7534 16.3491 8.0038 20.0987  
5 18.3180 16.0562 20.5798 12.2842 24.3518  
6 23.5724 21.4005 25.7442 17.5717 29.5731  
7 29.8595 27.7190 32.0001 23.8701 35.8490  
8 37.1288 34.8494 39.4083 31.0884 43.1693  
9 45.2078 42.6704 47.7452 39.0653 51.3503  
10 53.8012 51.0906 56.5119 47.5852 60.0173  
11 62.5258 59.8752 65.1763 56.3357 68.7159  
12 70.9744 68.4489 73.4999 64.8368 77.1119  
13 78.7893 75.7900 81.7885 72.4420 85.1365  
14    85.7175      81.2619          90.1730           78.5660          92.8690  
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Nonlinear Regression 
Equation: Sigmoidal, Sigmoid, 3 Parameter  
y= a/(1+exp(-(x-x0)/b)) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9988 0.9977 0.9972  1.3466  
 
 Coeff   Std. Error t P VIF  
a 98.4556 3.0551 32.2269 <0.0001 18.0898<  
b 2.7572 0.1168 23.6100 <0.0001 4.2377<  
x0 15.7636 0.2217 71.1153 <0.0001 16.0454<  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression  3 33949.7723 11316.5908  
Residual     9 16.3209 1.8134  
Total          12 33966.0932 2830.5078  
 
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression  2 7032.2427 3516.1213 1938.9296 <0.0001  
Residual      9 16.3209 1.8134  
Total          11 7048.5636 640.7785  
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Statistical Tests: 
PRESS  25.9563 
Durbin-Watson Statistic  2.2381 Passed  
Normality Test  Passed (P = 0.9661) 
K-S Statistic = 0.1373 Significance Level = 0.9661 
Constant Variance Test  Passed (P = 0.9737) 
Power of performed test with alpha = 0.0500: 1.0000 
Regression Diagnostics: 
Row       Std. Res. Stud. Res.  Stud. Del. Res.  
3 1.3814 1.5210 1.6638  
4 0.0748 0.0827 0.0780  
5 0.1257 0.1380 0.1303  
6 -1.1642 -1.2677 -1.3188  
7 -0.6436 -0.7023 -0.6810  
8 0.7903 0.8779 0.8656  
9 -0.8599 -0.9760 -0.9732  
10 0.3586 0.4078 0.3881  
11 0.2767 0.3089 0.2928  
12 1.4752 1.6414 1.8488  
13 -1.2454 -1.4824 -1.6077  
14 -0.0665 -0.0999 -0.0942  
 
Influence Diagnostics:  
Row    Cook's Dist  Leverage DFFITS  
3 0.1638 0.1752 0.7669  
4 0.0005 0.1812 0.0367  
5 0.0013 0.1708 0.0591  
6 0.0995 0.1566 -0.5682  
7 0.0313 0.1600 -0.2972  
8 0.0602 0.1897 0.4189  
9 0.0916 0.2238 -0.5226  
10 0.0163 0.2268 0.2102  
11 0.0078 0.1973 0.1452  
12 0.2138 0.1923 0.9020  
13 0.3054 0.2942 -1.0381  
14 0.0042 0.5562 -0.1054  
 
95% Confidence: 
Row    Predicted  95% Conf-L  95% Conf-U  95% Pred-L   95% Pred-U  
3 11.9998 10.7246 13.2750 8.6974 15.3022  
4 16.0693 14.7724 17.3662 12.7584 19.3802  
5 21.1808 19.9220 22.4396 17.8846 24.4769  
6 27.3778 26.1724 28.5833 24.1017 30.6540  
7 34.5767 33.3582 35.7953 31.2958 37.8577  
8 42.5358 41.2089 43.8627 39.2130 45.8585  
9 50.8680 49.4268 52.3092 47.4980 54.2380  
10 59.1072 57.6563 60.5580 55.7330 62.4813  
11 66.8073 65.4541 68.1606 63.4740 70.1407  
12 73.6335 72.2977 74.9692 70.3072 76.9598  
13 79.4071 77.7546 81.0595 75.9415 82.8727  
14 84.0996 81.8278 86.3714 80.2994 87.8997  
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Nonlinear Regression 
Equation: Sigmoidal, Sigmoid, 3 Parameter  
y= a/(1+exp(-(x-x0)/b)) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9939 0.9879 0.9830  2.8589  
 
            Coefficient Std. Error t P VIF  
a 86.0663 8.3950 10.2520 0.0002 22.3333<  
b 1.9689 0.3005 6.5511 0.0012 5.1963<  
x0 11.5400 0.4861 23.7416 <0.0001 17.5681<  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression3 19185.7901 6395.2634  
Residual 5 40.8672 8.1734  
Total 8 19226.6573 2403.3322  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression2 3328.6565 1664.3283 203.6265 <0.0001  
Residual 5 40.8672 8.1734  
Total 7 3369.5237 481.3605  
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Statistical Tests: 
PRESS  108.8205 
Durbin-Watson Statistic  2.2021 Passed  
Normality Test  Passed (P = 0.6219) 
K-S Statistic = 0.2521 Significance Level = 0.6219 
Constant Variance Test  Passed (P = 0.2067) 
Power of performed test with alpha = 0.0500: 1.0000 
 
Regression Diagnostics: 
Row       Std. Res.     Stud. Res.    Stud. Del. Res.  
1 -1.4811 -1.9733 -3.7529<  
2 1.0918 1.3499 1.5144  
3 0.3004 0.3475 0.3146  
4 0.2951 0.3486 0.3156  
5 0.0045 0.0055 0.0049  
6 -1.0992 -1.3166 -1.4569  
7 0.4459 0.5352 0.4930  
8 0.1730 0.3278 0.2964  
 
Influence Diagnostics:  
Row    Cook's Dist   Leverage          DFFITS  
1 1.0062 0.4367 -3.3042  
2 0.3211 0.3458 1.1011  
3 0.0136 0.2526 0.1829  
4 0.0160 0.2830 0.1983  
5 5.5351E-0060.3517 0.0036  
6 0.2511 0.3029 -0.9604  
7 0.0421 0.3058 0.3272  
8 0.0927 0.7213 0.4768  
 
95% Confidence: 
Row     Predicted   95% Conf-L   95% Conf-U       95% Pred-L   95% Pred-U  
1 14.7843 9.9279 19.6407 5.9756 23.5930  
2 21.5487 17.2269 25.8705 13.0230 30.0744  
3 30.1011 26.4073 33.7949 21.8759 38.3263  
4 39.9462 36.0364 43.8561 31.6218 48.2707  
5 50.1273 45.7687 54.4859 41.5829 58.6716  
6 59.5526 55.5078 63.5974 51.1639 67.9412  
7 67.4252 63.3610 71.4894 59.0272 75.8233  
8 73.4553 67.2137 79.6969 63.8134 83.0972  
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Appendix A.3- RADIOLABELING APPARATUS 
 An apparatus was designed to label powder with radioactive tracer for use in the 
study of deposition of nasal powders in rats. Gamma-camera imaging or time sequence 
lavaging were employed to follow deposition and clearance from Brown Norway rats. An 
ideal instrument will allow ultra fine particles to deposit evenly on the surface of nasal 
powders, labeling the powder uniformly with a radioactive marker. It is imperative that the 
labeling system does not alter any of the physico-chemical properties (flow properties, 
thermal properties, moisture content, etc.) of the powders, rendering them substantially 
different from unlabeled powder. This appendix describes a labeling apparatus that was 
constructed and evaluated for the purpose of studying nasal powders. 
Materials and Methods 
A schematic drawing of the label apparatus is shown (Figure A.4.1). A radiolabeled 
tracer, 99mtechnetium-labeled sulfur colloid (99mTc-SC), was used to label 25μm SFD- 
trehalose. The labeled colloid solution was freshly prepared according to the manufacturer's 
(Cis, Bedford, MA) instructions. A nebulizer (Pari LC Plus, PARI GmbH, Starnburg, 
Germany) was filled with 4 mL of 99mTc-SC and was used to produce droplets approximately 
1-3 µm in diameter when operating at 8 L/min. The nebulizer dispersed the droplets through 
a length of copper tubing, soldered as shown. Copper tubing has a higher thermal 
conductivity (379 J/s-m-K) than stainless steel (17.3 J/s-m-K) and was selected for this 
property since heat transfer is the purpose of the apparatus (Hickey and Ganderton 2001). 
The particles travel through a tube furnace (Type 21100, Barnstead International, Dubuque, 
IA) which was used to evaporate the water from the nebulized suspension (temperatures of 
250-300°C were evaluated). After passing through the copper tubing, the droplets travelled 
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through a diffusion dryer (Model 3062, TSI, Inc., Shoreview, MN) filled with desiccant 
(Silica gel, 1 Kg in 3 L) to remove water vapor. The diffusion dryer was set up to flow 
through in the opposite direction to that suggested by the manufacturer because the right 
angle bends in the copper tubing function to remove the large droplets. The intended vapor 
trap of the diffusion drier was used as a repository for the powder to be labeled. The trap was 
filled up with approximately one quarter volume of glass wool (Fisherbrand, Fisher 
Scientific, Pittsburgh, PA) to prevent the 99mTc-SC from exiting the labeling machine and a 
40 mesh basket (Hanson Research, Chatsworth, CA) filled with 1-3 g of powder is placed in 
the water trap. The labeling takes place in a hood approved for the use of radioactive 
materials. 
Results and Discussion 
Initial experiments were successfully completed with sieved trehalose as the powder 
to be labeled. The level of radioactivity measured on 5 mg powder samples was 40 µCi, 
sufficient to perform residence time studies for a long duration.  However, when 25 µm SFD 
particles were utilized, residual moisture caused the powder to collapse and aggregate. This 
system was unable to remove all of the water content from the nebulized suspension. While 
residual water content was not a great concern to the crystalline trehalose, the moisture was 
quickly absorbed by the amorphous SFD trehalose. When the system was run for short 
periods of time to prevent the moisture uptake, radioactivity levels were just above than the 
detectable limit of calibrator, which was not suitable for three hour studies. 
This system can still be utilized. Crystalline drug particles of sizes suitable for nasal 
delivery can be radiolabeled and imaging or residence time studies can be completed. The 
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label, itself, does not have to be radioactive. Fluorescein or an alternative fluorescent marker 
can be substituted for the 99mTc-SC, if exposure to radioactivity is a concern. 
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Figure A.4.1– A schematic drawing of an apparatus used to label nasal powders with 
radioactive tracer for use in deposition or residence time studies. 
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Appendix A.4- REGRESSION ANALYSIS OF RESIDENCE TIME STUDY IN 
BROWN NORWAY RATS 
Liquid- No MA
f=a*exp(-b*x)+c*exp(-d*x)
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R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9975 0.9949 0.9898  2.4341  
          Coefficient Std. Error t P VIF  
a 43.0648 5.6736 7.5904 0.0047 9.2661<  
b 0.0631 0.0159 3.9733 0.0285 5.4829<  
c 55.3306 5.7149 9.6818 0.0023 29.4424<  
d 0.0028 0.0008 3.3501 0.0441 8.0955<  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 30234.8992 7558.7248  
Residual 3 17.7746 5.9249  
Total 7 30252.6738 4321.8105  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 3482.9914 1160.9971 195.9536 0.0006  
Residual 3 17.7746 5.9249  
Total 6 3500.7660 583.4610  
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R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9835 0.9672 0.9344  6.2940  
 
  Coefficient Std. Error t P VIF  
a 16.8167              (NAN) (+inf) <0.0001 0.0000  
b 46.3546              (NAN) (+inf) <0.0001 0.0000  
c 83.1833              (NAN) (+inf) <0.0001 0.0000  
d 0.0058              (NAN) (+inf) <0.0001 0.0000  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 33223.2745 8305.8186  
Residual 3 118.8430 39.6143  
Total 7 33342.1175 4763.1596  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 3502.0666 1167.3555 29.4680 0.0100  
Residual 3 118.8430 39.6143  
Total 6 3620.9096 603.4849  
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Liquid- CMC HMW
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R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9861 0.9723 0.9446  4.6698  
 
          Coefficient Std. Error t P VIF  
a 34.2577 7.8524 4.3627 0.0223 4.1100<  
b 0.0940 0.0491 1.9137 0.1516 3.4297  
c 63.9457 7.2234 8.8526 0.0030 13.4677<  
d 0.0021 0.0010 2.1582 0.1198 5.0712<  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 33104.3571 8276.0893  
Residual 3 65.4199 21.8066  
Total 7 33169.7770 4738.5396  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 2296.4308 765.4769 35.1029 0.0078  
Residual 3 65.4199 21.8066  
Total 6 2361.8508 393.6418  
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Liquid- HPMC HMW
f=a*exp(-b*x)+c*exp(-d*x)
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R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9899 0.9799 0.9599  4.6286  
 
          Coefficient   Std. Error t P VIF  
a 28.4088 6.6616 4.2645 0.0237 2.3290  
b 0.2099 0.1223 1.7173 0.1844 1.9594  
c 72.0323 5.0355 14.3049 0.0007 5.6394<  
d 0.0043 0.0009 5.0208 0.0152 2.6979  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 31296.1077 7824.0269  
Residual 3 64.2720 21.4240  
Total 7 31360.3797 4480.0542  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 3139.6470 1046.5490 48.8494 0.0048  
Residual 3 64.2720 21.4240  
Total 6 3203.9190 533.9865  
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Powder- No MA
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R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9709 0.9426 0.8852  9.3568  
 
  Coefficient Std. Error t P VIF  
a 51.8757             (NAN)        (+inf) <0.0001 0.0000  
b 4762871.8556            (NAN) (+inf) <0.0001 0.0000  
c 48.1243             (NAN) (+inf) <0.0001 0.0000  
d 0.0057             (NAN) (+inf) <0.0001 0.0000  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 17853.0738 4463.2685  
Residual 3 262.6506 87.5502  
Total 7 18115.7244 2587.9606  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 4312.0000 1437.3333 16.4172 0.0229  
Residual 3 262.6506 87.5502  
Total 6 4574.6506 762.4418  
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Powder- SA
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R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9956 0.9912 0.9823  2.5894  
 
  Coefficient Std. Error t P VIF  
a 51.1864 3.3228 15.4046 0.0006 1.7891  
b 0.2455 0.0426 5.7631 0.0104 1.6233  
c 48.6658 2.1605 22.5253 0.0002 4.7820<  
d 0.0002 0.0004 0.3859 0.7253 3.0930  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 25683.5302 6420.8826  
Residual 3 20.1146 6.7049  
Total 7 25703.6448 3671.9493  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 2257.9312 752.6437 112.2536 0.0014  
Residual 3 20.1146 6.7049  
Total 6 2278.0457 379.6743  
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Powder- CMC HMW
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R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9709 0.9426 0.8851  7.8752  
 
  Coefficient Std. Error t P VIF  
a 43.7997 10.3956 4.2133 0.0244 1.7493  
b 0.5548 0.7253 0.7649 0.5000 1.5851  
c 56.2049 6.7886 8.2793 0.0037 3.7846  
d 0.0034 0.0015 2.2085 0.1143 2.3107  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 23241.9695 5810.4924  
Residual 3 186.0586 62.0195  
Total 7 23428.0280 3346.8611  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 3053.4095 1017.8032 16.4110 0.0230  
Residual 3 186.0586 62.0195  
Total 6 3239.4681 539.9113  
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Powder- HPMC HMW
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R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9978 0.9956 0.9912  2.5731  
 
  Coefficient Std. Error t P VIF  
a 72.8644 3.3134 21.9909 0.0002 1.8310  
b 0.2272 0.0272 8.3561 0.0036 1.6749  
c 27.3384 2.1879 12.4953 0.0011 5.0086<  
d 8.9305E-005 0.0008 0.1189 0.9129 3.1954  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 16438.8060 4109.7015  
Residual 3 19.8626 6.6209  
Total 7 16458.6686 2351.2384  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 4496.7616 1498.9205 226.3928 0.0005  
Residual 3 19.8626 6.6209  
Total 6 4516.6243 752.7707  
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Powder- Chitosan
f=a*exp(-b*x)+c*exp(-d*x)
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R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9772 0.9549 0.9099  7.5230  
 
  Coefficient Std. Error t P VIF  
a 34.3223            (NAN) (+inf) <0.0001 0.0000  
b 129558.4970            (NAN) (+inf) <0.0001 0.0000  
c 65.6777            (NAN) (+inf) <0.0001 0.0000  
d 0.0053            (NAN) (+inf) <0.0001 0.0000  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 25002.3906 6250.5977  
Residual 3 169.7861 56.5954  
Total 7 25172.1767 3596.0252  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 3598.9693 1199.6564 21.1971 0.0160  
Residual 3 169.7861 56.5954  
Total      6       3768.7554          628.1259  
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Appendix A.5- RESIDENCE TIME STUDY IN SPRAGUE DAWLEY RATS 
Materials and Methods 
Male Sprague Dawley rats (350-400g Charles River, Raleigh, NC) were kept under 
standard conditions in AAALAC approved facilities under IACUC approved protocol (06-
265.0-A). The animals were kept in a controlled temperature room (22 ± 1°C with 12 hour 
light and dark cycles and had free access to food and water. Rats were anesthetized by 
intraperitoneal injection of 40 mg/kg ketamine, 2 mg/kg xylazine and 0.75 mg/kg 
acepromazine before immunization. 
Liquid formulations of saline or 1% MA in saline containing insoluble 99mTc sulfur 
colloid (99mTc-SC) were delivered by placing 25 μL of solution into the right nostril of an 
anesthetized rat using a 10-100 μL pipette. To label powder formulations, saline containing 
insoluble 99mTc-SC were centrifuged at 12000 rpms for 10 minutes. Supernatant was 
removed and the pellet was washed three times with ethanol. The pellet was allowed to dry 
before being blended with the SFD- rat trehalose with a mortar and pestle. Five milligram 
quantities were weighed out and placed in gelatin capsules (size 3, Capsugel, Greenwood, 
SC). Powder formulations were delivered using compressed air at 20 psi through a timed 
solenoid switch and a 100 μL pipette containing the contents of one dosage capsule in the 
right nostril of the anesthetized rat. The time points analyzed were 5, 15, and 120 minutes 
(n=3) and 30, 60, and 180 minutes (n=1). Rats were euthanized following cardiac puncture 
by CO2 inhalation and nasal washes were collected by cannulating the trachea and rapidly 
instilling four aliquots of 1.5 mL of sterile saline. Fluid emerging from the nostrils was 
collected and analyzed in a radioisotope calibrator (Model CRC-4, Capintech, Inc. 
Pittsburgh, PA). All samples quantities were adjusted for radioactive decay. 
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Results and Discussion 
Comparing the percentage of radioactivity as a function of time, SFD trehalose 
powder resided longer in the nasal cavity of the Sprague Dawley rats than saline (Figure 
A.5.1). Liquid and powder formulations containing the MA and saline alone were compared. 
The curve for liquid HPMC HMW was similar to powder HPMC HMW, but the saline alone 
did not reside as long in the nasal cavity as the HPMC HMW formulations (Figure A.5.2). 
The curve for liquid CMC HMW was similar to saline alone at almost all of the time points, 
but the powder CMC HMW seemed to remain in the nasal cavity longer than the liquid 
formulations (Figure A.5.3). The initial removal of saline, liquid SA, and powder SA was 
similar, but the SA formulations plateaued at a higher percentage of radioactivity remaining 
than saline (Figure A.5.4). The powder chitosan was similar to saline alone at almost all of 
the time points, but lower quantities of radioactivity were detected for the saline at the 180 
minute time point (Figure A.5.5). 
Regression analysis was performed by mathematically fitting the data to assess 
residence time differences, similar to the Brown Norway rats. The correlation coefficient and 
parameters (a, b, c, and d) determined by the regression analysis are shown (Table A.5.1). All 
of the curves exhibited good fit (R2 > 0.94).  
Parameters a and b are representative of initial clearance of the radioactivity from the 
nasal cavity. With the exception of the liquid HPMC, the distribution constant (b) was larger 
for the powder formulations than the liquids. This is surprising because run-off and 
swallowing of the liquid formulations, unhindered clearance, was expected to account for a 
large, immediate decrease in the radioactivity remaining. However, the viscosity of 1% 
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HPMC HMW is much greater than 1% SA or CMC HMW, which may explain the increase 
in residence time.  
Parameters c and d are indicative of mucociliary clearance rate. The elimination 
constant (d) was very similar for all of the powder formulations and were larger than liquid 
HPMC HMW, CMC HMW, and SA, while the liquid NoMA was similar to the powder No 
MA.  
All of the liquid formulations with MA and powder formulations had larger areas 
under the radiolabeled preparation retention curve (AUC) than the saline (Liq- No MA, 
Figure A.5.5). All of the powders, with the exception of Pow- SA (trehalose and SA) had 
longer residence times than the liquid formulations with the same MA. The AUC of the Liq- 
SA and Pow- SA were the same. The rank order of powders was Pow- CMC>Pow- HPMC 
HMW, Pow- No MA>Pow- SA>Pow- Chit. Compared to the AUC of the Brown Norway 
rats, the residence time of the liquids in Sprague Dawley rats was significantly lower, while 
the residence time of the Pow- No MA and Pow- HPMC HMW were significantly greater.  
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Table A.5.1– Correlation coefficient and parameters determined by regression analysis of 
two-compartment model curves determined by the % radioactivity remaining as a function of 
time in Sprague Dawley rats of liquid and powder formulations containing saline (liquid, No 
MA) and 1% hydroxypropyl methylcellulose (HPMC), carboxymethylcellulose sodium 
(CMC), or sodium alginate (SA) or trehalose alone (powder, No MA) and 3% HPMC, CMC, 
SA, and Chit. 
 
Liquid Formulations Powder Formulations 
 No MA HPMC HMW 
CMC 
HMW SA No MA 
HPMC 
HMW 
CMC 
HMW SA Chit 
r2 0.9909 0.9914 0.9890 0.9932 0.9435 0.9747 0.9705 0.9773 0.9761 
a 73.113 62.3879 70.4395 71.1362 30.3649 40.88 41.7547 48.1498 56.9458 
b 0.0788 0.1519 0.0663 0.0697 0.2814 72.9289 0.1189 0.1736 7100.78 
c 26.6927 37.1257 25.4678 30.7308 69.6624 59.12 55.7585 51.9502 43.0542 
d 0.0074 0.0014 0.0011 1.28E-11 0.0074 0.0036 0.0036 0.0042 0.0048 
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Figure A.5.1– The percentage of radioactivity remaining in the nasal cavity of Sprague 
Dawley rats as a function of time when radiolabeled saline (Liq- No MA) or trehalose (Pow- 
No MA) is delivered (error bars represent standard deviations of n=3 at 15, 30, and 120 
minute time points). 
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Figure A.5.2– The percentage of radioactivity remaining in the nasal cavity of Sprague 
Dawley rats as a function of time when radiolabeled saline (Liq- No MA), 1% hydroxypropyl 
methylcellulose in radiolabeled saline (Liq- HPMC HMW) or 3% hydroxypropyl 
methylcellulose in radiolabeled trehalose (Pow- HPMC HMW) is delivered (error bars 
represent standard deviations of n=3 at 15, 30, and 120 minute time points). 
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Figure A.5.3– The percentage of radioactivity remaining in the nasal cavity of Sprague 
Dawley rats as a function of time when radiolabeled saline (Liq- No MA), 1% 
carboxymethylcellulose sodium in radiolabeled saline (CMC HMW) or 3% 
carboxymethylcellulose sodium in radiolabeled trehalose (Pow- CMC HMW) is delivered 
(error bars represent standard deviations of n=3 at 15, 30, and 120 minute time points). 
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Figure A.5.4– The percentage of radioactivity remaining in the nasal cavity of Sprague 
Dawley rats as a function of time when radiolabeled saline (Liq- No MA), 1% sodium 
alginate in radiolabeled saline (Liq- SA) or 3% sodium alginate in radiolabeled trehalose 
(Pow- SA) is delivered (error bars represent standard deviations of n=3 at 15, 30, and 120 
minute time points). 
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Figure A.5.5– The percentage of radioactivity remaining in the nasal cavity of Sprague 
Dawley rats as a function of time when radiolabeled saline (Liq- No MA)  or 3% Chitosan in 
radiolabeled trehalose (Pow- Chit) is delivered (error bars represent standard deviations of 
n=3 at 15, 30, and 120 minute time points). 
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Figure A.5.6– The area under the curve of the percentage of radioactivity as a function of 
time curves for liquid and powder formulations containing no mucoadhesive (No MA), 
hydroxypropyl methylcellulose (HPMC HMW), sodium alginate (SA), 
carboxymethylcellulose sodium (CMC HMW), and chitosan (Chit) in Sprague Dawley rats. 
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Nonlinear Regression 
Equation: Exponential Decay, Double, 4 Parameter 
f=a*exp(-b*x)+c*exp(-d*x) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9909 0.9818 0.9636  6.7951  
  Coefficient Std. Error t P VIF  
a 73.1130 19.0864 3.8306 0.0313 12.2889<  
b 0.0788 0.0353 2.2297 0.1120 5.8949<  
c 26.6927 19.3078 1.3825 0.2608 32.4989<  
d 0.0074 0.0075 0.9890 0.3956 6.0055<  
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 19021.7030 4755.4257  
Residual 3 138.5216 46.1739  
Total 7 19160.2245 2737.1749  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 7466.1258 2488.7086 53.8987 0.0042  
Residual 3 138.5216 46.1739  
Total 6 7604.6474 1267.4412 
 289
Liquid- HPMC HMW
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Nonlinear Regression 
Equation: Exponential Decay, Double, 4 Parameter 
f=a*exp(-b*x)+c*exp(-d*x) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9914 0.9830 0.9659  4.8065  
  Coefficient Std. Error t P VIF  
a 62.3879 6.7113 9.2960 0.0026 2.3973  
b 0.1519 0.0408 3.7239 0.0337 2.2241  
c 37.1257 5.1996 7.1401 0.0057 7.0252<  
d 0.0014 0.0013 1.0812 0.3588 3.5679  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 20356.2365 5089.0591  
Residual 3 69.3067 23.1022  
Total 7 20425.5432 2917.9347  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 3999.1647 1333.0549 57.7024 0.0038  
Residual 3 69.3067 23.1022  
Total 6 4068.4714 678.0786  
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Liquid- CMC HMW
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Nonlinear Regression 
Equation: Exponential Decay, Double, 4 Parameter 
f=a*exp(-b*x)+c*exp(-d*x) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9890 0.9781 0.9562  6.2130  
  Coefficient Std. Error t P VIF  
a 70.4395 12.0693 5.8363 0.0100 6.3075<  
b 0.0663 0.0239 2.7677 0.0697 4.5578<  
c 25.4678 11.8380 2.1514 0.1206 22.5579<  
d 0.0011 0.0036 0.3055 0.7799 8.0096<  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 20319.2690 5079.8173  
Residual 3 115.8056 38.6019  
Total 7 20435.0746 2919.2964  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 5167.8418 1722.6139 44.6252 0.0055  
Residual 3 115.8056 38.6019  
Total 6 5283.6474 880.6079  
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Liquid- SA
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Nonlinear Regression 
Equation: Exponential Decay, Double, 4 Parameter 
f=a*exp(-b*x)+c*exp(-d*x) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9932 0.9864 0.9728  4.6980  
  Coefficient Std. Error t P VIF  
a 71.1362 8.1286 8.7514 0.0031 4.9011<  
b 0.0697 0.0179 3.9020 0.0299 4.0114<  
c 30.7308 7.7394 3.9707 0.0286 18.9967<  
d 1.2833E-011 0.0019 6.7564E-009 1.0000 7.9468<  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 24498.4286 6124.6071  
Residual 3 66.2149 22.0716  
Total 7 24564.6434 3509.2348  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 4797.3457 1599.1152 72.4512 0.0027  
Residual 3 66.2149 22.0716  
Total 6 4863.5605 810.5934  
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Powder- No MA
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Nonlinear Regression 
Equation: Exponential Decay, Double, 4 Parameter 
f=a*exp(-b*x)+c*exp(-d*x) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9435 0.8901 0.7802  14.2452  
  Coefficient Std. Error t P VIF  
a 30.3649 21.4030 1.4187 0.2510 2.3932  
b 0.2814 0.5150 0.5465 0.6228 1.8643  
c 69.6624 16.2627 4.2836 0.0234 5.2493<  
d 0.0074 0.0038 1.9428 0.1473 2.4108  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 25808.1903 6452.0476  
Residual 3 608.7762 202.9254  
Total 7 26416.9665 3773.8524  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 4931.7780 1643.9260 8.1011 0.0598  
Residual 3 608.7762 202.9254  
Total 6 5540.5542 923.4257  
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Powder- HPMC HMW
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Nonlinear Regression 
Equation: Exponential Decay, Double, 4 Parameter 
f=a*exp(-b*x)+c*exp(-d*x) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9747 0.9501 0.9002  7.1955  
               Coefficient Std. Error      t  P VIF  
a 40.8800            (NAN) (+inf) <0.0001 0.0000  
b 72.9289            (NAN) (+inf) <0.0001 0.0000  
c 59.1200            (NAN) (+inf) <0.0001 0.0000  
d 0.0036            (NAN) (+inf) <0.0001 0.0000  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 24039.9717 6009.9929  
Residual 3 155.3264 51.7755  
Total 7 24195.2981 3456.4712  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 2956.4931 985.4977 19.0341 0.0186  
Residual 3 155.3264 51.7755  
Total 6 3111.8195 518.6366  
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Powder- CMC HMW
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Nonlinear Regression 
Equation: Exponential Decay, Double, 4 Parameter 
f=a*exp(-b*x)+c*exp(-d*x) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9705 0.9419 0.8839  8.7349  
 Coefficient Std. Error t P VIF  
a 41.7547 14.2332 2.9336 0.0608 3.5410  
b 0.1189 0.0941 1.2636 0.2956 2.9717  
c 61.1717 12.6041 4.8533 0.0167 10.4534<  
d 0.0036 0.0021 1.7183 0.1842 3.8976  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 29936.6071 7484.1518  
Residual 3 228.8972 76.2991  
Total 7 30165.5042 4309.3577  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 3713.7041 1237.9014 16.2243 0.0233  
Residual 3 228.8972 76.2991  
Total 6 3942.6013 657.1002  
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Powder- SA
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Nonlinear Regression 
Equation: Exponential Decay, Double, 4 Parameter 
f=a*exp(-b*x)+c*exp(-d*x) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9773 0.9551 0.9102  7.8972  
  Coefficient Std. Error t P VIF  
a 48.1498 11.7209 4.1080 0.0261 2.6030  
b 0.1736 0.1026 1.6929 0.1891 2.2141  
c 51.9502 9.3291 5.5686 0.0114 6.7230<  
d 0.0042 0.0021 1.9899 0.1407 2.9670  
 
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 23172.8914 5793.2229  
Residual 3 187.0968 62.3656  
Total 7 23359.9882 3337.1412  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 3982.0843 1327.3614 21.2836 0.0159  
Residual 3 187.0968 62.3656  
Total 6 4169.1811 694.8635 
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Powder- Chitosan
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Nonlinear Regression 
Equation: Exponential Decay, Double, 4 Parameter 
f=a*exp(-b*x)+c*exp(-d*x) 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
0.9761 0.9527 0.9054  8.5549  
               Coefficient Std. Error     t   P VIF  
a 56.9458               (NAN) (+inf) <0.0001 0.0000  
b 7100.7776               (NAN) (+inf) <0.0001 0.0000  
c 43.0542               (NAN) (+inf) <0.0001 0.0000  
d 0.0048               (NAN) (+inf) <0.0001 0.0000  
Analysis of Variance:  
Uncorrected for the mean of the observations: 
  DF SS MS  
Regression 4 16703.0326 4175.7582  
Residual 3 219.5567 73.1856  
Total 7 16922.5894 2417.5128  
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 3 4422.0123 1474.0041 20.1406 0.0172  
Residual 3 219.5567 73.1856  
Total 6 4641.5691 773.5948  
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